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2Abstract
Recognition, alleviation and control of pain are central to ensurin~ good wel.fare in food
producing animals. An intervention trial was conducted on 1.17 dairy c~ws ~Ith naturally-
occurring, mild or moderate, clinical mastitis in a single quarter m order to mv~stIgate the effect
of the administration of the non-steroidal anti-inflammatory drug. meloxicam (Metacam,
Boehringer Ingelheim Animal Health GmbH) used in conjunction with an ~n~amam~ary
antibiotic infusion of cefquinome (Cephaguard LC Intramammary, Intervet UK Limited, MIlton
Keynes). Cows with clinical mastitis were allocated rando~ly to one of 3 ~~u~s: Group 1:
antibiotics only; Group 2: antibiotics and one dose of meloxicam; Group 3: antIblotIc~ and three
doses of meloxicam on day of diagnosis, day 0, and on days 3 and 6. Healthy animals were
recruited as controls.
Clinical and laboratory parameters were investigated to assess their usefulness as objective
markers of pain. Measuring the cows' response to a mechanical stimulus assessed altered pain
processing. All cows were examined clinically on 6-8 occasions over a 42 day perio~.
Seventy out of the 117 cases of clinical mastitis were followed for the full period; 47 cases
dropped out due to re-occurrence of mastitis, development of mastitis in more than one quarter or
the development of another inflammatory focus. Of the 117 mastitis cases 56 were classed as mild
in severity and 61 were classed as moderate. In the 70 complete mastitis cases 41 were mild and
29 were moderate. More moderate cases of mastitis dropped out compared to mild cases
(p=0.005). Heart rates, respiratory rates and rectal temperatures of cows were higher in moderate
cases compared to mild cases of clinical mastitis (p<O.OOl).The hindleg stance of cows, as
measured by hock-to-hock distance, with clinical mastitis was greater than in normal cows
(p<O.OOl).Alterations in the response to mechanical stimulation were recorded in cows with
both mild and moderate clinical mastitis and treatment with meloxicam was shown to attenuate
the mechanical alterations (p=0.04). There was however, no difference in cows that received one,
compared to three doses of meloxicam (p>0.05). On bacteriological examination of the recruited
cases, 30% of isolates yielded S uberis, 24% yielded no growth, 22% E coli, 11% Staph aureus,
six per cent other microbiological species, four per cent A pyogenes and three per cent S
dysgalactiae. When compared with mild cases of mastitis the moderate cases had a greater
proportion of isolations of S uberis (p<O.O1) and a smaller proportion of no growths (p<O.O1). The
median log individual quarter somatic cell count were greater in the quarter from the affected
gland of cows with mild or moderate mastitis than the diagonally opposite quarter of these cows
and normal cows (p<O.OOI),however, there was no difference between the median log IQSCC of
the affected quarter from mild and moderate cases of mastitis (p>0.05). There was no effect of
mastitis on the fat percentage of milk, as judged by the comparison of affected quarters to
diagonally opposite quarters and to normal cows. The protein content of milk increased with
mastitis and the lactose content decreased compared to diagonally opposite quarters and normal
cows (p<O.OO1). The most common somatic cell type in quarters affected with mild and moderate
mastitis on the day of recruitment to the study were polymorphonuclear cells, whereas large
mononuclear cells were the predominant cell type in normal animals. In both mild and moderate
mastitis, the milk from the affected quarter had greater haptoglobin concentrations than in milk
from normal cows (p<O.OOI), and in each group the concentration was higher in the affected
quarter than in the diagonally opposite quarter (p<O.OOI).The concentration of haptoglobin in
milk from the affected quarters of cows with moderate mastitis was greater (p<0.0 1) than that in
milk from affected quarter of cows with mild mastitis. Mammary-associated serum amyloid A
concentrations were higher in the affected quarter of cases of mild and moderate clinical mastitis
than in normal cows (p<O.OOI), and within each group the concentration was greater in the
affected quarter than the diagonally opposite quarter (p<0.05 for mild and p<O.OI for the
moderate mastitis group). Concentrations of the inflammatory mediator, prostaglandin E2 in milk
were lower in mild cases of clinical mastitis compared to moderate cases (p<O.05).
In c?~clusion, physiological and laboratory parameters may serve as indicators of clinical
mastltIs~help diff~rentiate between different severities of clinical mastitis and, therefore, aid in
a~p~opnate ~getmg of therapy. Alterations in the pain pathways are present in animals with
clinical mesnns of both mild and moderate severity, and treatment with meloxicam was shown to
restore n~rmal threshold responses to mechanical stimuli. These results indicate that a single dose
of meloxicam may provide beneficial analgesic therapy to dairy cows with clinical mastitis .
.' .... ',",.. '\
.~, ,
List of Contents
Abstract 2
List of Contents 3
List of Tables 7
List of Figures 11
Acknowledgements 16
Author's Declaration 18
Publications and Presentations 19
List of Abbreviations 20
Dedication 22
Chapter 1 23
Introduction 23
1.1.Mastitis 23
1.1.1. Clinical mastitis 26
1.1.2. Subclinical mastitis 27
1.1.3. Diagnostic tests 27
1.1.3.1. Bacteriology 28
1.1.3.2. Somatic cell counting 29
1.1.3.3. Miscellaneous tests 30
1.1.4. Genetics and resistance to mastitis 31
1.2. Inflammation 32
1.2.1. Inflammatory mediators 32
1.2.2. Acute phase proteins 35
1.2.2.1. Haptoglobin 36
1.2.2.2. Serum Amyloid A 36
1.2.2.3. Diagnostic value of acute phase proteins 37
1.3. Assessment ofpain 39
1.3.1. Pain classification 41
1.3.2. Pathophysiology of pain 42
1.3.2.1. Innervation to the udder 43
1.3.3. Measurement ofpain 44
1.3.3. Pain threshold testing 45
1.4. Pathogenesis of clinical mastitis 48
1.5. Treatment of clinical mastitis 49
1.5.1. Antimicrobials 50
1.5.2. Anti-inflammatory drugs and analgesics 52
41.5.2.1. Corticosteroids 52
1.5.2.2. Non-steroidal anti-inflammatory drugs 54
1.5.2.3. Analgesic drugs 59
1.5.3. Supportive therapy 63
1.6. Aims and objectives 63
Chapter 2 ••••••••••.••••.•••••••••••.•••••••••..••••••64.............................................................................. .
Materials and methods ••••••••.••••.•••••••••••••••••••••••.•••.•••••.••••.•..•..•.•.•••••••••••••••••••••••••••••••••••••••64
2.1. Study population 64
2.1.1. Cow details 64
2.2. Case recruitment 64
2.3. Study design 65
2.4. Milk sampling 66
2.5. Bacteriological examination ···..·· 67
2.6. Somatic cell counting and milk quality 67
2.7. Differential somatic cell counting 67
2.8. Acute phase proteins 68
2.9. Prostaglandin E2 69
2.9.1. Preparation ofstandards · · · 69
2.9.2. Preparation of milk samples ·..· 71
2.9.3. Protocol for radio-immunoassay 71
2.1O.Meloxicam 72
2.10.1. Chemical structure · 72
2.10.2. Reagents 72
2.10.3. Equipment 73
2.10.4. Chromatographic conditions 73
2.10.5. Stock solutions 73
2.10.6. Extraction 76
2.10.7. Assay characteristics 76
2.11. Data handling and statistical analysis 78
Chapter 3 79
On farm assessment of pain in cows with clinical mastitis 79
3.1. Introduction 79
3.2. Materials and Methods 80
3.2.1. Study population and case recruitment 80
3.2.2. Study design 80
3.2.3. Clinical examination 81
53.2.4. Mechanical threshold measurement ·..· ·········· 83
3.2.5. Data handling and statistical analysis ············ 86
3 3 Results 86. . .
3.3.1. Cases recruited 86
3.3.2. Demographic details · ·· 87
3.3.3. Homogeneity and goodness offit · · 89
3.3.4. Clinical examination 89
3.3 .4.1. Heart rate, respiratory rate and rectal temperature 91
3.3.4.2. Udder skin temperature 92
3.3.4.3. Hock-to-hock distance 92
3.3.4.4. Temperament, udder cleanliness and teat lesions 93
3.3.5. Mechanical threshold measurement 110
3.3.6. Milk yield 119
3.4. Discussion 120
Chapter 4•••••.•••••••••.•••••••••••.••••••.•.•.••••••••••••••.•••••••••••.•.••••••••••••••••••.••••••••••••••••••••••••••••.••••••130
Laboratory assessment of pain and inflammation in cows with clinical mastitis •••••130
4.1. Introduction 130
4.2. Materials and methods 132
4.2.1. Sampling 132
4.2.2. Statistical analysis 132
4.3. Results 133
4.3.1. Cases recruited 133
4.3.2. Bacteriological examination 133
4.3.3. Somatic cell counting 134
4.3.3. Milk quality 141
4.3.3. Differential somatic cell counting 154
4.3.4. Acute phase proteins 156
4.4. Discussion 177
Chapter 5 185
Prostaglandin El and meloxicam concentrations in milk from cows with clinical
mastitis ................................................•............................................................................. 185
5.1. Introduction 185
5.2. Materials and methods 186
5.2.2. Sample selection 186
5.2.2. Data analysis 186
5.3. Results 187
5.3.1. Prostaglandin E2 187
65.3.2. Meloxicam 196
5.3.2.1. One dose ofmeloxicam 196
5.3.2.2. Three doses of meloxicam 198
5.4. Discussion 201
Chapter 6 205
General discussion and conclusions 205
6.1. Overview 205
6.2. Study objectives 206
6.3. Study design 206
6.4. Physiological parameters 207
6.5. Laboratory parameters 209
6.6. Future direction 212
6.7. Conclusions 213
Appendix 1 215
Appendix 2 217
Appendix 3 219
Appendix 4 221
Appendix 5 227
References 233
Table 2.1:
Table 3.1:
Table 3.2:
Table 3.3:
Table 3.4:
Table 3.5:
Table 3.6:
Table 3.7:
Table 3.8:
Table 3.9:
Table 3.10:
Table 3.11:
Table 3.12:
Table 3.13:
7
List of Tables
PAGE
Mean (± standard deviation) recovery, intra-assay and inter-assay 77
variation in recovery of meloxicam from milk fortified at known
concentrations
Dimensions of plate and pin of the cuff of the mechanical 85
threshold device and calculated pressure and force
Reasons for cases dropping out of study before 45 days (n=47) 88
Mean/median (SEIIQR) for clinical parameters of normal animals 90
(n=45), mild (n=41) and moderate (n=29) cases of clinical mastitis
on the day of recruitment to the study (day 0)
Final multivariable mixed effects model of explanatory variables 95
that were associated with heart rate of mild and moderate cases of
clinical mastitis for the first seven days after recruitment to the
study
Final multivariable mixed effects model of explanatory variables 95
that were associated with heart rate of mild and moderate cases of
clinical mastitis for 45 days after recruitment to the study
Final multivariable mixed effects model of explanatory variables 96
that were associated with respiratory rate of mild and moderate
cases of clinical mastitis for the first seven days after recruitment
to the study
Final multivariable mixed effects model of explanatory variables 96
that were associated with respiratory rate of mild and moderate
cases of clinical mastitis for 45 days after recruitment to the study
Final multivariable mixed effects model of explanatory variables 97
that were associated with rectal temperature of mild and moderate
cases of clinical mastitis for the first seven days after recruitment
to the study
Final multivariable mixed effects model of explanatory variables 97
that were associated with rectal temperature of mild and moderate
cases of clinical mastitis for 45 days after recruitment to the study
Final multivariable mixed effects model of explanatory variables 98
that were associated with heart rate, respiratory rate and rectal
temperature of normal animals for the first seven days after
recruitment to the study .
Final multivariable mixed effects model of explanatory variables 98
that were associated with heart rate, respiratory rate and rectal
temperature of normal animals for 45 days after recruitment to the
study
Two-by-two tables to test the ability of heart rate to differentiate 99
between cases of clinical mastitis and normal animals detailing the
sensitivity, specificity, negative predictive values, positive
predictive values and accuracy
Two-by-two tables to test the ability of respiratory rate to 99
differentiate between cases of clinical mastitis and normal animals
detailing the sensitivity, specificity, negative predictive values,
positive predictive values and accuracy
8Table 3.14: Two-by-two tables to test the ability of rectal temperature to 100
differentiate between cases of clinical mastitis and normal animals
detailing the sensitivity, specificity, negative predictive values,
positive predictive values and accuracy
Table 3.15: Two-by-two tables to test the ability of heart rate to differentiate 100
between moderate and mild severity of clinical mastitis detailing
the sensitivity, specificity, negative predictive values, positive
predictive values and accuracy
Table 3.16: Two-by-two tables to test the ability of respiratory rate to 101
differentiate between moderate and mild severity of clinical
mastitis detailing the sensitivity, specificity, negative predictive
values, positive predictive values and accuracy
Table 3.17: Two-by-two tables to test the ability of rectal temperature to 101
differentiate between moderate and mild severity of clinical
mastitis detailing the sensitivity, specificity, negative predictive
values, positive predictive values and accuracy
Table 3.18: Final multivariable mixed effects model of explanatory variables 103
that were associated with udder temperature difference of mild and
moderate cases of clinical mastitis for the first seven days after
recruitment to the study
Table 3.19: Final multivariable mixed effects model of explanatory variables 103
that were associated with udder temperature difference of mild and
moderate cases of clinical mastitis for 45 days after recruitment to
the study
Table 3.20: Final multivariable mixed effects model of explanatory variables 105
that were associated with hock-to-hock distance of mild and
moderate cases of clinical mastitis for the first seven days after
recruitment to the study
Table 3.21: Final multivariable mixed effects model of explanatory variables 106
that were associated with hock-to-hock distance of mild and
moderate cases of clinical mastitis for 45 days after recruitment to
the study
Table 3.22: Two-by-two tables to test the ability of hock-to-hock distance to 107
differentiate between cases of clinical mastitis and normal animals
detailing the sensitivity, specificity, negative predictive values,
positive predictive values and accuracy
Table 3.23: Final multivariable mixed effects model of explanatory variables 117
that were associated with threshold difference of mild and
moderate cases of clinical mastitis for the first seven days after
recruitment to the study
Table 3.24: Final multivariable mixed effects model of explanatory variables 117
that were associated with threshold difference of mild and
moderate cases of clinical mastitis for 45 days after recruitment to
the study
Table 4.1: Final multivariable binary logistic regression model of explanatory 138
variables that were associated with microbiological culture results
of S uberis, E coli, Staph aureus or no growth from samples taken
on day of recruitment (day 0) of mild and moderate clinical
mastitis
Table 4.2:
Table 4.3:
Table 4.4:
Table 4.5:
Table 4.6:
Table 4.7:
Table 4.8:
Tale 4.9:
Table 4.10:
Table 4.11:
Table 4.12:
Table 4.13:
Table 4.14:
9
Median, mean and ranges of individual quarter somatic cell count 139
(IQSCC) x 103 cells/ml of milk in normal animals and cases of
mild or moderate mastitis on day of recruitment
Final multivariable mixed effects model of explanatory variables 148
that were associated with log individual quarter somatic cell count
(IQSCC) x 103 cells/ml of mild and moderate cases of clinical
mastitis for the first seven days after recruitment to the study
Final multivariable mixed effects model of explanatory variables 150
that were associated with log individual quarter somatic cell count
(IQSCC) x 103 cells/ml of mild and moderate cases of clinical
mastitis for the 45 day study period
Mean (SE) and ranges of percentages of fat, protein and lactose in 151
the milk of normal animals and cases of mild or moderate clinical
mastitis on the day of recruitment to the study (day 0)
Mean (SE) and ranges of polymorphonuclear neutrophils (PMNs), 157
lymphocytes and macrophages over the 45 day study period for
mild cases of mastitis
Mean (SE) and ranges of polymorphonuclear neutrophils (PMNs). 157
lymphocytes and macrophages over the 45 day study period for
moderate cases of mastitis
Median, mean and ranges of concentrations of haptoglobin and 160
mammary-associated serum amyloid A in the milk of normal
animals and cases of mild or moderate mastitis on the day of
recruitment to the study (day 0)
Final multivariable mixed effects model of explanatory variables 172
that were associated with haptoglobin concentrations in milk from
mild and moderate cases of clinical mastitis for the first 12 days
after recruitment to the study
Final multivariable mixed effects model of explanatory variables 172
that were associated haptoglobin concentrations in milk from mild
and moderate cases of clinical mastitis for the first seven days after
recruitment to the study
Final multivariable mixed effects model of explanatory variables 173
that were associated with mammary-associated serum amyloid A
concentrations in milk from mild and moderate cases of clinical
mastitis for the first 12 days after recruitment to the study
Final multivariable mixed effects model of explanatory variables 173
that were associated with mammary-associated serum amyloid A
concentrations in milk from mild and moderate cases of clinical
mastitis for the first seven days after recruitment to the study
Two-by-two tables to test the ability of haptoglobin concentrations 173
to differentiate between cases of clinical mastitis and normal
animals detailing the sensitivity, specificity, negative predictive
values, positive predictive values and accuracy
Two-by-two tables to test the ability of haptoglobin concentrations 175
to differentiate between moderate and mild severity of clinical
mastitis detailing the sensitivity, specificity, negative predictive
values, positive predictive values and accuracy
10
Table 4.15: Two-by-two tables to test the ability of mammary-associated 175
serum amyloid A concentrations to differentiate between cases of
clinical mastitis and normal animals detailing the sensitivity,
specificity, negative predictive values, positive predictive values
and accuracy
Table 4.16: Two-by-two tables to test the ability of haptoglobin concentrations 176
to differentiate between moderate and mild severity of clinical
mastitis detailing the sensitivity, specificity, negative predictive
values, positive predictive values and accuracy
Table 5.1: Median and inter-quartile ranges of prostaglandin E2 (ng/ml) 188
concentrations in the milk of cases of mild and moderate clinical
mastitis treated with antibiotics only (group 1) or antibiotics and
meloxicam (groups 2 and 3) on the day of recruitment to the study
(day 0) and on the following two days (day 1 and 2)
Table 5.2: Median and inter-quartile ranges ofPGE2 (ng/ml) concentrations in 194
the milk of cases of mild and moderate clinical mastitis caused by
S uberis (n=19), E coli (n=15), no growth (n=18), Staph aureus
(n=9), S dysgalactiae (n=3), A pyogenes (n=2) and miscellaneous
organisms (n=2) on the day of recruitment to the study (day 0) and
the following two days (day 1 & 2)
Table 5.3: Two-by-two tables to test the ability oflog PGE2 concentrations to 195
differentiate between moderate and mild severity of clinical
mastitis detailing the sensitivity, specificity, negative predictive
values, positive predictive values and accuracy
Table 5.4: Meloxicam concentrations (ug/ml) in milk from eight cows treated 199
with antibiotics and one dose of meloxicam (group 2) administered
on day O. Milk samples taken prior to the administration of
meloxicam
Table 5.5: Meloxicam concentrations (ug/ml) in milk from eight cows treated 200
with antibiotics and three doses of meloxicam (group 3)
administered on day 0, 3 and 6. Milk samples taken prior to the
administration of meloxicam
Figure 1.1:
Figure 1.2:
Figure 2.1:
Figure 2.2:
Figure 2.3:
Figure 2.4:
Figure 3.1:
Figure 3.2:
Figure 3.3:
Figure 3.4:
Figure 3.5:
Figure 3.6:
Figure 3.7:
Figure 3.8:
Figure 3.9:
11
List of Figures
PAGE
51
58
66
Sites of action of common anti-inflammatory agents
Actions of the two known isofonns of COX
Cow with mild (A) mastitis in front left quarter showing no udder
changes and cow with moderate (B) mastitis in back left quarter
exhibiting signs of udder swelling and redness
Typical antibody binding curve for prostaglandin E2 standards (in 70
duplicate) prepared with milk as the dilutant
Chemical structure of meloxicam and piroxicam (internal standard) 74
Typical chromatogram of milk spiked with meloxicam (0.5 ug/ml) 75
and piroxicam (0.5 ug/ml)
Measurement of hock-to-hock distance (mm) to assess the hindleg 82
stance of cows with clinical mastitis and normal animals
Gas driven ramped mechanical threshold device for the 84
measurement of nociceptive threshold (kPa) in cows with
unilateral clinical mastitis and in normal animals to calculate the
threshold difference between the contra-lateral and ipsi-lateral
hindlegs
Schematic diagram of cuff of the mechanical threshold device 85
Mean (SE) (A) Heart rate (beats/minute), (B) respiratory rate 94
(breaths/minute), (C) rectal temperature (CC) for cases of clinical
mastitis treated with antibiotics only (n=21), antibiotics and one
dose of meloxicam (n=29), antibiotics and three doses of
meloxicam (n=20) and normal animals (n=19) over six days after
recruitment to the study
Udder temperature difference for mild (n=41) and moderate (n=29) 102
cases of clinical mastitis and normal animals (n=19) on the day of
recruitment to the study (day 0)
Mean hock-to-hock distance ± SE for cases of clinical mastitis 104
treated with antibiotics only (n=21), antibiotics and one dose of
meloxicam (n=29), antibiotics and three doses of meloxicam
(n=20) and normal animals (n=19) over 45 days after recruitment
to the study
Percentage of cases of clinical mastitis that completed (n=70) and 107
cases of clinical mastitis that did not complete (n=47) and normal
animals (n=19) in the three temperament categories on the day of
recruitment to the study (day 0)
Percentage of cases of clinical mastitis that completed (n=70) and 108
cases of clinical mastitis that did not complete (n=47) and normal
animals (n=19) in the three udder cleanliness categories on the day
of recruitment to the study (day 0)
Percentage of teat lesions for cases of clinical mastitis that 109
completed (n=70) and cases of clinical mastitis that did not
complete (n=47) the 45 day study period and normal animals
(n=19) on the day of recruitment to the study (day 0)
Figure 3.10:
Figure 3.11:
Figure 3.12:
Figure 3.13:
Figure 3.14:
Figure 3.15:
Figure 3.16:
Figure 3.17:
Figure 4.1:
Figure 4.2:
Figure 4.3:
Figure 4.4:
Figure 4.5:
12
Mechanical threshold measurements (kPa) for the ipsi-lateral Ieg 112
(n=70) and contra-lateral leg (n=70) to the quarter with clinical
mastitis on the day of recruitment to the study (day 0)
Mechanical threshold measurements (kPa) for the ipsi-lateral leg 113
(n=70) and contra-lateral leg (n=70) in cases of mild and moderate
mastitis and for normal animals (n=45) on the day of recruitment
to the study (day 0)
Mechanical threshold difference (kPa) for mild (n=41) and 114
moderate (n=29) cases of clinical mastitis and normal animals
(n=45) on the day of recruitment to the study (day 0)
Mechanical threshold difference (kPa) for cases of clinical mastitis 114
in the front quarter (n=36) and in the back quarter (n=34) on the
day of recruitment to the study (day 0)
Mean mechanical threshold difference (kPa) ± SE for cases of 115
clinical mastitis treated with antibiotics only (n=21), antibiotics
and one dose of meloxicam (n=29), antibiotics and three doses of
meloxicam (n=20) and normal animals (n=19) over 45 days after
recruitment to the study
Mean mechanical threshold difference (kPa) for cases (mild, 116
moderate) of clinical mastitis treated with antibiotics only (n=13,
8), antibiotics and meloxicam (n=28, 21) and normal animals
(n=19, 19) over 45 days after recruitment to the study
Kaplan-Meier survival function for duration of alteration in 118
response to mechanical stimulation in mild and moderate cases of
clinical mastitis treated with antibiotics only (n=21) and antibiotics
and meloxicam (n=49)
Milk yield (litres) before the cow had clinical mastitis and for 12 119
days after clinical mastitis for cases treated with antibiotics only
(n=4), antibiotics and one dose of meloxicam (n=3), antibiotics and
three doses of meloxicam (n=3)
Microbiological isolates from 117 cases of clinical mastitis on the 135
day of recruitment to the study (day 0)
Pattern of microbiological isolates from cases that completed the 136
45 day study (n=70) and cases that did not complete the 45 day
study (n=47) on the day of recruitment to the study (day 0)
Pattern of microbiological isolates from mild (n=41) and moderate 136
(n=29) cases of clinical mastitis on the day of recruitment to the
study (day 0)
Log individual quarter somatic cell count (IQSCC) x 103cells/ml 140
for affected (n=69) and diagonally opposite quarters (n=70) from
cases of clinical mastitis and from the selected quarters of normal
animals (n=19) on the day of recruitment to the study (day 0)
Log individual quarter somatic cell count (lQSCC) x 10Jcells/rnl 142
for mild (n=41) and moderate (n=28) cases of clinical mastitis and
normal animals (n=19) on the day of recruitment to the study (day
0)
13
Figure 4.6: Log individual quarter somatic cell count (IQSCC) x 103.cellS/~1 143
for normal animals (n=19), affected quarters of cows WIth mild
(n=41) or moderate (n=28) clinical mastitis and from quarters
diagonally opposite (n=41 for mild and n=29 for moderate) those
with clinical mastitis on the day of recruitment to the study (day 0)
Figure 4.7: Median log individual quarter somatic cell count (IQSCC) x 144
103cells/ml ± Cl for affected (n=69) and diagonally opposite
(n=70) quarters for mild and moderate cases of clinical mastitis
and from selected quarters from normal animals (n=19) over 45
days after recruitment to the study
Figure 4.8: Median log individual quarter somatic cell count (IQSCC) x 145
103cells/ml ± Cl for mild and moderate cases of clinical mastitis in
antibiotics only (n=21), antibiotics and one dose of meloxicam
(n=28) and antibiotics and three doses of meloxicam (n=20)
treatment groups and diagonally opposite quarters (n=70) and from
selected quarters from normal animals (n=19) over 45 days after
recruitment to the study
Figure 4.9: Median log individual quarter somatic cell count (IQSCC) x 146
103cells/mi ± Cl for mild cases of clinical mastitis in antibiotics
only (n=13), antibiotics and one dose of meloxicam (n=16) and
antibiotics and three doses of meloxicam (n=12) treatment groups
and diagonally opposite quarters (n=41) and from selected quarters
from normal animals (n=19) over 45 days after recruitment to the
study
Figure 4.10: Median log individual quarter somatic cell count (IQSCC) x 147
103cells/ml ± Cl for moderate cases of clinical mastitis in
antibiotics only (n=8), antibiotics and one dose of meloxicam
(n=12) and antibiotics and three doses of meloxicam (n=8)
treatment groups and diagonally opposite quarters (n=29) and from
selected quarters from normal animals (n=19) over 45 days after
recruitment to the study
Figure 4.11: Fat percentages (%) in milk from affected quarters of cases of mild 152
(n=4l) or moderate (n=28) clinical mastitis, quarters from
diagonally opposite those with clinical mastitis and from normal
animals (n=19) over the 45 day study period
Figure 4.12: Mean fat percent for mild (n=4l) and moderate (n=28) cases of 152
clinical mastitis and normal animals (n=19) over the 45 day study
period
Figure 4.13: Protein percentages (%) in milk from affected quarters of cases of 153
mild (n=4l) or moderate (n=28) clinical mastitis, quarters from
diagonally opposite those with clinical mastitis and from normal
animals (n=19) over the 45 day study period
Figure 4.14: Mean protein percent ± SE for mild (n=4l) and moderate (n=28) 153
cases of clinical mastitis and normal animals (n=19) over the 45
day study period
Figure 4.15: Lactose percentages (%) in milk from affected quarters of cases of 155
mild (n=4l) or moderate (n=28) clinical mastitis, quarters from
diagonally opposite those with clinical mastitis and from normal
animals (n=19) over the 45 day study period
14
Figure 4.16: Mean lactose percent ± SE for mild (n=4l) and moderate (n=28) 155
cases of clinical mastitis and normal animals (n=19) over the 45
day study period
Figure 4.17: Polymorphonuclear neutrophils (PMNs) in a milk sample from 158
cow 189 with moderate clinical mastitis on the day of recruitment
to the study (day 0) at magnification x 400 and stained with May
Grunwald and Giemsa
Figure 4.18: Milk sample from cow 171 with moderate clinical mastitis on the 159
day of recruitment to the study (day 0) showing high cellularity
with mainly polymorphonuclear neutrophils (PMNs) but also
lymphocytes and macrophages with a background of red blood
cells at magnification x 400 and stained with May Grunwald and
Giemsa
Figure 4.19: Haptoglobin concentrations (Cube root) in milk from normal 162
animals (n=15), affected quarters of cases with mild (n=41) or
moderate (n=28) clinical mastitis and from quarters diagonally
opposite those with clinical mastitis (n=lO for mild and n=l l for
moderate) on the day of recruitment to the study (day 0)
Figure 4.20: Mammary-associated serum amyloid A (M-SAA) concentration 163
(Cube root) in milk from normal animals (n=IS), affected quarters
of cases with mild (n=4l) or moderate (n=28) clinical mastitis and
from quarters diagonally opposite those with clinical mastitis
(n=lO for mild and n=ll for moderate) on the day of recruitment
to the study (day 0)
Figure 4.21: Mean haptoglobin (Hp) concentration (Cube root) ± SE for mild 164
(n=4l) and moderate (n=28) cases of clinical mastitis and the
diagonally opposite quarters (n=2l) and normal animals (n=lS)
Figure 4.22: Mean haptoglobin (Hp) concentration (Cube root) ± SE for mild 166
cases of clinical mastitis in antibiotics only (n=13), antibiotics and
one dose of meloxicam (n=16) and antibiotics and three doses of
meloxicam (n=ll) treatment groups and the diagonally opposite
quarters (n=2l) and normal animals (n=lS)
Figure 4.23: Mean haptoglobin (Hp) concentration (Cube root) ± SE for 167
moderate cases of clinical mastitis in antibiotics only (n=8),
antibiotics and one dose of meloxicam (n=12) and antibiotics and
three doses of meloxicam (n=8) treatment groups and the
diagonally opposite quarters (n=2l) and normal animals (n=lS)
Figure 4.24: Mean mammary-associated serum amyloid A (M-SAA) 168
concentration (Cube root) ± SE for mild (n=4l) and moderate
(n=28) cases of clinical mastitis and the diagonally opposite
quarters (n=2l) and normal animals (n=lS)
Figure 4.25: Mean mammary-associated serum amyloid A (M-SAA) (Cube 169
root) ± SE for mild cases of clinical mastitis in antibiotics only
(n=13), antibiotics and one dose of meloxicam (n=16) and
antibiotics and three doses of meloxicam (n=ll) treatment groups
and the diagonally opposite quarters (n=2l) and normal animals
(n=lS)
Figure 4.26:
Figure 5.1:
Figure 5.2:
Figure 5.3:
Figure 5.4:
Figure 5.5:
Figure 5.6:
Figure 5.7:
Figure 5.8:
Figure 5.9:
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Mean mammary-associated serum amyloid A (M-SAA) 170
concentration (Cube root) ± SE for moderate cases of clinical
mastitis in antibiotics only (n=8), antibiotics and one dose of
meloxicam (n=12) and antibiotics and three doses of meloxicam
(n=8) treatment groups and the diagonally opposite quarters (n=21)
and normal animals (n=15)
Log prostaglandin E2 concentration for mild (n=41) and moderate 189
(n=28) cases of clinical mastitis on the day of recruitment to the
study (day 0)
Log prostaglandin E2 concentration ± SE for mild (n=41) and 190
moderate (n=28) cases of clinical mastitis on the day of
recruitment to the study (day 0) and the following two days (day 1
&2)
Log prostaglandin E2 concentration ± SE for mild and moderate 190
cases of clinical mastitis given antibiotics only (n=21) and
antibiotics plus meloxicam (n=48) on the day of recruitment to the
study (day 0) and the following two days (day 1 & 2)
Log prostaglandin E2 concentration ± SE for mild cases of clinical 192
mastitis given antibiotics only (n=13) and antibiotics plus
meloxicam (n=28) on the day of recruitment to the study (day 0)
and the following two days (day 1& 2)
Log prostaglandin E2 concentration ± SE for moderate cases of 193
clinical mastitis given antibiotics only (n=8) and antibiotics plus
meloxicam (n=20) on the day of recruitment to the study (day 0)
and the following two days (day 1& 2)
Log prostaglandin E2 concentration for clinical mastitis caused by 195
S uberis (n=19), E coli (n=15), no growth (NO) (n=18), Staph
aureus (n=9), S dysgalactiae (S dys) (n=3), A pyogenes «n=2) and
miscellaneous organisms (Mise) (n=3) on the day of recruitment to
the study (day 0)
Typical chromatogram of meloxicam concentrations in the milk 197
from the affected quarter of a cow (cow 14) treated with antibiotics
and three doses of meloxicam (group 3) and spiked with piroxicam
(0.5 ug/ml) from day of recruitment to the study (day 0), day 1,
day 2, day 3, day 6, day 7 and day 12 after recruitment
Mean meloxicam concentration ± SE for eight cases of clinical 199
mastitis that were treated with antibiotics and one dose of
meloxicam (group 2) followed for six days after recruitment to the
study
Mean meloxicam concentration ± SE for eight cases of clinical 200
mastitis that were treated with antibiotics and three doses of
meloxicam (group 3) followed for 12 days after recruitment to the
study
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Chapter 1
Introduction
1.1. Mastitis
Mastitis is inflammation of the mammary gland and is characterised by physical and
chemical changes in the milk, and an increased number of somatic cells, especially
leucocytes (Tolle 1975). Milk somatic cells consist of leucocytes and epithelial cells
(O'Rourke and Blowey 1992; Blowey and Edmondson 2000). Somatic cell counts (SCC)
provide a good estimate of the degree of inflammation present in the udder at the time of
sampling (Sears and others 1993; Logue 1997). Mastitis is a complex disease syndrome
and is a major disease problem for the dairy industry (Booth 1988; Sischo and others
1990; Bramley 1992; O'Rourke and Blowey 1992; Smith and Hogan 1996; Whitaker and
others 2000; Morin 2004; Whitaker and others 2004), causing significant economic
losses (Wilson and Kingwilll975; Esslemont and Peeler 1993; Hortet and Seegers 1998;
Ya1cin and others 1999; Kossaibati and Esslemont 2000). Economic losses associated
with mastitis are due to loss of production, the cost of treatment and prevention (De
Graves and Fetrow 1993; Reneau 1993; Radostits and others 2000), discarded milk, early
culling, drug costs, veterinary expenses, increased labour (De Graves and Fetrow 1993;
Reneau 1993) and reduced milk yields (Janzen 1970; Nickerson 1985). Clinical mastitis
increased the risk of culling (Erb and others 1985). The greatest loss caused by clinical
mastitis is in milk production; there is a reduction in milk yield and milk needs to be
discarded due to the use of antibiotics (Kossaibati and Esslemont 1995). Kossaibati and
Esslemont (2000) calculated that the total cost per affected cow per year, using the
market values in February 2000, for mild, severe and fatal cases of mastitis was £145,
£436 and £1,418, respectively. The variation in costs is affected by milk price and the
value of replacement heifers, where prices have fluctuated widely in the last few years.
Based on the proportions of mild, severe and fatal cases recorded in DAISY (the Dairy
Information System) monitoring, the authors calculated an average total cost of £176 per
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affected cow per year, and that clinical mastitis caused losses of £4,389 per year for an
average 100 cow herd using data from 2000 (Kossaibati and Esslemont 2000). These
figures are comparable to the costs of mastitis calculated by others. Esslemont and Peeler
(1993) reported an average cost of £187 per cow atTected by clinical mastitis, while
Yalcin and others (1999) in a study using multiple regression analysis of field data,
estimated the minimum total cost of mastitis as £65.50 per cow in the herd per year. In a
study by Bartlett and others (1991) using daily milk production data, temporal patterns of
milk loss as a consequence of clinical mastitis were followed. These authors reported that
cows that developed clinical mastitis sutTered an immediate drop in production and did
not regain production levels during the 60 days following clinical onset. Multiparous
cows lost approximately twice as much milk as first lactation cows, and cows with
mastitis occurring before 150 days in lactation lost 1.4 times as much milk compared
with other cows (Bartlett and others 1991). Hortet and others (1998) estimated that for an
average Holstein cow the milk losses as a result of clinical mastitis would be 4-6% of
lactational yield. with 40% of cases having negligible loss, 30% losing 150-250
kgllactation, and 30% losing 950-1,050 kgllactation. Using this data and according to the
current milk price. 18 pence per litre (Dairy Farmer July 2004). an average Holstein cow
producing 8,500 litresllactation could lose £61.20-£91.80 per lactation due to yield losses
as a consequence of clinical mastitis.
Mastitis has until recently been classified as either contagious mastitis or environmental
in origin (Rebhun 1995). Contagious mastitis was defined as being caused by organisms
that colonised the mammary gland and were spread by the milking procedure.
contaminated machinery (Tolle 1975; Cullor and Tyler 1996; Logan and Gillespie 1996),
the hands of milkers' (Tolle 1975; Fox and Gay 1993; Rebhun 1995; Cullor and Tyler
1996; Smith and Hogan 1996) and nursing calves (Cullor and Tyler 1996). The main
contagious pathogens were Staphylococcus aureus, Streptococcus agalactiae,
Streptococcus dysgalactiae and many Mycoplasma spp. (Bramley and Dodd 1984). In
contrast, environmental mastitis occurred due to opportunistic invasion of environmental
pathogens that gained entry to the udder when contamination of the cow's teats, udder or
milking machine occurred (Rebhun 1995). Gram-negative enterobacteriaceae and
environmental streptococci, i.e. coliforms and Streptococcus uberis were the primary
environmental pathogens (Bramley and others 1979). Coliforms included Escherichia
coli, Klebsiella pneumoniae, Klebsiella oxytocia. Enterobacter aerogenes, Citrobacter
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spp., Serratia spp. and Proteus spp. (Smith and others 1985). It is no longer considered
appropriate to class mastitis-causing organisms as contagious or environmental, due to
increasing evidence that Streptococcus uberis, which is an organism found ubiquitously
in the environment can also behave in a contagious manner (Peeler and others 2000;
Phuektes and others 2001; Zadoks and others 2001). Furthermore there is recently
documented evidence that E coli, which was historically classed as an environmental
organism that was quickly eliminated from the gland, can persist in the mammary gland
(Bradley and Green 2001).
Mastitis may also be classified as subclinical, where the mammary gland and milk appear
normal, or clinical, which is characterised by observable inflammatory changes in the
mammary gland, such as heat or swelling, alterations in the appearance of the milk
(philpot 1984; Sears and others 1993; Cullor and Tyler 1996) and systemic effects in
some cases.
Clinical mastitis can be further classified as peracute, acute, subacute or chronic (Tolle
1975; Radostits and others 1994; Cullor and Tyler 1996) and is often also defined as
mild, moderate or severe. Authors often use different grades to aid in the classification of
severity of clinical mastitis. Guterbock and others (1993) described mild mastitis as the
occurrence of abnormal milk, flakes or chunks in normal or watery milk, with or without
swelling of the affected quarter. Eckersall and others (2001) used a similar classification
system, cases were classed as mild when there was clots in milk and classed as moderate
when there was clots and observable inflammation in the infected quarter such as heat,
redness or swelling. Hogan and others (1989a) and Bradley and Green (2001) ascribed
numbers to the severity coding. Hogan and others (1989a) ascribed 3 to abnormal milk
with no apparent swelling of the quarter; 4 to normal or abnormal milk with swelling of
the quarter; 5 to abnormal milk with swelling of the quarter and systemic signs. Bradley
and Green (2001) used the following severity grades, grade 1 milk changes only (e.g.
clots); grade 2 milk and udder changes (e.g. swelling and/or heat); grade 3 systemic signs
(e.g. depression and/or pyrexia).
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1.1.1. Clinical mastitis
The European Union Health and Hygiene Directive 92/461EEC requires bulk milk to
have a total bacterial count (TBC) of < 100,000 bacteria/ml and SCC < 400,000 cells/ml.
In addition to reducing SCC, pressures to reduce the incidence of clinical cases of
mastitis, to produce milk free of antibiotics, other chemical residues and potential human
pathogens are increasing (Smith and Hogan 1993). There is very limited information on
the incidence of clinical mastitis at a national level. Studies in the 1980's estimated the
incidence of clinical mastitis to be 37 cases per 100 cows per year (Booth and Rowlands
1990). From DAISY recorded herds, the incidence for 1997 was given as 40 cases per
100 cows per year (Kossaibati and others 1998), while Booth (1997) estimated the
national incidence in 1997 to be 35-40 cases per 100 cows per year. Whitaker and others
(2000) used data collected as part of health assurance schemes to calculate the incidence
of important diseases in 340 dairy farms. They reported that clinical mastitis was
recorded in 36.6% of cows in the year of the study with the top quartile having clinical
mastitis in 13% of cows, and the bottom quartile having 70% of cows with clinical
mastitis. A later study by Whitaker and others (2004) calculated the overall incidence of
clinical mastitis on 244 dairy farms in 200112002 as 43.4 cases per 100 cows per year.
On six Somerset farms with three-month geometric mean bulk milk somatic cell count
(BMSCC) of < 250,000 cells/ml the mean annual incidence of mastitis was 41.6 cases
per 100 cows per year (Bradley and Green 2001). In a recent retrospective study of low
BMSCC herds, Peeler and others (2000) reported a mean incidence of clinical mastitis of
23 cases per 100 cows per year. In a study in Devon, where herds were not selected on
level of BMSCC, the mean number of cases was 17 cases/lOO cows/year in herds with a
median BMSCC of 142,000 cells/m! (Milne and others 2002).
The widespread application of control measures has been successful in reducing the
incidence of contagious mastitis but has had limited effect on environmental pathogens
(Dodd and Neave 1970; Bramley and Dodd 1984; Hill 1992). Thus, environmental
organisms have been reported increasingly as a cause of clinical mastitis in cattle
(Bramley 1984; Jayarao and others 1999; Leigh 1999).
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1.1.2. Subclinical mastitis
Subclinical mastitis occurs when the mammary gland is infected and the number of
leucocytes (somatic cells) is increased., but the milk appears to be grossly normal and
there is no clinically detectable sign of inflammation in the mammary gland (Sears and
others 1993; Cullor and Tyler 1996). Mastitis is most often subclinical (Radostits and
others 1994) and indeed subclinical mastitis was reported to account for 70% of all
infected quarters (Newbould 1984). Over time, repeated or persistent bouts of subclinical
mastitis may lead to fibrosis of mammary tissue producing firmer glands and a reduction
in milk production (Cullor and Tyler 1996). Contagious pathogens are more likely to
produce subclinical infections, and hence higher SCC, than environmental pathogens
(Eberhart and others 1982; Blowey and Edmondson 2000). This is due to the rapid
elimination of environmental organisms in cases of environmental mastitis, when high
SCC usually occurs only during the period of clinical mastitis (Blowey and Edmondson
2000). Chronically infected glands can however have a low SCC because of the cyclic
shedding of organisms (Sears and others 1993; Lawrence 1997). The main cause of high
BMSCC in Scottish dairy herds was subclinical infection with S agalactiae infection,
which was recorded in 83% of the herds sampled; the bacteriological examinations were
assessed from individual cow or quarter sampling (Logue 1997). Staphylococcus aureus
infection was reported as the most prevalent pathogen in herds where the BMSCC
remained above 400,000 cells/ml for at least one year after the first sampling (Logue
1997). The average reduction in milk output per quarter per lactation resulting from
subclinical mastitis has been reported to be 15-40% depending on the type, severity and
duration of infection (Hale and others 1956; Beck and others 1992).
1.1.3. Diagnostic tests
Diagnostic tests are used to identify the nature and extent of a mastitis problem in a dairy
herd andlor to identify an individual animal for segregation, treatment or culling
(Bramley 1992). Clinical mastitis is detected by the presence of abnormal milk. Clinical
signs alone are considered to be insufficient to differentiate between infections caused by
Gram-positive and Gram-negative bacteria with certainty (White 1987). but recent work
indicates that some clinical signs, e.g. demeanour of cow and milk yield changes, are
more likely to be associated with certain types of pathogens than others (Milne and
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others 2003). Optimal treatment of mastitis relies on the identifcation of the causal
organism and its antibiotic sensitivity (Waage and others 1994).
1.1.3.1. Bacteriology
In general, pathogenic microorganisms, usually bacteria (Wilson and Richards 1980;
Sandholm and others 1990; Watts 1990; Sears and others 1993; Cullor and Tyler 1996)
cause mastitis, although the organism may be undetectable by the time of examination
(Sears and others 1993). Bacteriological culture of milk samples is therefore useful to aid
in the identification of the cause of mastitis.
The prognosis and treatment of a cow with clinical mastitis depends on the causal agent,
with antibiotic selection often being different for Gram-positive and Gram-negative
organisms. Following concerns about antimicrobial resistance, the British Veterinary
Association (BVA) produced guidelines regarding good clinical practice, recommending
that narrow spectrum antimicrobials be used in preference to broad-spectrum
antimicrobials (Anon 2000). The need to rapidly instigate treatment prior to
bacteriological investigation, however, often results in the use of a broad-spectrum
treatment. The ability to differentiate between mastitis caused by Gram-negative agents
and mastitis caused by Gram-positive agents using clinical parameters would, therefore,
be beneficial, as it would allow more appropriate antimicrobial selection. In order to
diagnose mastitis accurately by culture techniques, milk samples need to be taken
carefully (Watts 1990). Poor sampling technique often leads to contamination of milk
samples and confusion over the significance of the organisms isolated (Buswell 1995). A
negative bacterial result will be obtained in 10-30% of clinical samples, which may be
due to the infection being controlled by natural defence mechanisms with rapid
elimination of the bacteria (Radostits and others 2000), continued activity of natural
inhibitors in the milk between sampling and CUlturing, the presence of non-viable
bacteria, or the presence of exogenous inhibitory substances. Zorah and others (1993)
showed that 51% of 84 samples that showed no growth on bacteriological culture were
identified as containing E coli antigen.
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1.1.3.2. Somatic cell counting
Intramammary infections are the most important factor influencing the concentration of
somatic cells in milk (Reneau 1986). Normal milk from uninfected dairy cows contains
approximately 200 x 103 cells/ml of milk for the majority of the lactation (Hillerton
1997). A healthy quarter can be considered as one that has a SCC <100,000 cells/ml and
is free of mastitis pathogens (Dohoo and Meek 1982; Harmon 1994; Hamann 1996).
Other factors influencing SCC include breed, age, stage of lactation and physiological
stresses such as excitement, high temperatures or trauma (Reichmuth 1975; Tolle 1975;
Philpot 1984; Rebhun 1995). A massive recruitment of additional leucocytes, mainly
neutrophils, is elicited into the gland in response to bacterial invasion of the udder (Ziv
1992). White blood cells enter the milk from the blood in response to inflammation and
epithelial cells are shed from the lining of the udder tissue (Philpot 1984; Nickerson
1985; Blowey and Edmondson 2000).
Somatic cell counting is a practical and effective method of evaluating a herds' mastitis
status and gives a good indication of the level of infection in a herd (Booth 1985; Dohoo
and Meek 1982; Sears and others 1993). Somatic cell counting can be done (i) at the
quarter level when individual milk samples are collected from each quarter Le. individual
quarter somatic cell count (IQSCC), or (ii) at the cow level, when a composite sample of
equal volumes of milk is collected from all quarters of the cow into one container i.e.
individual cow somatic cell count (ICSCC), or (iii) at the bulk tank level i.e. bulk milk
somatic cell count (BMSCC) (Jackson 1980; Newbould 1984; Sears and others 1993;
Biggs 1996). Somatic cell couting may help monitor response to treatment.
The SCC changes dramatically during the early stages of acute infection reaching a peak
within hours or days, depending on the challenge organism. An experimental study by
Sears and others (1990) reported a rapid increase in the IQSCC, which peaked, at the
approximately 2,000 xl03 cells/mI, by two to three days post-infusion. An ICSCC of200
- 5,000 x l 0
3
cells/ml can be seen in cases of clinical mastitis, the magnitude depending
on the severity of the infection and the type of organism (Cullen 1966). Clumps of
bacteria can interfere with the counting methods. A preservative, such as potassium
dichromate, is used to try to reduce further clumping of bacteria during transport to the
laboratory .
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1.1.3.3. Miscellaneous tests
Clinical mastitis is detected by the presence of abnormal milk; in-line filters, foremilk
stripping, udder palpation, and electronic sensors can be used to detect clinical disease
(Morresey 1999). Milner and others (1997) assessed the impact of electrical conductivity
detection of clinical mastitis compared to conventional diagnosis, such as the recognition
of clots in the milk. They found that the time required for sce to reduce to less than
400,000 cells/ml was significantly shorter, and that the bacteriological and clinical
response to treatment was more complete in cases detected by conductivity rather than
conventional means. The usefulness of the conductivity test was confirmed by studies
assessing the ability of automated detection systems to detect clinical mastitis. These
studies showed that the use of milk conductivity and milk yield in automated systems
were suitable methods to detect mastitis at a farm level (Mol and Ouweltjes 2000).
N-acetyl-(3-D-glucosarninidase (NAGase) is a cell-associated enzyme in milk and a high
level indicates cellular damage (Mattila and Sandholm 1985) and correlates with high
cell count (Ball and others 1989). The NAGase test is suited to rapid handling of large
numbers of samples, as it is an automated test and it can be performed on fresh milk with
the results available on the same day (Ball and others 1989). It is considered to be the
most accurate of the indirect tests, being equivalent to sec in predicting the infection
status of a quarter (Radostits and others 2000) and is related to both the presence and
types of pathogen, in addition to the sec (Kitchen and others 1984).
The ability to differentiate between Gram-positive and Gram-negative pathogens to
enable optimal, targeted therapy has been the focus of many new diagnostic tests. The
Limulus amebocyte lysate (LAL) cow side test to determine endotoxin was trialled by
Waage and others (1994) against standard laboratory bacteriology identification. These
researchers achieved a 93% agreement between the test and culture result, with the
positive predictive value (PPV) of the LAL test result being 70% and the negative
predictive value (NPV) being 95%. These results suggested that the LAL test might be a
valuable cow-side test to aid in the selection of initial anti-microbial therapy.
Yazdankhah and others (2001) described another cow-side test making use of selective
decolourisation of Gram-negative bacteria following the dilution, filtration and staining
of a milk sample from a mastitic quarter. This test had an overall specificity of 86%
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when compared to bacteriological culture. The HyMast test also claimed to differentiate
Gram-negative bacteria from Gram-positive bacteria. Jansen and others (1999) reported
that this test, which involved the incubation of milk, had reasonable sensitivity when read
after 36 hours but resulted in several false positives. The ColiMast test consists of a
selective growth medium in a vial that detects coliform organisms after inoculation with
milk and an incubation period of 12 hours by virtue of a colour change from blue to pink.
This test has a sensitivity of74% and specificity of78% (Leslie and Dingwe112002).
The acute phase proteins in milk show considerable potential for use as biological
markers of mastitis. Eckersall and others (2001) assessed the value of acute phase
proteins in the diagnosis of mastitis by comparing the concentrations in mild and
moderate mastitis with concentrations from quarters of healthy cows. The sensitivity,
specificity and accuracy of the haptoglobin test in milk for differentiating between
mastitic and normal cows were 86%, 100% and 93%, respectively; and for milk-
associated serum amyloid A they were 93%. 100% and 97%. respectively.
The California Mastitis Test (CMT) is an indirect method of estimating SCC and is based
on a gelling reaction between the nucleic acid of the somatic cells and an anionic surface-
active agent with bromocresol-violet as an indicator (Schalm and Noolander 1957).
Although it is not very sensivie or specific. the CMT is a practical and useful on-farm
test to identify individual cows and quarters with subclinical mastitis (Jaartsveld 1975).
1.1.4. Genetics and resistance to mastitis
Genetic variation associated with disease resistance in dairy cattle with direct relevance
to mastitis was reviewed as early as the 1950s (Legates and Grinnells 1952). Direct
selection of animals which may possess enhanced disease resistance with regard to
mastitis. is limited due to the lack of accurate and standard recording of clinical
incidence, mainly due to the difficulty and cost of collecting such information (Mrode
and others 1998). The heritability of clinical mastitis was estimated to vary from two to
eight percent (Emmanuel son and others 1988). Udder health, in the past, has been
overlooked in preference for improvement in production traits. A negative gentic
correlation between milk production and resistance to mastitis has been shown (Shook
1989), indicating that the incidence of mastitis will continue to increase if the selection
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criteria of improved production traits are maintained. There is, however, increasing
pressure to include mastitis resistance in breeding programs for diary cattle for welfare
and economic reasons.
1.2. Inflammation
Inflammation was recognised by Celsius around 35 A.D. as being characterised by
'redness, swelling, heat and pain', and in the 19th century, Virchow added 'loss of
function'. The complex set of reactions that follow injury, trauma or infection of a tissue
serve to prevent further tissue damage, isolate and destroy the infective organism and
activate repair processes to return the tissue to normal function (Higgins and Lees 1984;
Baumann and Gauldie 1994). At the site of injury, a number of responses by the tissue
itself and the vascular system involving platelets, clot formation, leakage and
inflammatory cells are elicited (Gruys and others 1994). This homeostatic process is
known as inflammation and the early and immediate sets of reaction are known as the
acute phase response (Baumann and Gauldie 1994). These responses in turn are
associated with the production of cytokines and other mediators, which activate receptors
on different target cells leading to a systemic reaction (Gruys and others 1994; Moshage
1997). The tissue macrophage or blood monocyte are most commonly associated with
the initiation of the acute phase response as they subsequently release inflammatory
mediators (Baumann and Gauldie 1994; Kushner 1982; Koj 1996).
1.2.1. Inflammatory mediators
Pathophysiological changes underlying acute and chronic inflammatory responses are
brought about by chemical mediators acting locally within tissues (Cunningham and Lees
1994). Many chemical mediators have been implicated in the acute inflammatory
response. To date, the inflammatory mediators identified in milk include bradykinin
(Eshraghi and others 1999), prostaglandins (PGs) (Anderson and others 1985).
leukotrienes (Rose and others 1989), histamine and serotonin (Schalm and others 1971),
complement components (Kehrli and others 1991), interleukins (ILs) (Shuster and others
1993; Daley and others 1991), tumour necrosis factor a (lNFa) (Babiuk and others
1991; Shuster and others 1993), interferon (Babiuk and others 1991) and leukotriene B4
(Babiuk and others 1991; Daley and others 1991; Kehrli and others 1991). In addition to
Maureen H. Milne Chapter 1, 33
acting on the tissues locally, circulating cells and the microcirculation, these mediators
interact with one another (Cunningham and Lees 1994).
The activation of the kinin-forming system is mediated via injury, trauma, infection and
immune complexes and once activated causes release of other powerful mediators, such
as PGs, histamine and cytokines (Eshraghi and others 1999). The kinins result in
vasodilation, increased vascular permeability, stimulation of ion transport and fluid
secretion, contraction of intestinal and uterine smooth muscle and sensitisation of pain
nerve endings. Eshraghi and others (1999) reported kinins, such as bradykinin, to be the
most potent mediators of pain and oedema in bovine clinical mastitis.
Prostaglandins are potent biological mediators derived from arachidonic acid and are
produced in many tissues where they induce a wide variety of responses (Xie and others
1992). The PGs are divided into subgroups using the letters A-J, and the presence and
number of double bonds in the alkyl side chains is denoted by a numerical subscript.
Vasodilator PGs enhance both pain inducing and permeability increasing activities of
other mediators (Moncada and others 1975). The production of PGs begins with the
liberation of arachidonic acid from membrane phospholipids by phospholipase A2 in
response to inflammatory stimuli, following which arachidonic acid is then converted to
PGH2 by cyclooxygenase enzymes, COX-l and COX-2 (Harris and others 2002). Cell
specific prostaglandin synthases convert PGH2 into series of PGs including PGh, PGF2a.,
PGD2 and PGE2.
Thromboxanes are also derived from arachidonic acid and cause vasoconstriction and
platelet aggregation. Thromboxane A2 (TXA2) is a highly unstable bicyclic compound
with strong biological effects while thromboxane B2 (TXB2) is its stable derivative
(Samuelsson 1983).
Cytokines are peptides released from inflammatory tissue, connective tissue and immune
system cells. There at least 50 known cytokines (Rang and others 1999) that have been
implicated in modulating immune responses (Babiuk and others 1991). Cytokines are
extremely potent and each one can exert multiple functions and they often act
synergistically. An example of the synergistic action is the induction of acute phase
proteins, such as serum amyloid A (SAA) and haptoglobin (Hp), by IL-6-like cytokines
Maureen H. Milne Chapter 1, 34
syngerising with IL-1-like cytokines (Moshage 1997). The cytokine superfamily includes
interleukins, chemokines, colony-stimulating factors, growth factors, interferons,
transforming growth factor and tumour necrosis families.
Studies comparing the inflammatory response following intramammary inoculation with
Aerobacter aerogenes in reversibly induced neutropaenic cows with normal cows,
demonstrated that the degree of inflammatory response was decreased in neutropaenic
cows. These animals had minimal changes in the swelling of the udder, reduced degree
of leukocyte infiltration to udder, normal appearance of milk, minimal changes in the
concentration of albumin in milk compared to non-neutropaenic cows (Jain and others
1968). These results indicate that neutrophils playa significant role in producing changes
in vascular permeability, which are necessary for the initiation of the inflammatory
reaction and the production of the cardinal signs of inflammation. Inoculation of
histamine into the bovine mammary gland produced an increase in vascular permeability
leading to oedema and hardening of the gland accompanied by an increase in serum
albumin concentrations, but not leukocytes numbers in the milk (Jain and others 1972).
Inoculation of serotonin produced slight oedema and marked tenderness of the gland and
inoculation of washed leukocytes, disrupted leukocytes and lyososomal preparations
from leukocytes all produced signs of acute inflammation; swelling and hardening of the
gland, increased concentrations of blood serum albumin in the milk and diapedesis of
neutrophil leukocytes from blood to milk (Jain and others 1972). The results of these
studies suggest that histamine and serotonin are mediators of inflammation, and
leukocyte products are more potent mediators of inflammation in the bovine mammary
gland.
In experimental studies, thromoxane and PGh concentrations were increased in equine
endotoxic shock (Bottoms and others 1982). Thomas and others (1997) demonstrated
increased concentrations of PGE2 in experimental models of bovine inflammation using
Mannnheimia (Pasteurella) haemolytica and S uberis-inoculated dialysis sacs. Endotoxin
was instilled into the teat of four cows at differing doses and resulted in increased
concentrations of PGF2a and 6-keto-PGFla but no increase in TXB2 or PGE2 (Giri and
others 1984). Atroshi and others (1987) reported that PGE2, PGF2a and TXB2
concentrations in samples from the affected quarter of cows with mastitis were
approximately 40%, 15% and 44% higher, respectively, than the concentrations of
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normal control cows. Anderson and others (1985) reported an increase PGF2a and TXB2
in bovine mastitis and that the increases in the concentrations corresponded to the clinical
severity of the mastitis. Bradykinin levels in the milk increase in bovine mastitis and
increasing levels were correlated with increasing severity of mastitis (Eshraghi and
others 1999).
1.2.2. Acute phase proteins
An acute phase protein (APP) has been defined as one whose plasma concentration
increases (positive APP) or decreases (negative APP) (Kushner and MacKiewicz 1987)
by at least 25% during inflammatory disorders (Kushner and others 1981). Negative APP
are pre-albumin (retinal binding protein and transthyretin), transferrin and albumin
(Gruys and others 1994). The positive APPs, including Hp, SAA, alpha-l-anti-trypsin,
ceruloplasmin and fibrinogen, are mainly glycoproteins released by hepatocytes upon
specific stimulation by cytokines, IL-6, IL-l and TNFa. that are produced by leucocytes
and macrophages during infection and inflammation (Bornstein 1982; Laurell 1985;
Marinkovic and others 1989; Gruys and others 1994; Eckersall and others 1999). As a
result of the total changes in blood protein composition during the acute phase response,
the plasma viscosity and erythrocyte sedimentation rate increases (Gruys and others
1994). The functions of APP include scavenging for haemoglobin, free radicals and cell
nests, binding bacterial components, activating complement and having a role in the
cholesterol distribution, and promotion of immunoglobulin production (Kushner and
others 1981). The serum profile of APP varies between species and depends on the type
of inflammatory stimulus (Eckersall and Conner 1998; Conner and others 1988;
Eckersall and others 1999).
In cattle, Hp, ceruloplasmin, o-I proteinase inhibitor, fibrinogen and u-I acid
glycoprotein have all been shown to increase during the acute phase response (Conner
and others 1986; Conner and others 1988; Conner and others 1989; Itoh and others 1990;
Skinner and others 1991; Morimatsu and others 1992; Motoi and others 1992). In cattle
the most useful acute phase proteins to distinguish healthy cows from those with
inflammatory diseases were Hp and SAA (Alsemgeest and others 1994; Horadagoda and
others 1999). Haptoglobin and 8AA are defined as major APPs, as their concentrations
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can increase 100-fold during an infection (Eckersall and others 2001) and have low or
undetectable concentrations in normal animals.
1.2.2.1. Haptoglobin
Haptoglobin is a macromolecular protein complex of>l,OOOkilodaltons (kD), consisting
of subunits of 16, 40 and 67 kD (Gruys and others 1993). Haptoglobin is an anti-oxidant
and stimulates angiogenesis, thus aiding in wound repair (Gabay and Kushner 1999).
Haptoglobin was detected in bovine plasma in the late 1950s (Liang 1957), but it was not
until the mid-1960s that it was discovered that healthy cows had low to zero
concentrations of plasma Hp (Bremner 1964). Bovine Hp has been identified in cattle
with a variety of inflammatory conditions; mastitis (Spooner and Miller 1971; Conner
and others 1986), liver abscesses and Corynebacterium spp. infected abscesses (Spooner
and Miller 1971), pyometra, traumatic reticulitis, traumatic pericarditis and abomasal
displacement (Panndorf and others 1976; Makimura and Suzuki 1982). It was previously
thought that haptoglobin was not stimulated by viral disease. Spooner and Miller (1971)
reported no increase in Hp concentrations in samples from cattle naturally infected with
the viral condition rinderpest, and Godson and other (1996) reported no increase in Hp
after experimental infection with bovine herpes virus. Heegaard and others (2000),
however, did report significantly increased Hp concentrations following experimental
infection of calves with bovine respiratory syncytial virus (BRSV). Haptoglobin
concentrations were reported to be normal in non-infectious conditions, such as milk
fever and ketosis, and in chronic endometritis, but were significantly increased in
infectious conditions (Skinner and others 1991). It should be noted that Hp cannot be
accurately measured in the presence of haemolysis, as haemoglobin binds to Hp and the
complex is then removed by the liver (Bremner 1964). Haptoglobin disappeared from the
blood when free haemoglobin was injected and was also absent during haemolytic crises
due to babesisois (Bremner 1964).
1.2.2.2. Serum Amyloid A
Serum amyloid A is a non-glycosylated 14kD apolipoprotein (Gruys and others 1993).
Serum amyloid A has been identified in cattle with a variety of inflammatory conditions;
mastitis (Gruys and others 1993; Horadagoda and others 1999; Eckersall and others
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2001; Nielsen and others 2004), abomasal ulceration, traumatic reticulitis, traumatic
pericarditis (Gruys and others 1993; Horadagoda and others 1999), mucosal disease,
pulmonary thromboembolism, meningitis and acute respiratory disease (Horadagoda and
others 1999) including BRSV (Heegaard and others 2000). Serum amyloid A
concentrations also increased following parturition (Alsemgeest and others 1993),
suggesting SAA concentrations increase in the presence of acute inflammation, whereas
Hp increase following infectious disease processes (Alsemgeest and others 1994; Gruys
and others 1994).
Serum amyloid A gene expression has been described at several extra-hepatic sites, and
several cell types have been found that can synthesise the protein (Vreugdenhill and
others 1999). This, together with recent identification of a unique isoform of the protein
in normal bovine colostrum (McDonald and others 2001), suggests that SAA might be
synthesised locally during episodes of mastitis. Indeed Eckersall and others (2001) and
Winter and others (2003) reported no correlation between serum and mammary-
associated SAA (M-SAA) in cows and sheep, respectively, with clinical mastitis. It was
proposed that M-SAA might prove to be more sensitive than bacteriological examination
and less influenced by the physiological state of the cow than either the sec or electrical
conductivity of the milk (Biggadike and others 2002) and thus may be valuable as a rapid
test for the presence of mastitis. A recent study, by Nielsen and others (2004), comparing
the levels of M-SAA in healthy cows, cows with clinical mastitis and cows with extra-
mammary inflammatory disease, such as interdigital phlegmon, purulent metritis and/or
periarthritis/bursitis, reported that M-SAA levels were within normal ranges in the group
with extra-mammary inflammation despite serum SAA being increased in 36% (4/11) of
cases. Thus intramammary stimulus is required for the concentration of M-SAA to
increase (Nielsen and others 2004).
1.2.2.3. Diagnostic value of acute phase proteins
Haematological examination has been perceived as the recommended diagnostic method
for assessing inflammation. Ruminants, however, rapidly develop neutrophilia and
lymphopaenia during severe, acute bacterial infection to give an increased white blood
cell count and thereafter the rate of destruction of neutrophils exceeds their rate of
production and there is a reduction in the white blood cells (WBC), despite a marked
Maureen H. Milne Chapter 1, 38
positive neutrophil response (Jain and others 1978; Skinner and Roberts 1994). Studies
comparing the use of haematological screening and the measurement of APP reported
that APP were more sensitive indicators of inflammation than haematological screening,
in dogs (SoIter and others 1991), in sheep (Skinner and Roberts 1994), and in cattle
(Horadagoda and others 1999). The APP concentrations remain increased in the
circulation for at least 24 hours and often for several days (HoI and others 1987).
Heegaard and others (2000) reported peak levels of SAA and Hp on day seven after
experimental infection with BRSV. Acute phase proteins are stable and can be measured
in previously frozen samples (Horadagoda and others 1999), whereas haematological
examination requires fresh blood samples.
Concentrations of APP have been used to differentiate between diseased and healthy
animals (Spooner and others 1971; Conner and others 1986; Skinner and others 1991;
SoIter and others 1991; Gruys and others 1993; Skinner and others 1994; Eckersall and
others 2001; Nielson and others 2004). The concentrations of APP can also provide an
indication of the severity of the inflammatory disease (Horadagoda and others 1999). An
experimental study by Conner and others (1988) used turpentine as a model for
inflammation and they demonstrated that Hp concentrations increased incrementally
when the amount of turpentine injected subcutaneously was increased; their results
suggest that Hp concentrations increase with increasing inflammation. Concentrations of
Hp correlated with severity of clinical signs in bovine respiratory cases (Godson and
others 1996). Sheldon and others (2001) reported that the concentrations of APP were
increased relative to severity of bacterial contamination of uterus post-calving. The
concentrations of APP in serum and milk correlated with the severity of clinical signs of
mastitis (Eckersall and others 2001) and with an increase in CMT score (Nielsen and
others 2004).
In cattle, SAA is reported to be the more sensitive indicator of inflammation but Hp is
the more specific indicator. Eckersall and others (2001) reported the sensitivity,
specificity and accuracy of Hp in milk for differentiating between mastitic and normal
cows were 86%, 100% and 93%, respectively; and for SAA they were 93%, 100% and
97%. Gruys and others (1993) reported sensitivities and specificities for Hp and SAA in
distinguishing between cattle with diseases, such as abomasal ulceration, mastitis,
endocarditis, peritonitis, and normal animals of 80% and 100% and 100% and 50%,
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respectively. The ratio of Hp/SAA in the blood could aid in distinguishing between acute
and chronic inflammation, as SAA is an indicator of more acute inflammation and Hp of
more chronic inflammation (Alsemgeest and others 1994), a higher ratio indicates
chronicity.
In addition to differentiating between healthy and diseased animals, APP can be used to
monitor disease progression and thus act as a prognostic aid. In humans, APPs are used
to monitor the progression of disease in patients with chronic illness and used to
differentiate between types of disease, e.g. rheumatoid arthritis can be differentiated from
osteoarthritis using APP profiles (Kushner and MacKiewicz 1987).
1.3. Assessment of pain
The Farm Animal Welfare Council (FAWC), the independent advisory body established
by the British Government in 1979, has provided a framework to define ideal states that
are applicable to all animal production systems termed the 'Five Freedoms'. The third
freedom states "Freedom from pain, injury or disease". Pain assessment in animals and
man is inherently difficult, and it has been recognised from work in the human field that
pain refers to an endless variety of qualities that are categorised under a single linguistic
label and not a specific sensation that varies only in intensity (Melzack and Torgerson
1971; Melzack 1975). Beecher (1975) reviewed the literature from over 106 years of
experimental work and concluded that pain could not satisfactorily be defined, and that
the pain threshold could not be demonstrated as being constant from subject to subject or
from one time to another in the same subject. He concluded that many factors, such as
sex, age, anxiety and fear, circulatory change, distraction, inattention, lethargy, and
training in the protocol (human) produced variations in pain thresholds.
Nociceptors are specialised sensory receptors that are activated by high intensity noxious
insults to peripheral tissues and pain is mediated by physiological pathways, however,
nociception does not necessarily lead to the experience of pain (Kandel and others 2002).
Instead the perception of pain is the product of the brain's abstraction and elaboration of
sensory input, thus pain is highly individual and subjective making it difficult to define
and treat clinically (Kandel and others 2002). Beecher (1975) suggested that in animals,
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neonates and non-communicative humans it might be the reaction to pain we are
assessing, whereas in communicative man it is the perception of pain.
Pain has been defined by the International Association for the Study of Pain (IASP) as
'an unpleasant sensory and emotional experience associated with actual or potential
tissue damage or described in terms of such damage' (Merskey and others 1979).
Building on this Molony (1997) described animal pain as 'an aversive sensory and
emotional experience representing an awareness by the animal of damage or threat to the
integrity of its tissues; it changes the animal's physiology and behaviour to reduce or
avoid the damage, to reduce the likelihood of recurrence and to promote recovery; non-
functional pain occurs when the intensity or duration of the experience is not appropriate
for the damage sustained and when physiological and behavioural responses are
unsuccessful in alleviating it'. Kitchell (1987) had previously suggested that the
protective motor actions can lead to learned avoidance, and may modify species-specific
traits of behaviour, including social behaviour. Species-specific guidelines for the
assessment of pain were suggested by a working party for the Association of Veterinary
Teachers and Research Workers to be used in the regulation of animal experiments
(Sanford and others 1986). The judgement of the severity of pain was based on the
recognition and assessment of a wide range of parameters by trained and experienced
observers (Sanford and others 1986). They suggested that cattle in pain often appear dull
and depressed with little interest in the surroundings, can be inappetant with subsequent
weight loss and in milking cows, a sudden drop in milk yield. In severe pain, they noted
that rapid shallow respirations were observed and that on handling cattle may react
violently or adopt a rigid posture possibly designed to immobilise the painful region. The
rigid posture might lead to a lack of grooming due to unwillingness to turn the neck.
Grunting and grinding of the teeth may be heard and in abdominal pain cattle may look
at, bite or kick abdomen, get up and lie down frequently, walk in circles, or roll.
In assessing pain physiological parameters, such as heart rate, respiratory rate, blood
pressure, sweating, piloerection, gut motility, have been suggested as useful indicators,
however, they should not be used alone, as they have been reported to be inaccurate due
to the interaction with other variables, e.g. drug administration (Carroll 1996; Holton and
others 1998a; Livingston and Chambers 2000). Endocrine changes and the release of
hormones are again unreliable indicators of pain when used alone, but are often used in
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combination with other parameters in animal studies (Livingston and Chambers 2000). In
a study assessing post-operative pain in horses some correlation between pain scores and
J3-endorphin concentration was found, but not during the immediate post-operative
period (Raekallio and others 1997). Any change in the behaviour or temperament from
the animal's normal state may be important (Morton and Griffiths 1985; Haskins 1987),
and this has historically been the basis for the pain scoring systems.
1.3.1. Pain classification
Pain can be divided into two distinct and qualitatively different categories. The simplest
form is physiological pain, which represents the transient response of the system to
potentially damaging noxious stimuli but is not associated with extensive inflammatory
response or damage to the nervous system (Woolf 1989). Pathological pain, or clinical
pain, is the sensation that arises as a result of either the inflammatory response that is
associated with severe injury, or damage to the nervous system (Woolf 1989).
Physiological pain can be induced by mechanical, thermal or chemical stimulation and
clearly defined thresholds can be established experimentally at which the sensation stops
being one of pressure, hot or cold and becomes painful (LaMotte and others 1983).
Pathological pain differs from physiological pain in that there is no measurable threshold
at which stimulation will induce pain, as pathological pain can occur in the absence of an
apparent stimulus. In response to the mildest stimulation, the sensation can be excessive
or more prolonged than would be expected the response for the nature of the stimulation
(Woolf 1989). Physiological pain is a sensation that reflects certain specific types of
peripheral stimuli, whilst pathological pain is a sensation that is a consequence of
changes within the nervous system that result in an alteration in the way information
from the periphery is handled (Woolf 1989). Pathological pain can be subdivided into
inflammatory pain and neuropathic pain. Theories have evolved to suggest that
inflammatory pain retains some resemblance to physiological pain in that it has a
protective role e.g. tenderness helps avoid further damage whilst the injured area heals
(Woolf 1989), whereas neuropathic pain represents the pathological product of a
disturbed nervous system (Woolf 1989). In inflammatory reactions there are (1)
peripheral sensitisation of primary afferents, (2) central sensitisation of dorsal horn
neurones and (3) abnormal properties in the central circuits of the central nervous system
(CNS). In neuropathic pain there are (1) central sensitisation of dorsal horn neurones, (2)
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abnormal properties of the central circuits in the eNS and (3) permanent changes in the
nervous system (Woolf 1989).
1.3.2. Pathophysiology of pain
The specificity and gate-control theories were considered to be the basis for pain
transmission (Jones 1992). Descartes devised the concept of the specificity theory in
1664; he described nerves as tubes composed of large numbers of fine threads that
connect the brain with end organs in the skin and in other tissues. This theory was
developed, by use of experimental work stimulating localised points and histological
examination of skin sections, to find that each area is associated with a specific sensory
end organ and that pain is a distinct sensation in itself with its own sensory apparatus.
The gate-control theory was proposed by Melzack and Wall in 1965 and attempted to
explain mechanisms by which cutaneous and cognitive factors can modulate pain
transmission. It was hypothesized that in the superficial laminae of the dorsal horn of the
spinal cord, the afferent input was modulated by neuronal activity in large and small
afferent fibres before being conveyed to transmission neurons located in the deep dorsal
horn laminae (Melzack and Wall 1965). The aspect of the gating system is not clear, as
not all neurons in the superficial laminae receive input from both small and large fibres.
The current theory of pain (Jones 1992) is that pain is considered to be an afferent
sensory experience with the transmission of pain information being modulated by
afferent input from the periphery, descending inhibitory systems and cognitive and
emotional factors. Pain perception reflects activation of the nociceptors (either direct
noxious stimulation or by mediators released from injured tissue), afferent transmission
to the spinal cord, and relay via dorsal horn to higher centres (Jones 1992; Yaksh 1999).
Pain perception can be divided into two major components; the sensory discriminative
component, which describes the location and quality of the stimulus and is transmitted
via the myelinated fibres and relayed to the higher centres, which activates the motor
component to result in the withdrawal from the noxious stimulus and the tonic input to
the system from higher levels of the central nervous system (eNS) exerts inhibitory
effects on the sensory input. The classic injury response was termed the 'triple response'
and is characterised by increased blood flow, tissue oedema and sensitisation of
nociceptors (Lewis 1936). Most inflammatory processes lead to the development of
hyperalgesia (Lewis 1936; LaMotte and others 1982; Nolan and others 1987; Ley and
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others 1989; Chambers and others 1990; Coderre and others 1993; Whay and others
1996; Fitzpatrick and others 1998; Lascelles and others 1998; Yaksh 1999). Hyperalgesia
defines the altered state of sensibility in which the intensity of pain sensation induced by
noxious stimulation is greatly increased (Merskey and others 1979; LaMotte and others
1982; Raja and others 1984; Raja and others 1988). Two classes of hyperalgesia have
been defined; primary hyperalgesia, which is the enhanced sensitivity at the injury site
and occurs within minutes of the injury, and secondary hyperalgesia, which refers to
changes in the non-traumatised regions surrounding the injured tissue and has a delayed
onset (Lewis 1936). Secondary hyperalgesia involves both peripheral sensitisation and
changes in the CNS (Hardy and others 1950; Woolf 1983; Woolf 1989). The changes in
the CNS (central sensitisation) are considered to arise from inputs from the periphery
overwhelming the inhibitory mechanisms and triggering long lasting changes in the
dorsal receptive fields, which may outlast the changes observed peripherally (Woolf
1983; Coderre and Melzack 1987; Cook and others 1987; Woolf 1989; Yaksh 1999).
Clinical manifestations of central sensitisation include increased pain intensity, allodynia,
prolonged facilitation of ipsi-lateral and contra-lateral flexion reflexes and alteration in
regional sympathetic tone (Woolf 1989). Allodynia refers to the state where ordinarily
non-noxious stimulation (pressure, light touch) is perceived as being exquisitely painful
(Merskey and others 1979; Raja and others 1988) and is a feature of some clinical pain
states, e.g. trigeminal neuralgia. Hypoalgesia is the state of having reduced sensivity to
noxious stimulation (Merskey and others 1979). Dairy cows subjected to acute stressors,
which involved alterations in their housing environment, displayed hypoalgesia towards
nociceptive laser stimulation (Herskin and others 2004).
1.3.2.1. Innervation to the udder
There is a diffuse arrangement of innervation to the udder, with multiple innervations
from lumbar and sacral spinal nerves. The skin covering the udder is supplied from three
directions. The ventral branches of the first and second lumbar nerves pass
caudoventrally to supply the cranial parts of the forequarters; the genitofemoral nerve
(comprising branches from second, third and fourth lumbar spinal nerves) passes
throught the inguinal canal and sends superficical branches to the skin over the middle
section of the udder; the mammary brances of the pudendal nerve descend through the
perineum to supply the skin over the caudal aspect of the hindquarters (Dyce and others
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1987). The gland substance and the deeper parts of the teat walls are served byt the
genitofemoral nerve only (Dyce and others 1987).
1.3.3. Measurement of pain
Reflexive behaviours are useful for certain pharmacological tests, but they have serious
limitations as methods of quantifying animal pain, as changes in reflex activity can result
from alterations in motor as well as sensory processing (Chapman and others 1985).
Combinations of behaviour and physiological measures are generally more
comprehensive than either alone (Sanford and others 1986). Pain scoring systems have
been used in the medical field since the 1920's (Freyd 1923). Scoring systems include
the simple descriptive scale (SDS) (Huskisson 1974; Taylor and Houlton 1983;
Waterman and Kalthum 1986; Holton and others 1998b), visual analogue scale (VAS)
(Huskisson 1974; Reid and Nolan 1991; Nolan and Reid 1993; Welsh and others 1993;
Holton and others 1998b) and the numerical rating scale (NRS) (Taylor and Houlton
1983; Taylor and Herrtage 1986; Welsh and others 1993; Holton and others 1998b) and
have been reviewed by Dobromylskyj and others (2000). Keele originally described the
SDS in 1948. The simple descriptive scale is a categorical scale comprising four or five
expressions used to describe various levels of pain intensity (no pain, mild pain,
moderate pain and severe pain) (Keele 1948). Each expression is assigned an index
value, which becomes the pain score for the animal. The visual analogue scale (VAS)
consists of a 100mm line anchored at one end 'no pain' and at the other end 'worst pain
imaginable'. The clinician assessing the patient places a mark on the line to indicate the
amount of pain they believe the patient to be suffering. The distance in mm from the 'no
pain' end of the line to the mark is the pain score (Freyd 1923; Welsh and others 1993).
The numerical rating scale (NRS) is similar but the observer assigns a numerical score
for the pain intensity (Ley and others 1989; Welsh and others 1993) rather than placing a
mark on the line, typically a scale from zero is used. In animals the most commonly used
methods to assess pain rely on SUbjectiveobservation of animal's behaviour and the use
of SDS, VAS or NRS systems. Holton and others (l998a) investigated the association
between physiological parameters, heart rate, respiratory rate and pupil dilation, and a
subjective pain score using the NRS in groups of dogs which had undergone orthopaedic
surgery, undergone soft tissue surgery, had non-painful medical conditions or were
medically normal. They found that none of these variables were likely to be useful
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indicators of pain in hospitalised dogs. Welsh and others (1993) used the VAS and NRS
when assessing lameness in sheep and found good agreement between the two different
systems and between two observers, but the VAS was more sensitive. Holton and others
(I998b) compared the SDS, VAS and NRS as means of assessing pain in dogs post-
operatively and found that while there was significant inter-observer variation, agreement
amongst the different methods was reasonable. They suggested that the NRS system
provided a suitable compromise between the over interpretation that can be a feature of
the VAS and the lack of sensitivity that can be associated with the SDS. Morton and
Griffiths (1985) suggested the use of a scoring system using a combination of
appearance, appetite and water intake, behaviour, clinical signs and behavioural response
to external stimuli to assess the presence of pain in animals. A similar approach was
taken by Holton and others (2001) who constructed a composite scale based on
observations of behaviour and the use of words and expressions similar to the approach
described by Melzack (1975) for quantification of pain in humans. Words and
expressions were allocated into seven behavioural categories (demeanour and response to
people, posture, mobility, activity, response to touch, attention to painful area and
vocalisation) to produce, in the authors' opinion, a more detailed scale than previously
reported scales for assessing pain in dogs. In some instances animals, particularly prey
animals may have evolved ways of disguising responses to pain or suppressing both
nociception and pain, and this can confound pain assessment (Rutherford 2002), leading
to requirement for a more qualitative assessment of pain.
1.3.3. Pain threshold testing
The phenomenon of hyperalgesia accompanying tissue and/or nerve damage has led to
the use of pain threshold measurements in an attempt to quantify pain in various disease
conditions. Pain threshold testing is the induction of physiological pain, with the level of
response in normal animals compared to that In animals with tissue
damage/inflammation. Various stimuli, including thermal, electrical, mechanical and
chemical. can be used in pain threshold measurements (Beecher 1975). The skin with its
greater accessibility of receptor organs is used more commonly than the viscera in
experimental studies of pain (Beecher 1975). Threshold response testing using thermal
stimulation involves the application of a heat stimulus, which could be direct contact
applied to the skin by hot or cold objects or by radiant heat using projection lamps or
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conducted heat using hot plate methods (Beecher 1975). An example of thermal
stimulation from conducted heat was used in the studies by Nolan and others (1987) and
Robertson and others (2003). Nolan and others (1987) used a resistor housed in a fine
copper tube which was attached to the pinna of the ear in sheep to produce a clear
flicking motion when the pain threshold was reached and Robertson and others (2003)
used a heater element attached to the thorax of cats with twitching, flinching, turning to
bite the stimulus and jumping forward indicating the pain threshold. Methods of
mechanical stimulation includes the von Frey technique of producing pain by bending the
epithelium, applying gross pressure to areas of the body, applying tourniquets to induce
muscle ischaemia and causing distension of viscera by inflation of a balloon (Beecher
1975). An example of threshold response testing using gross pressure as the mechanical
stimulation has been described by Nolan and others (1987) and Chambers and others
(1990). Briefly, it involves a gas-driven moveable blunt-ended pin applying pressure to
the limb and once the pain threshold is reached the response is the lifting of the limb or
shifting of weight from that limb.
For a method to be useful in the assessment of pain and monitoring of analgesics the
technique used must be reproducible and reliable with clear identification of the pain
threshold and no damage to the tissue integrity. It might be expected that the responses to
thermal stimulation may vary with the ambient temperature. The subject must be
accustomed to application of the device to deliver the thermal stimulation to avoid
pressure and touch affecting the threshold results. In both mechanical and thermal
stimulation adaptation to the stimulation may be a problem, therefore sufficient time
must be allowed between repeat measurements to allow the tissue to return to the state it
was prior to the stimulation.
Hyperalgesia has been documented in many species with inflammatory disease (Nolan
and others 1987; Ley and others 1989; Chambers and others 1990; Whay and others
1996; Fitzpatrick and others 1998; Lascelles and others 1998). A study assessing footrot
in sheep measured the thermal and mechanical thresholds in the presence of the lesion
after temporary alleviation of pain using local anaesthesia and following resolution of the
lesion and compared the results to normal healthy sheep (Ley and others 1989). There
was no significant difference in the thermal mechanical threshold between the normal
sheep and the sheep with footrot at any of the time points. The sheep with footrot had a
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significantly lower mechanical threshold response (mean 2.5Newtons (N) SE±0.6 low
severity footrot and mean 2.7N SE±O.4 high severity footrot) than normal sheep (mean
4.4N SE±0.2). The application of the local anaesthetic resulted in the mechanical
threshold of the sheep with footrot rising to levels that were not significantly different to
the control sheep. Approximately three weeks after treatment and apparent resolution of
the lesions the sheep with high severity footrot still had significantly lower mechanical
threshold (mean 2.8N SE±0.3) than normal sheep. A larger study monitoring the pain
thresholds in lame sheep compared to sound sheep used the mean threshold values on a
flock basis and subtracted the measurements obtained from the lame sheep from the
measurements from the sound sheep on the same flock to give a difference in threshold
(Ley and others 1995). They found that 44% (12/27) of the flocks had a significant
difference between the thresholds of sound sheep and lame sheep (mean difference 2.0N
SE±O.4). In cattle, Ley and others (1996) reported significantly lower thresholds on the
lame limb (mean 5.84N SE±0.3) compared to the thresholds of normal (mean 6.82N
SE±O.l) cows. However, they found no correlation with qualitative severity using
lameness scoring. A study by Welsh and Nolan (1995) monitored the effects of
abdominal surgery on the response to thermal and mechanical stimulation in sheep every
30 minutes for a two hour period. They showed that thermal but not mechanical
hyperalgesia was induced. These studies suggest that central changes in the processing of
noxious information may not be detected by mechanical stimulation in the same time
course as thermal stimulation. A group of heifers were monitored for a four month
period, which spanned parturition, to assess the occurrence of lameness and monitor the
pain threshold measurements (Whay and others 1997). These authors reported a
significant decrease in pain threshold as the lameness severity increased, as judged by a
NRS, indicating increased sensitisation to noxious stimulus with increasing severity of
lameness The mean pain threshold for sound heifers was approximately 12N and for
severely lame heifers 8N. A case-control study on pain induced by lameness in dairy
cattle assessed using the response to noxious mechanical stimulation, found a significant
reduction in the pain threshold on lame limb (mean 7.9N SE±O.3) compared to control
cows (mean 13.3N SE±0.3), however, in cows that were bilaterally lame the pain
threshold was only slightly decreased (mean 11.3N SE±0.8) (Whay and others 1998).
The unilaterally lame cows were re-examined one month later and the pain threshold was
still significantly reduced in cows with solar ulcers (mean 8.8N SE±0.5) and white line
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disease (mean 9.7N SE±0.5) but not in cows with acute digital tissue infection, which
included 'foul-in-the-foot' and digital dermatitis (mean 12.7N SE±0.6) compared to
normal cows (mean 13.3N SE±0.3) assessed on day of recruitment to the study (Whay
and others 1998), indicating that the persistence of hyperalgesia differed between lesion
type.
Pain threshold measurements can be used to assess the efficacy of analgesics (Ley and
others 1989; Chambers and others 1990; Welsh and Nolan 1994; Lascelles and others
1998). Mean mechanical thresholds for sheep with mild and severe footrot were
increased from 2.5N (SE±0.6) and 2.7N (SE±OA) to 4.0N 9SE±1.0) and 3.6N (SE±0.5),
respectively, following administration of a local anaesthetic block and local infiltration
above the affected foot and below the mechanical testing device using 0.25%
bupivacaine HCI (Ley and others 1989). Welsh and Nolan (1994) conducted a study
involving the application of a tourniquet to induce localised ischaemia in sheep to allow
the investigation of the efficacy of analgesic drugs. Noxious mechanical stimulation was
used to assess the presence of pain. It was found that the application of the tourniquet
decreased the pain thresholds on the ipsilateral leg (mean 1.7N SE±O.3) but not on the
contra-lateral leg (mean 3.lN SE±O.3), thereby indicating that the mechanical
hyperalgesia observed was a local peripheral effect. They reported that intravenous
administration of flunixin meglumine, at 1.0 mg/kg, and carprofen, at 0.7 mg/kg had a
beneficial pain relieving affect, in that the administration of these drugs lessened the
degree of reduction in pain thresholds brought about by the application of the tourniquet.
Lascelles and others (1998) used combination of a VAS scoring system and mechanical
pain threshold testing to assess the efficacy of the non-steroidal anti-inflammatory drug
(NSAID), carprofen, in bitches undergoing elective ovariohysterectomy. They reported
that both pre- and post-operative carprofen administration significantly reduced the
degree of pain exhibited, however, pre-operative carprofen had greater analgesic
properties in the early post-operative period compared to post-operative carprofen.
1.4. Pathogenesis of clinical mastitis
The primary defence mechanism of the mammary gland is the teat canal, as this
represents the portal of entry for nearly all mastitis-causing micro-organisms (Bramley
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and Dodd 1984; Craven and Williams 1985; Nickerson 1985; Sandholm and others 1990;
Bramley 1992; Vestweber and Leipold 1993). Injury to the teat end and teat canal almost
always leads to intramammary infection (Benedixen 1935; Ferguson 1944; Smith and
Hogan 1996). The development of intramammary infections occurs by the contamination
of the teat end with pathogenic organisms (Tolle 1975; Bramley and Dodd 1984),
followed by penetration into the teat canal and the colonisation by the organisms in the
sinuses, ducts or alveolar tissue (Kingwill 1980; Bramley and Dodd 1984). Any infection
gaining access to the gland must remain adherent to the inner surfaces, despite the out-
flow of milk, and escape the action of the defence mechanisms (Reichmuth 1975). The
division of the udder into four independent quarters helps to restrict the spread of
infection (Reichmuth 1975). The transfer of some pathogens between quarters, however,
is inevitable at milking time, even under the best hygienic conditions (Philpot 1975).
Most infections which occur in the dry period develop in the first two or three weeks
after drying off and are thought to be due to pathogens remaining in the udder from the
lactation (Philpot 1975).
1.5. Treatment of clinical mastitis
Elimination of infection from infected quarters within a herd can be achieved by (1) the
defence mechanisms of the udder eliminating the pathogen Le. spontaneous cure, (2) by
treatment during lactation, (3) by treatment during the dry period, or (4) by culling
infected animals (Bramley and Dodd 1984). Spontaneous recoveries often equal the
number of infections eliminated by antibiotic therapy in lactating cows (Griffin and
others 1982), but spontaneous recoveries often take longer Le. there may be a prolonged
period of infection before recovery occurs (Bramley and Dodd 1984). The proportion of
spontaneous elimination is low for staphylococcal infections at < 20%, high for E coli at
> 70%, and intermediate for streptococcal infections 40-60% (Bramley 1992). Treatment
of mastitis is carried out for many reasons: (1) to treat clinical infections in order to
regain normal milk secretion. (2) prevent progression of the disease, (3) improve the
welfare of the cow, (4) eliminate clinical or subclinical infections, or at least reduce their
number and frequency, so that the milk yield from the herd is improved, (5) prevent the
spread of infection, by eliminating the main source of bacteria, in the case of infectious
organisms. (6) prevent development of infection in an animal or herd exposed to a
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particular or temporary risk, and (7) avoid penalties imposed by milk purchasers for milk
with high sec (plommet and le Louedec 1975; Blowey and Edmondson 2000).
1.5.1. Antimicrobials
Antimicrobials have been used in the treatment of mastitis for over 50 years. Mastitis is
now the most frequent reason for the use of antimicrobials in dairy herds (Meek and
others 1986; Gardner and others 1990; Grave and others 1999). With intramammary
treatment, the antimicrobial drug tends to remain within the treated quarter, but some will
diffuse into the blood, circulate systemically and diffuse into untreated quarters,
therefore, milk from all quarters should be withheld from the bulk tank for the prescribed
withdrawal period for that particular preparation (Blowey and Edmondson 2000). The
extent of drug crossing into the circulation will depend on the physico-chemical
properties of the drug and the degree of inflammation.
The therapeutic success of antimicrobial therapy in mastitis depends on; (1) the
sensitivity of the organism and its' ability to evade the effects of the antimicrobial, (2)
the concentration and persistence of the drug in the environment of the pathogen, and (3)
the contribution made to exclusion of the organism by the host immunity, which may be
influenced by concurrent therapy, disease or age (McKellar 1996). Treatment efficacies
for intramammary infections during lactation reported by Smith and Hogan (1996) were:
80-90% for S agalactiae, 50-60% for coagulase negative staphylococcal infections, 50%
for environmental streptococcal infections, 30-50% for Staph aureus, < 10% for Gram-
negative infections and no response was seen in infections caused by yeasts, moulds,
Mycoplasma spp. and Prototheca spp., using the antimicrobials benzathine penicillin and
cephalosporins. Similar cure rates were recorded by Huber (1977) using a benzathine
penicillin, novobiocin and penicillin product or a spiramycin product: 100% for S
dysgalactiae, 98% for S agalactiae, 82% for S uberis and only 35% for Staph aureus.
Antimicrobial therapy is more effective in the dry period than during lactation, and is
more effective after the first clinical episode than after further repeated episodes of
infection, i.e. younger cows respond better than older cows (Sandholm and others 1990;
Meaney 1992; Lawrence 1997). The intramammary route is a practical, inexpensive and
convenient route for the treatment of bovine mastitis (McKellar 1991; Vestweber 1993).
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In acute severe disease, however, the distribution of intramammary antibiotics may be
impaired by inflammation within the udder (Sandholm and others 1990; Prescott and
Baggot 1993) and the presence of systemic signs due to bacteraemia may, therefore,
necesitate parenteral antibiotics. A study by Wenz and others (2001) reported that 32%
(46/144) of cows with naturally occurring acute coliform mastitis were bacteraemic,
assessed by the identification of bacteria in blood. The choice of antibiotic will depend
on the in vitro sensitivity of the organism, and it should be remembered that the
sensitivity may change over a period of time, especially following intensive antibiotic
usage, and also on different farms (Owens and Watts 1988; McKellar 1991). The
antibiotic for mastitis therapy should be chosen after considering the activity,
pharmacodynamics and pharmocokinetics of the drug, the probable cause of mastitis, the
milk withdrawal period (McKellar 1991) and finally after all other considerations, the
cost, though the cost of discarded milk may be more significant than the cost of the
antimicrobial drug (Prescott and Baggot 1993).
Penicillin G is probably the most effective antibiotic against penicillin-sensitive
organisms and where Streptococcus spp, Arcanobacterium pyogenes or sensitive Staph
aureus are the aetiological agents (McKellar 1991). Penethamate is a basic ester of
penicillin G that has similar but enhanced physicochemical characteristics and therefore
has similar overall activity to penicillin G. Penicillin is less effective against many Staph
aureus strains due to the production of ~-lactamase which renders the organism resistant
to penicillin (Sandholm and others 1990). Clavulanic acid is a synthetic drug that results
in the irreversible inhibition of p-Iactamase (Sandholm and others 1990; McKellar 1991).
It is combined in commercial preparations with amoxycillin to produce a drug with a
broad spectrum of activity and good action against p-Iactamase producing Staph aureus
(Sandholm and others 1990; McKellar 1991). Cloxacillin and nafcillin are potentiated
penicillins with better activity than amoxycillin against Staph aureus and are also
effective against p-Iactamase producing strains (McKellar 1991). Cephalosporins are
semi-synthetic, bactericidal antibiotics with good activity against Gram-positive bacteria
and are resistant to p-Iactamase (McKellar 1991). Macrolides are bacteriostatic
antibiotics with good tissue distribution, high intracellular concentrations and activity
against Gram-positive bacteria, including Staph aureus, and Mycoplasma spp. (McKellar
1991). The Gram-negative activities of aminoglycosides are useful to combat coliform
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organisms. Many products contain penicillin and aminoglycoside combinations.
Tetracyclines are active against Gram-negative and Gram-positive organisms with some
activity against ~-lactamase producing Staph aureus (McKellar 1991).
1.5.2. Anti-inflammatory drugs and analgesics
Anti-inflammatory drugs are widely used in veterinary practice in order to provide
symptomatic relief in the treatment of both acute and chronic inflammatory conditions
(Cunningham and Lees 1994). The principal value of these drugs is to relieve pain and
reduce swelling. The most commonly used drugs are the corticosteroids (glucocorticoids)
and NSAID. These drugs act by inhibiting the formation or release of mediators with
inflammatory properties, Figure 1.1 shows the site of action of the common anti-
inflammatory agents. Common uses in veterinary medicine include the management of
musculoskeletal and joint disorders and in endotoxaemic conditions such as E coli
mastitis.
1.5.2.1. Corticosteroids
Glucocorticoid agents are reported to be the most effective anti-inflammatory agents
(Langston 1999). These drugs inhibit the activity of the enzyme phospholiase A2 (Figure
1.1), thus inhibiting the formation of prostaglandins, thromboxane, leukotrienes and
platelet activating factor (Cunningham and Lees 1994; Langston 1999). There are several
different glucocorticoid agents with differing formulations causing the onset and duration
of action and routes of administration to vary. As a group, these drugs are associated with
a wide range of side-effects and in general they tend to delay healing and the
immunosuppressive effects and modification of the inflammatory reactions may facilitate
the progression of concurrent infectious disease. Of particular importance in the therapy
of food animals is the abortifacient activity of the glucocorticoids; the non-methylated
compounds given parenterally, such as prednisolone, have a lower risk of inducing
abortion (Lauderdale 1972). Corticosteroids are often added to antibiotics in
intramammary preparations to reduce inflammation in the udder tissue. Prednisolone has
not been shown to adversely affect the function of white blood cells in the udder, despite
being proven to be generally immunosuppressive (McKellar 1991).
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Figure 1.1. Sites of action of common anti-inflammatory agents (Langston 1999)
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In experimental models of mastitis, when used in combination with antibiotics 10mg of
prednisolone infused by the intramammary route significantly increased the resolution of
swelling compared to antibiotics only (McKellar 1991). Experiments by Bywater and
others (1988) showed that prednisolone effectively increased the rate of reduction of the
swelling seen in mastitis, with no effect on SCC in milk.
1.5.2.2. Non-steroidal anti-inflammatory drugs
Non-steroidal anti-inflammatory drugs are relatively weak acids and are well absorbed
from the upper gastrointestinal tract (Jenkins 1987). As a group, NSAIDs have anti-
inflammatory, analgesic (peripheral and central sites of action) and anti-pyretic
properties (central site of action) (Nolan 2000). They inhibit the transformation of
arachidonic acid to stable POs (Le. POE2 and prostacyclin), by inhibition of cyclo-
oxygenase (COX) enzymes, whose products elicit many signs of inflammation. There is,
however, a lack of evidence to generalise this hypothesis to all products of the
arachidonic acid cascade and all NSAIDs at all dosages (Abramson and Weissmann
1989). There are three general types of COX inhibitors: reversible competitive inhibitors,
irreversible inhibitors and anti-oxidant radical trapping inhibitors (Jenkins 1987). It was
discovered in the 1990's that there were two isoforms of the COX enzyme inhibitors (Xie
and others 1991) and a third isoform was identified in the 2000's (Willoughby and others
2000). Cyclo-oxygenase oxidises arachidonic acid to P002 through a COX activity and
then peroxidises P002 to POH2. Following this cell specific prostaglandin synthases
convert POH2 into a series ofPOs including POh, POF2a, PGD2 and POE2•
Cyclo-oxygenase-l (COX-I) is a constitutive enzyme concerned with such roles as
gastroprotection, renoprotection and, through the release ofTXA2, platelet aggregation in
the process of blood clotting (Monacada and others 1976; Whittle and others 1980; Vane
1994; Lees and others 1998). Cyclo-oxygenase-z (COX-2) is normally absent from
tissues but may be induced by mitogens, lipoploysaccharide and inflammatory mediators
including interleukin-l ~ (lL-l~) and TNFa., resulting in the synthesis and release of
mediators such as POE2 at sites of inflammation (Xie and others 1992; Lees and others
1998). Synthesis of TXB2 and exudate POE2 is mediated by COX-l and COX-2
respectively (Landoni and Lees 1997), thus the degree of inhibition of serum TXB2 is
used as an indictor of COX-l and the degree of inhibition of PGE2 in inflammatory
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tissue/fluid is used as an indicator of COX-2 (Lees and others 1998). The actions of
COX-l and COX-2 are summarised (Vane 1994) in Figure 1.2. The activation of COX-l
leads to the production of prostacyclin which, when released by the endothelium, is anti-
thrombogenic (Monacada and others 1976) and when secreted by the gastric mucosa, is
cytoprotective (Whittle and others 1980).
The second isoform, inducible enzyme COX-2 is unregulated in damaged tissue and is
believed to be primarily responsible for synthesis of PGs that increase the sensitivity of
the nociceptive fibres to pain stimuli and pain mediators after injury (Ricketts and others
1998). Cycloxygenase-2 is found at sites of inflammation, whereas COX-l is considered
to be the 'housekeeping' enzyme serving physiological roles (Landoni and Lees 1997).
Vane (1994) reported that the undesirable side-effects ofNSAIDs are due to their ability
to inhibit COX-I, whereas their anti-inflammatory (therapeutic) effects are due to
inhibition ofCOX-2. The roles of COX-l and COX-2 may not be as clear as previously
reported. Wallace (1999) reported that there are examples where COX-l derived PGs
contribute to the generation of inflammation and COX-2 derived PGs playa crucial role
in the maintenance of gastro-intestinal integrity. Therefore, suggesting that selective
inhibition of COX-2 might not produce anti-inflammatory effects comparable to those
achieved by combined COX-l and COX-2 inhibition (Wallace 1999). A comparative in
vitro study demonstrated that meloxicam inhibited the synthesis of PGE2 (Ricketts and
others 1998). The identification of selective inhibitors of each isoform will not only
provide an opportunity to test this hypothesis but also lead to advances in the therapy of
inflammation (Vane 1994). Prostaglandin E2 is directly involved in the maintenance of
mucosal blood flow and involved in the production of gastric mucus macromolecular
glycoproteins that protect the gastric mucosa, thus drugs with significant efficacy and
potency against COX-l are highly ulcerogenic (Nolan 2000). Thus, COX-2 is thought to
be the optimal therapeutic target. Nephropathy is another important toxic effect of
NSAIDs, however, in healthy animals NSAIDs have very little effect on the renal
function (Jenkins 1987).
The third COX isoform was identified by Chandrasekharan and others (2002), but its
presence was postulated earlier by Willoughby and others (2000). Willoughby and others
(2000) detected the presence of a second substantial increase in COX-2 like protein
expression by Western blotting when investigating the duration of selective and dual
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COX inhibitors. Cyclooxygenase-3 is unlike COX-1 and COX-2 in that it does not
produce pro-inflammatory prostanoids instead it produces anti-inflammatory members of
the prostanoid family (Willoughby and others 2000). Chandrasekharan and others (2002)
demonstrated using insect cells that COX-3 was more sensitive to acetaminophen
(paracetamol) than COX-1 or -2. The inhibition of COX-3 might be the long sought after
mechanism of action for aceteminophen and could represent a primary central
mechanism by which the NSAIDs could decrease pain and possibly pyrexia
(Chandrasekharan and others 2002) and may prove to be the new therapeutic target
(Willoughby and others 2000).
Non-steroidal anti-inflammatory drugs inhibit the isoenzymes to various degrees (Kay-
Mugford and others 2000), thereby resulting in a wide variation in the profiles of the
available NSAIDs. It was thought that NSAIDs only inhibit prostanoid function and thus
have no effect on other inflammatory mediators involved in mastitis, and therefore will
have no direct effect on milk SCC or bovine serum albumin (persson 1990). McCormack
and Brune (1991) and Twomey and Dale (1992) suggest that there is evidence that
NSAIDs may have anti-inflammatory and other effects, which are independent of COX
inhibition. Landoni and others (1995a, 1995b. 1996) reported that flunixin, ketoprofen
and tolfenamic acid effectively inhibited l3-glucuronidase activity, and bradykinin
induced swelling in calves, in addition, to inhibition of COX. Other actions of NSAIDs
have been reported but not assessed for therapeutic effects (Abramson and Weissman
1989; Vane 1994). At high doses aspirin, sodium salicylate and newer NSAIDs (at anti-
inflammatory doses) inhibit non-PG dependent processes, such as the activity of
enzymes, proteoglycan synthesis by chondrocytes, transmembrane ion fluxes,
chemoattractant binding (Abramson and Weissmann 1989). The ability of NSAIDs to
inhibit the activation of inflammatory cells such as the neutrophil may contribute to the
anti-inflammatory properties of this class of drug (Abramson and Weissmann 1989).
Non-steroidal anti-inflammatory drugs are highly protein bound, > 99% in some cases.
The extent of protein binding explains the extended therapeutic activity in inflamed
tissues that these drugs display relative to their plasma elimination half-lives (Nolan
2000). Many of the NSAIDs are available as solutions for parenteral administration, but
most preparations are highly alkaline and are thus tissue irritant (Jenkins 1987).
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A number of studies have shown that there is a marked species difference in the
pharmacokinetic parameters such that data cannot be transposed between species
(McKellar and others 1990; Welsh and others 1993; McKellar and others 1994;
Cunnigham and Lees 1994; Landoni and others 1995a; Landoni and others 1995b;
Landoni and others 1996). Jenkins (1987) suggested that the elimination kinetics of
NSAIDs showed the greatest differences between species of all the drugs used in
animals. The elimination rate of NSAIDs in ruminants tends to be slower than in
monogastric species such as the horse and dog, e.g. the half-life of phenylbutazone in
plasma was 3 to 6 hours in the horse, but 36 to 72 hours in cattle (Jenkins 1987) and the
elimination half-life for meloxicam was 13 hours in cattle, four hours in the mini-pig and
two hours in the horse, but 12-36 hours in the dog (Lees and others 1991). The impact of
the anti-pyretic, anti-inflammatory and analgesic effects produced by these drugs is
largely dependent on the stage of the inflammatory process at which treatment is
commenced (Baggot 2001), e.g. early diagnosis of coliform mastitis and prompt
initiation of treatment with flunixin allowed maximal anti-pyretic and anti-inflammatory
actions to be exhibited.
Non-steroidal anti-inflammatory drugs have been advocated for the treatment of coliform
mastitis (Lohuis 1991; Ziv 1992). DeGraves and Anderson (1990) observed beneficial
effects on various clinical, haematological, biochemical and pathological parameters,
however, they suggested that there was no evidence that these drugs actually improved
cow survival or milk production. In field cases of clinical mastitis, Shpigel and others
(1994) reported that 2 g of ketoprofen administered intramuscularly once daily for a
maximum of five days significantly improved recovery from clinical mastitis in dairy
cows; recovery was categorised as a return to at least 75% of the pre-mastitis daily milk
production. Many studies have been conducted over the last decade investigating the use
of NSAIDs in castration and dehorning procedures. Ketoprofen was found to reduce
behavioural signs of pain in calves after hot-iron dehorning (McMeekan and others 1999;
Faulkner and Weary 2000) and was found to attenuate the increase in plasma cortisol
associated with calf castration (Earley and Crowe 2002). In lambs, the use of carprofen
did not have any effect on the behavioural aspects of discomfort when the rubber ring
method was used to castrate and/or dock tails (Price and Nolan 2001). In bovine
respiratory disease there was found to be no difference clinically in the degree of
depression, illness score, dyspnoea or coughing between groups of calves treated with
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antibiotics (ceftiofur) alone, antibiotics plus carprofen, antibiotics plus ketoprofen and
antibiotics plus flunixin (Lockwood and others 2003). There was, however, less lung
consolidation in the three groups treated with NSAIDs, but this was only significant for
the group that were treated with flunixin (Lockwood and others 2003).
At present the NSAIDs that are licensed for use in lactating dairy cattle include; flunixin
meglumine, ketoprofen, meloxicam and tolfenamic acid. Flunixin meglumine is a
nicotinic acid derivative. Flunixin is licensed for use by the intravenous route, at a dose
rate of 2.2 mg/kg once daily for up to five days and has a half-life of eight hours.
Ketoprofen is a propionic acid NSAID. Ketoprofen is licensed for use by the
intramuscular or intravenous routes at a dose rate of 3 mg/mkg once daily for up to three
days and has a half-life of 0.4 hours. Tolfenamic acid belongs to the fenamate group.
Tolfenamic acid is licensed for use by the intravascular route at a dose rate of2 mg/kg as
a single administration and has a half life of 11.3 hours. Meloxicam is an enolic acid
derived NSAID of the oxicam group. Meloxicam is licensed for use by the intravenous
and subcutaneous routes at dose rate of O.Smg/kg as a single dose and has a half-life of
13 hours by the intravenous route.
Meloxicam preferentially inhibits human COX-2, but at higher concentrations is an
equipotent inhibitor of COX-l and COX-2 in humans (Churchill and others 1996). In rats
and guinea pigs, meloxicam was consistently shown to be COX-2 preferential in vitro,
but also capable of sustained COX-2 inhibition in vivo (Engelhardt and others 1995).
Meloxicam has a more favourable gastrointestinal profile, in rats and guinea pigs,
compared to other NSAIDs and is reported to be a potent anti-inflammatory agent in
acute and chronic inflammation (Engelhardt and others 1995; Churchill and others 1996).
Meloxicam was licensed for use as an oral solution in dogs in 1993. In 1998 meloxicam
was licensed for use in non-lactating cattle as a Smg/ml solution for injection, and
subsequently gained its licensed for use in lactating cows in 2001. This was later
followed by the development and launch of a 20mg/ml solution for injection. Meloxicam
can be administered by a single subcutaneous or intravenous injection at a dose rate of
0.5mg meloxicamlkg bodyweight. It is indicated for (a) use in acute respiratory infection
with appropriate antibiotic therapy to reduce clinical signs in cattle (b) use in diarrhoea in
combination with oral rehydration therapy, to reduce clinical signs in calves of over one
week of age and young non-lactating cattle, and (c) adjunctive therapy in the treatment of
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acute clinical mastitis, in combination with antibiotic therapy. The elimination half life is
26 hours and 17.5 hours after subcutaneous injection in young cattle and lactating cows,
respectively (Anon 2003).
1.5.2.3. Analgesic drugs
The term analgesia means the absence of pain, but is commonly used to mean a reduction
in perceived pain (Carstens 1987). In animals, analgesia is usually defined as an increase
in threshold and/or latency for withdrawal reflexes (Carstens 1987). The administration
of analgesic agents in association with other treatments may affect the magnitude and
duration of hyperalgesia through the modulation of noxious inputs to the spinal cord
(Lascelles and others 1998; Slingsby and Waterman-Pearson 1998; Whay and others
1998). Analgesic drugs can be categorised into (1) opioids, (2) NSAIDs, (3) local
anaesthetics, (4) <lradrenoceptor agonists, (5) centrally acting non-opioid drugs, e.g.
antidepressants, which appear to have an analgesic action in patients not suffering from
depression, (6) drugs used for specific painful conditions e.g. ergotamine for migraine,
and (7) miscellaneous e.g. ketamine, combination product containing phenylbutazone,
and ramifenazone.
The main type of drug used for analgesia in severe pain is the opioids, which have been
available for animal use since the 1960s (Branson and Gross 2001). The opioids act at
specific sites in the central nervous system (CNS) and other tissues. Three are three main
receptor types; J.l. (mu), K (kappa) and 0 (delta). Stimulation of J.l. receptors results in
analgesia, mainly at supraspinal sites, respiratory depression, miosis, reduced
gastrointestinal motility and euphoria. Stimulation of le receptors produces analgesia
mainly at the spinal cord level and less intense miosis and respiratory depression.
Stimulation of B receptors probably provides analgesia. The opioid analgesics act at one
or more of these receptors as agonists, antagonists, or a combination of both (partial
agonists). There are major species differences in the responses elicited by opioids. Cats,
horses, cattle, sheep, goats and pigs often become hyperexcited at high doses. Excitement
is, however, less likely in animals in pain compared to pain-free animals. Opioids are
subject to the Misuse of Drugs Regulations 1985 due to the potential addiction in humans
and it is recommended that they be used only when there is no non-opioid alternative for
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moderate to severe pain and where possible newer, less addictive drugs should be used
rather than morphine or methadone. At present there are no opioids licensed for use in
ruminants.
The most widely available analgesics for cattle in the UK are the non-steroidal anti-
inflammatory drugs. Ketoprofen, flunixin meglumine, tolfenamic acid and meloxicam
are all licensed for use in lactating cattle and carprofen is licensed for use in calves. The
NSAIDs interfere with the initiation of peripheral pain impulses (Einstein and others
1994).
Xylazine, medetomidine, romifidine and detomidine are a.2-adrenergic agonists, they are
used as dose-dependent sedatives. They are classed as having analgesic and skeletal
muscle relaxant properties, in addition to being a sedative (Gross 2001). They are
generally used for restraint, to facilitate handling and transport and to modify behaviour
and not as a primary analgesic agent. Xylazine can be used by the epidural route to
provide sensory anaesthesia with minimal ataxia. Xylazine is licensed for use by the
intramuscular route in cattle.
Ketamine is a dissociative anaesthesic. It interrupts the association between the limbic
and cortical sytems such that an animal may appear to be under a light plane of
anaesthesia but is insensitive to surgical stimulation. It is often combined with an 0.2-
adrenergic agonist to improve muscle relaxation. Ketamine is not licensed for use in
ruminants.
Tomanol® is a combination product that contains the NSAIDs phenylbutazone, and
ramifenazone. It is used for analgesia and inflammation in soft tissue injury and lameness
in the horse.
Local anaesthetics are drugs that when applied locally to nerve tissue cause reversible
blockade of nerve impulse conduction, thus they prevent the perception of pain (Einstein
and others 1994). The blockade of conduction along pain fibres is useful for diagnostic
purposes and to permit minor surgery. The speed of onset of the nerve blockade depends
on the drug used, its concentration, the accuracy of injection and the diameter of the
nerve. The duration of activity depends on the type of drug, the amount used, the site of
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injection and whether or not a vasoconstrictor, such as adrenaline, has been used. The
only licensed local anaesthetic product for ruminants is procaine hydrochlroide, which
has a short duration of activity as it is absorbed rapidly and destroyed quickly (Mama and
Steffey 2001).
Carroll (1996) suggested that if analgesics were successfully used in the peri-operative
period, then post-operatively the animal should be eating, drinking, urinating and
grooming as normal and its heart rate, respiratory rate and mucous membranes colour
should be within the normal ranges. Many studies have been conducted over the last
decade looking into the use of NSAIDs in castration and dehorning procedures.
Ketoprofen was reported to reduce behavioural signs of pain in calves after hot-iron
dehorning (McMeekan and others 1999; Faulkner and Weary 2000) and it attenuated the
increase in plasma cortisol associated with calf castration (Earley and Crowe 2002). It is
believed that pre-operative administration of analgesics has the greatest effect by
reducing or eliminating the 'wind-up' mechanism generated by the barrage of stimulation
of the nociceptors created as a result of surgical procedures. This was exhibited in a study
testing the efficacy of carprofen in bitches undergoing elective ovariohysterectomy. Both
pre- and post-operative carprofen administration significantly reduced the degree of pain
exhibited, however, pre-operative carprofen had greater analgesic properties in the early
post-operative period compared to post-operative carprofen (Lascelles and others 1998).
In lambs the use of carprofen before castration or docking, however, did not have any
effect on the behavioural aspects of discomfort when the rubber ring method was used to
castrate and/or dock tails (price and Nolan 2001).
The administration of NSAIDs intravenously or intramuscularly in cattle, in addition to
the normal treatment for both mastitis and lameness, has been found to result in
significant reductions in the levels or duration of hyperalgesia (Whay and others 1998;
Fitzpatrick and others 1999).
A small study to investigate and control pain in cows with natural mastitis was conducted
by Fitzpatrick and others (1998). These authors reported that on application of a
mechanical stimulus cows with clinical mastitis showed an increased sensitivity to pain
compared to normal animals. They showed that 2.2 mg/kg of intravenous flunixin
megluine, a short duration NSAID, attenuated mechanical hyperalgesia in cows with
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mild mastitis, but only for a short period, and not in moderate cases. These results
suggest that NSAIDs were beneficial in reducing the hypersensitivity in bovine mastitis.
A larger study with a longer duration NSAIDs and/or repeat dosing may show an
extended duration of effect and might produce an effect in more severely affected cases.
1.5.3. Supportive therapy
In addition to NSAIDs and glucocorticoids, a number of other options are available as an
adjunct to antibiotics in cases of clinical mastitis. Possible additional treatments include
the adminstration of oxytocin and/or frequent milkout of the gland, adminstration of
calcium, adminstration of intravenous isotonic or hypertonic saline solutions, oral
electrolytes (Ziv 1992; Morin 1999) use of uddermint, herbal treatments, homeopathy
and cold water massage (Hovi 1998). Green and others (1997) compared three treatments
for toxic clinical mastitis: 45 litres intravenous isotonic electrolyte and flunixin, fluid
therapy alone, or flunixin alone. In addition, all cases were treated with parenteral and
intramammary oxytetracycline, oxytocin and calcium boroglconate. These authors found
that there was no significant difference in the rate of survival between the treatment
groups.
1.6. Aims and objectives
Clinical mastitis remams one of the most costly diseases in dairy farming and is
associated with adverse animal welfare with the induction of pain and prolonged
hyperalgesia. Several different inflammatory mediators have been recognised with APP
promising to have good predictive value in early recognition of clinical mastitis.
Antimicrobials have been used in the therapy of clinical mastitis for decades but it is only
recently that interest has moved to adjunctive therapies such as NSAIDs. Further
information on the benefits, both from a welfare and economic point of view, of
concurrent non-antimicrobial therapies would be valuable for dairy cattle and farmers in
the UK.
Consequently it was considered timely to carry out a study of naturally occurring cases of
acute mastitis using commercial dairy farms in order to study :
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(1) subjective and objective clinical measurements of pain assessment m cows
presenting mild or moderate acute mastitis,
(2) the clinical response in vivo of the NSAIDs, meloxicam, in cows with acute
clinical mastitis on commercial farms,
(3) to establish, using mechanical stimulation, whether cows with acute mastitis
display mechanical hyperalgesia, and if so for how long,
(4) to investigate the production effects of a typical acute incident of mastitis in terms
of milk yield and milk quality, and
(5) to study inflammatory mediators and APP in milk and to quantify the effect of
NSAIDs.
Maureen H. Milne Chapter 2,
64
Chapter 2
Materials and methods
2.1. Study population
The cows in this study were commercial dairy cows milked twice daily, kept at one
institute farm and 11 commercial dairy farms. The farms varied in size from 60 to 300
dairy cows, and the majority of cows were HolsteinlFriesian. Other breeds included
pedigree Holstein, Guernsey, Shorthorn, Ayrshire and crossbreds.
2.1.1. Cow details
On-farm records were referred to for details on the stage of lactation, parity and age of
the cows recruited onto the study. The data for daily milk yield in litres per day were
recorded from milk meters, where available, or from recording jars by the farmer.
2.2. Case recruitment
Fanners were asked to telephone the author on detection of a cow with mild or moderate
clinical mastitis. Clinical mastitis was recognised by the dairyman on each farm by
inspection of the milk and by observation and/or palpation of the udder at milking times.
The same researcher (MM) visited each cow within two hours of mastitis being detected
by the farmer and confirmed the presence of clinical mastitis. Cases were recruited only
if they fitted the definition of mild or moderate clinical mastitis and did not include any
of the exclusion criteria (Appendix 1). The severity of mastitis was assessed using
clinical criteria as previously described (Hogan and others 1989a; Bradley and Green
2001; Eckersall and others 2001). Clinical mastitis was defined as 'mild' when there
were changes in the milk appearance but the udder was normal, and 'moderate' when
there were changes in the milk appearance and the udder was hot, swollen or painful to
touch, but the cow was not off her food, dull or requiring systemic antibiotic therapy
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(Figure 2.1). Adult cows that developed acute clinical mastitis were studied for up to six
weeks. Cows were excluded from the study if they were suffering from severe acute or
peracute mastitis or were suffering from any other inflammatory condition (Appendix 1)
in addition to having mild or moderate mastitis. Normal, healthy cows (no history of any
inflammatory condition within the last two months) (Appendix 1) were monitored as
controls. Normal cows were recruited the same day as case cows and were either being
milked directly before or after case cows. Case cows and normal cows were recruited and
studied from October 2002 to June 2003.
2.3. Study design
Cows with one quarter affected by clinical mastitis were treated and assessed over a 45
day period. Normal cows (n=45) were recruited to act as controls for day 0 parameters
(day of recruitment) and twenty of these cows were followed for a 45 day period to serve
as controls for the time period. All cases of clinical mastitis were treated by the
researcher according to routine veterinary practice, with intramammary antimicrobial
drugs on the day of diagnosis after all measurements and samples had been collected. A
broad spectrum antimicrobial preparation was selected, 25mg cefquinome/ml
(Cephaguard LC Intramammary, Intervet UK Limited, Milton Keynes), and this was
infused every 12 hours for three treatments for every case of mastitis. Cases were
allocated randomly to one of three treatment groups using the random data function in
Minitab Statistical Software release 13 (Minitab Inc.) (Appendix 2).
Group 1: antibiotics only
Group 2: antibiotics and one dose of 20mg meloxicamlml (Metacam solution for
injection, Boehringer Ingelheim Limited, Bracknell) (at dose rate 0.5mg/kg i.v.ls.c.)
Group 3: antibiotics and three doses of meloxicam (at dose rate 0.5mglkg Lv.ls.c. every 3
days)
For cases of mastitis and normal cows, recordings were made on the day of recruitment
(day 0), and subsequently on days 1, 2, 6, 20 and 42-45 after initial diagnosis.
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Measurements were also taken on days 3 and 7 after initial diagnosis for cases in
treatment group 3.
Figure 2.1: Cow with mild (A) mastitis in front left quarter showing no udder changes
and cow with moderate (B) mastitis in back left quarter exhibiting signs of udder
swelling and redness
2.4. Milk sampling
Milk samples were obtained from the affected mammary gland of each case cow for
somatic cell counting and bacteriological examination and additional samples were taken
from the unaffected diagonally opposite quarter for somatic cell counting. Differential
somatic cell counting was carried out in milk sampled from the mastitic quarter of case
cows. Bacteriological examinations were performed on samples collected on days 6, 12,
20 and 42-45. Milk samples from mastitic and diagonally opposite quarters were stored
at -20°C and -70°C for analysis of acute phase proteins, prostaglandin E2 and
meloxicam concentrations. From the normal animals (n=20) that were followed for the
45 day study period, a quarter was randomly selected using the random data function in
Minitab and milk samples were collected from these quarters and subject to the same
tests as the milk samples from the affected quarter of cases of clinical mastitis. The
farmers were requested to take the milk samples, using an aseptic technique (Appendix
3), from the affected and diagonally opposite unaffected quarters in the cases of clinical
mastitis and from the nominated quarters in the normal cows.
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2.5. Bacteriological examination
Milk samples were submitted to University of Glasgow Veterinary Bacteriology
laboratory for bacteriological examination. On arrival the samples were mixed
thoroughly and O.OSmlsample of the milk was plated, using a 7mm bacteriological wire
loop, on 5% sheep blood agar, blood aesculin (Edwards' media) and MacConkey's agar.
The plates were incubated at 37°C for 24 hours then examined; the number of colonies,
type of haemolysis and probable identification of micro-organisms were noted. Bacteria
were identified by recognised standard laboratory techniques, such as Gram, catalase,
oxidase and coagulase testing, Rapidec Staph and API strips (Anon 1987). Agar plates
were re-incubated for a further 24 hours then re-examined as above. Any agar plates that
showed no visible growth after 48 hours were discarded and recorded as no growth.
2.6. Somatic cell counting and milk quality
Milk samples from all the affected and unaffected diagonally opposite quarters of
mastitic cases and nominated quarters from control cows (n=20) were submitted for
somatic cell counting and milk fat, protein and lactose percentages on all sampling days.
The milk was collected into a universal container with a preservative (Potassium
dichromate) and sent by first class mail to Scottish Milk (Scottish Milk Laboratories,
Paisley, Glasgow) for automated cell counting using the Fossomatic method.
2.7. Differential somatic cell counting
Milk samples from the affected quarters of cases of clinical mastitis and the nominated
quarters from the 20 control cows were submitted for differential somatic cell counting
on all sampling days. Milk samples were sent fresh by first-class mail to The Clinical
Pathology Laboratory, Companion Animal Diagnostic Services at the University of
Glasgow Veterinary Faculty. On arrival the samples were mixed thoroughly and a wedge
smear was made on a glass microscope slide using one drop of milk. The smear was air
dried by fan then fixed in methanol and stained using May Grunwald and Giemsa stains.
A concentrated spot of milk cells was prepared by using a Shandon cytospin centrifuge.
This centrifuge uses a specialised metallic cassette holder onto which the following is
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placed, in order from bottom to top, a labelled glass slide (labelled side up), a filter paper
(with a hole cut out of it near the bottom) and finally a funnel shaped sample chamber.
150 III milk was pipetted into the sample chamber followed by 150 III saline. The
dilution was then centrifuged at 750 rpm for five minutes. The resulting cytospin
preparation was air dried by fan. The cytospins were subsequently fixed in methanol and
stained using May Grunwald and Giemsa stains.
The cytospin preparation allows a greater number of cells to be readily examined. In
some samples, particularly where fat content is high, the cytologist would revert to the
wedge smear. The smear and cytospin were microscopically examined, using oil
immersion. The cell populations were differentiated to obtain percentages of neutrophils,
lymphocytes and macrophages, and report on other findings, e.g. presence of intra-
cellular bacteria, fungal hyphae, and degenerate cells.
2.8. Acute phase proteins
Milk samples were stored at -20°C for a mean of 11.7 months (standard deviation ± OJ
months), median 12.9 months and range 8 - 14.6 months. The samples were transported
on ice for analysis to the Centre for Integrated Diagnostic Systems (CIDS) at the
University of Glasgow. Haptoglobin (Hp) and mammary-associated serum amyloid A
(M-SAA) concentrations were assessed in the milk samples from the 70 complete cases
of clinical mastitis, 15 control cows and 20 unaffected diagonally opposite quarters using
ELISA kits obtained from Tridelta Development plc (Dublin, Ireland). The control cows
and diagonally opposite quarter samples were randomly selected using the random data
function in Minitab. Haptoglobin and M-SAA concentrations were measured using an
automated ELISA system including on-board analysis of data (Grifols Triturus 4, Biostat
Ltd, Stockport, UK). In addition 100 samples were measured using manual ELISA but
with the data processed by the analysis programme on the Triturus 4 system. Complete
methods for the manual ELISA for Hp and M-SAA are detailed in Appendix 4 and were
performed according to the manufacturer's instructions. The samples were initially
diluted 1:50 in assay buffer, but if the concentration was greater than the range of the
standard curve, they were diluted as necessary. The assay limits of quantification for Hp
and M-SAA were 0.26 ± 16 ug/ml and 0.05 ± 0.04 ug/ml (mean ± SD, n=l1),
respectively. The intra-assay coefficients of variance were 3.7% and 3.5% for milk Hp
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(n=8) at levels of223 ug/ml and 2.7 ug/ml respectively and were 4.5% and 10% for M-
SAA (n=8) at levels of 55 ug/ml and 10.2 ug/ml respectively. Inter-assay coefficients of
variance were 22.4% and 21.4% for milk Hp at 5.3 ug/ml (n = 6) and 164 ug/ml (n=19)
respectively, and were 15.4% and 14.7% for M-SAA at levels of 24 ug/ml (n=34) and
108 ug/ml (n=33) respectively.
2.9. Prostaglandin E2
Milk samples were stored at -70°C for a mean 13.8 months (± 0.3 months), median 15
months and range 10.2 - 16.7 months. Prostaglandin E2 (PGE2) concentrations were
measured in milk samples from the affected quarter of the 70 complete cases on day 0, 1
and 2 using a radio-immunoassay (RIA). The mean limit of detection across the assays
was 0.03 (±0.03). An example of a standard curve (two replicates) is calculated from the
normalised percent bound as a function of the 10glOPGE2 concentration and is shown in
Figure 2.2. The normalised per cent bound is calculated from (standard/sample counts
per minute - buffer counts per minute) I (zero standard counts per minute - background
count) x 100. The antibody binding was -20%, non-specific binding or buffer binding
(NSB) was 1.7%. The working range of the standard curve was between 0.08 and 5.00
ng/ml.
2.9.1. Preparation of standards
Five microlitres of the 1mg/ml prostaglandin E2 '(PGE2) standard (Sigma Chemical
Company, Poole, England) was diluted with 5ml phosphate buffer saline (PBS), 0.1%
bovine serum albumin (BSA) (Sigma Chemical Company, Poole, England) and 0.1%
sodium azide (azide) (Sigma Chemical Company, Poole, England) to produce a PGE2
concentration of lOug/ml, which was diluted further with 5ml of the PBS, BSA and
azide buffer to produce 100ng/ml prostaglandin standard. 3200J.lI of fresh semi-skimmed
milk was added to 800J.lI of the 100ng/ml standard to give a 2Ong/ml prostaglandin
solution. Serial dilutions were then performed with milk to produce prostaglandin
standards with concentrations of 10, 5, 2.5, 1.25, 0.62, 0.32, 0.16, 0.08, 0.04 and 0.02
ng/ml.
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Figure 2.2: Typical antibody binding curve for prostaglandin E2 standards (in duplicate)
prepared with milk as the dilutant
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2.9.2. Preparation of milk samples
Milk samples from cases of clinical mastitis were thawed and 2ml placed in a glass test-
tube. 2ml of 0.1% tri-fluroacetic acid (TFA) (Sigma Chemical Company, Poole,
England) was added to each milk sample and PG standard. The samples and standards
were subjected to ultra-sonification using a Vibra Cell ultrasonificator (Sonics &
Materials Inc., Connecticut, USA) for approximately five seconds before being
centrifuged at 3000g at 4°C for 30 minutes (GS-6R Centrifuge, Beckman, USA).
After centifugation the samples and standards were extracted using Sep-paks (Strata x
33um Polymeric sorbent 200mgl6ml). Sep-paks were initialised using 4ml of 60%
Acetonitrile (ACN) (Rathburn Chemicals Limited, Walkerburn, Scotland) in 0.1% TFA
then 2ml of the centrifuged milk samples and standards were pipetted into sep-paks. The
sep-paks were then washed three times using Sml 0.1% TFA. Test-tubes were labelled
and the elutant generated from adding 4ml of 60% ACN was collected. This elutant was
dried under medium using centrifuge and vacuum system (Speed Vac Plus SCZIOA,
Savant Instruments Inc., New York. USA). When the samples and standards were dry,
2ml of the PBS, BSA and Azide buffer was added and the samples were ultra-sonificated
for approximately five seconds to allow mixing.
2.9.3. Protocol for radio-immunoassay
One hundred 111of each standard and sample was added to labelled tubes. Six hundred,
800 and 100JlI of PBS, BSA and Azide buffer to tubes labelled NSB, TC and BO,
respectively. Reconstituted freeze-dried antibody was made up to 5ml using PBS, BSA
and azide buffer. The antibody was then made up to SOml (dilution of 1:10) using the
PBS, BSA and azide buffer and Sml of this was diluted further in 50ml (dilution of
1:100). The antibody was kept cool in an ice bucket. Five hundred 111of 1:100 antibody
was added to all the tubes except NSB and TC and the tubes were incubated at 4°C for 30
minutes. Eight JlIof the radioactive tracer eHpGE2) was added to 10ml of PBS, BSA and
azide buffer to provide sufficient tracer for 100 tests. One hundred l1t of the diluted tracer
was added to all tubes and the tubes were mixed using an Autovortex Mixer SA2 (Stuart
Scientific). The tubes were then incubated overnight at 4°C. Twenty mg dextran was
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dissolved in 20ml of PBS, BSA and azide and then 200mg inactivated charcoal was
added and the solution stirred for a minimum of 30 minutes on ice. This provided
sufficient solution for 100 tests. Two hundred J.11of the charcoal/dextran was added to all
tubes except TC. The tubes were then mixed using Autovortex Mixer SA2 and incubated
at 4°C for 10 minutes. All tubes were then centrifuged at 3000 g at 4°C for 10 minutes.
The supernatant was removed from each tubes and placed into a scintillation vial. Five
ml of scintillation fluid was added to each tube. The scintillation tubes were then placed
in racks and radioactivity was counted using the Liquid Scintillation Analyser 1600TR
(Packard, Pangbourne). Results were then entered into Assay zap (Biosoft, Cambridge)
computer program.
2.10. Meloxicam
Milk samples were stored at -70°C for a mean of8.8 months (± 0.3 months), median 9.9
months and range 5.1 - 11.6 months. Meloxicam concentrations were measured in 16
cases of clinical mastitis: eight cases were randomly selected from treatment Group 2 and
eight were randomly selected from treatment Group 3. The meloxicam assay used in this
study was a modification of the reverse-phase High Performance Liquid Chromatography
(HPLC) method described by Velpandian and others (2000).
2.10.1. Chemical structure
The chemical structure of meloxicam was very similar to piroxicam (Figure 2.3) and the
chromatography, extraction and detection properties of piroxicam meant it was an ideal
internal standard to control for volume variability.
2.10.2. Reagents
Meloxicam and piroxicam (internal standard) standard compounds were purchased from
Sigma Chemical company (Poole, England). All solvents were HPLC grade and were
purchased from Rathburn Chemicals Limited (Walkerburn, Scotland). Potassium di-
hydrogen orthophosphate was obtained from BDH Laboratory Supplies (Poole,
England). Water used in the mobile phase was freshly de-ionised via Purite Select.
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2.10.3. Equipment
A Spectra Systems Liquid delivery system pump connected to Auto injector AS3000 and
degasser SCM 1000 with a Focus UV Detector Focus were used. For data acquisition and
integration Software PCI000 by Spectra Systems was used. In addition, a Beckman GS-
6R, GH 3.8 rotor centrifuge, Rotary mixer by B&T, Sample concentrator by Techne
DB3, pH meter by Kent 7065, Stirrer hot plate by Corning and an Autovortex mixer SA2
were used.
2.10.4. Chromatographic conditions
Column RP C18 (150 x 4.6 mm; 511mparticle size) was used for analytical separation
and C18 ODS, Octadecyl (4.0 x 3.0 mm) was used as a guard column. The mobile phase
consisted of an aqueous solution of potassium di-hydrogen orthophosphate (10mM) and
methanol: acetonitrile (90:10) at pH 4.5 in the ratio 50:50 delivered at 1mllmin. The
instrument was operated at ambient temperature of 20°C. UV detection was achieved at
364nm. The retention times for piroxicam and meloxicam were 5.7 and 7.1 minutes,
respectively and a typical chromatogram is shown in Figure 2.4.
2.10.5. Stock solutions
A stock solution was prepared by dissolving IOmg of meloxicam in 100ml of methanol
(I0011g/ml). Serial dilutions to produce 50.0, 25.0, 10.0, 5.0, 2.5, 0.5, 0.25 ug/ml were
used to fortify samples known to be free of the analyte. Dilutions 5.0, 1.0, 0.5, prepared
inmobile phase, were used as external standards for the quantification of the unknowns.
Piroxicam stock solution was prepared by dissolving 10mg in 100ml of methanol to give
1001lg/ml.Serial dilutions to produce 0.5 and 5.0 ug/ml were used as internal standards
for the quantification of the unknowns.
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Figure 2.4: Typical chromatogram of milk, spiked with meloxicam (O.S....g/ml) and
piroxicam (O.S....g/ml)
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2.10.6. Extraction
200J.lIof meloxicam and piroxicam standard dilutions were added to 2ml of milk known
to be free of the analyte to produce a range of spikes (0.025, 0.05, 0.1, 0.25. 0.5, 1.0 and
2.5J.lg/mL).200J.lIof piroxicam 5.0 ug/ml, was added to 2ml of sample, giving a final
internal standard concentration of 0.5 ug/ml., Spikes and samples were mixed using an
Autovortex Mixer SA2 for 30 seconds. 2ml of hydrochloric acid was added and mixed
using an Autovortex Mixer SA2 for 30 seconds. 6ml of chloroform was added to the
spikes and samples which were mixed on a slow rotary mixer for 20 minutes. Spikes and
samples were centrifuged at 1850g for 20 minutes. The lower organic layer (4ml) was
transferred to another tube and dried at 45°C under a stream of nitrogen (oxygen free).
Dried extracts were re-suspended in at least 250 J.lIof mobile phase. 100 J.llof this
product was injected into the analytical column.
2.10.7. Assay characteristics
Recovery of meloxicam from milk samples was approximately 100%. Table 2.1. shows
typical recoveries of meloxicam, and the intra-assay and inter-assay variations.
Calculation of the inter-assay coefficient of variation for recovery of meloxicam from
fortified milk allowed an assessment of the precision of the assay to be made. The mean
inter-assay variation was 7.4% ±3.5 and mean intra-assay variation was 8.8% ±5.0.
Simple regression was used to determine the linearity of concentration with respect to
peak height for fortified samples. The correlation coefficient (r) for concentrations
ranging from 0.025 ug/ml to 10 ug/ml of meloxicam in milk was 0.999. The limit of
quantification (LOQ), the smallest amount of analyte for which the method is valid, was
0.025 ug/ml and the limit of detection (LOD), based upon 4 x baseline noise, was 0.0013
J.lg/ml.
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Concentration of Intra-assay Intra-assay
Meloxicam in milk recovery (%) coefficient
(ug/ml) (n=4) Mean ± SD variation (%)
Inter-assay Inter-assay
recovery (%) coefficient
Mean ± SD variation (%)
0.025 NS 99.0 ±4.85 4.80
0.05 105.2± 13.6 14.3 87.7 ± 16.5 14.5
0.1 NS 106.2 ± 6.50 6.90
0.25 93.0±2.97 2.88 104.1 ± 5.34 5.56
0.5 NS 99.8 ± 9.51 9.49
1.0 102.4± 11.7 11.9 105.3 ± 5.20 5.47
2.5 93.79 ± 11.6 10.8 102.2 ± 4.07 4.16
5.0 NS 99.3 ± 4.68 4.65
10.0 NS 106.9 ± 9.91 10.6
Average variation 8.78 ±4.97 7.35 ± 3.49
NS nosample
SO = standard deviation
Table 2.1: Mean (± standard deviation) recovery, intra-assay and inter-assay variation in
recovery of meloxicam from milk fortified at known concentrations.
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2.11. Data handling and statistical analysis
In order to allow information to be stored, collated and analysed, all data were entered
into Microsoft Access 2000 (Microsoft Corporation), a relational database management
system that allows storage and retrieval of data from related tables. Basic statistical
analysis was conducted using Microsoft Excel (Microsoft Corporation) and Minitab
Statistical Software version 13 (Minitab INC). One-way ANOVA, Kruskal-Wallis and
"!!-square tests were used as appropriate to compare groups. Where appropriate, data
were transformed to improve normality and stabilise variances. Outcome variables for
the physiological and laboratory data were analysed in S-Plus 2000 (Professional release
3, MathSoft Inc.) and MlwiN version 1.1 (Rasbach and others 2000) by the linear mixed
effects method, which takes the dependency of the data into account and is suitable for
the statistical analysis of repeated measurements. A backward stepwise regression model
was used; this method used maximum likelihood techniques for estimating the fit of the
model, in which variables remained in the model if they significantly improved the fit as
assessed by the change in deviance. The farm and identity of the cow were used as
random effects. Initial univariable screening used a critical probability of p~0.25 to select
which variables to offer to the multivariable regressions. Multivariable regressions used a
critical probability of p<0.05. Analysis was performed for data up to the first week after
recruitment into the study and for the complete 45 day study period. Two-by-two tables
were constructed and the sensitivity, specificity, predictive values, and accuracy of
physiological and laboratory parameters were calculated (Dohoo and others 2003).
Likelihood ratios were calculated using the prevalence of moderate cases of mastitis from
the study data.
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Chapter 3
On farm assessment of pain in cows with clinical
mastitis
3.1. Introduction
Mastitis is a prevalent disease of dairy cows worldwide. A survey conducted in Northern
Ireland reported that 17 per cent of dairy cow deaths were attributed to mastitis (Menzies
and others 1995). Another study of cows with toxic mastitis in mid-Somerset reported
mortality of approximately 50% (Green and others 1997). Cows affected by the peracute
form of mastitis are generally considered by veterinary surgeons and fanners to be in
severe pain and distress, and veterinary surgeons often use analgesics in the management
of the disease, especially the non-steroidal anti-inflammatory drugs (NSAID) in
conjunction with antibiotics and other supportive therapies. The NSAID are used for
their anti-inflammatory and anti-endoxic properties (Ziv 1992). In stoical species such as
ruminants, it is difficult to assess whether less severe mastitis, such as mild or moderate
cases, also cause pain, or if NSAID therapy would improve recovery. The Farm Animal
Welfare Council's (FAWC) third freedom states 'Freedom from pain, injury or disease',
therefore it is important to be able to quantify and control pain in a disease such as
mastitis, which has an average incidence of 35-40 cases per 100 cows per year (Booth
1997). A recent study assessed the welfare of dairy cattle in the Midlands and south-west
of England by making use of animal-based measurements. A panel of 50 experts reported
that over 60% of the study farms needed to take action to reduce the incidence of mastitis
(Whay and others 2003), again highlighting mastitis as an important disease from a
welfare aspect.
Alterations in the nociceptive pathways frequently accompanies inflammation and has
this has led to the development of pain threshold testing, which relies on the induction of
physiological pain, to act as a proxy measure for the presence of pain. These methods can
be used to assess the level of response to a mechanical stimulus in normal animals
compared to animals with inflammatory disease. Studies to measure pain thresholds have
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been reported in the horse (Szabuniewicz and Szabuniewicz 1975; Pippi and Lumb
1979), in sheep (Nolan and others 1987; Ley and others 1995) and in cattle (Whay and
others 1998). The techniques in cattle and sheep were applied in the assessment of
lameness, and Fitzpatrick and others (1998) showed that they could also be applied to
study bovine mastitis.
The objective of this study was to assess if physiological and pathological parameters
measured on farm could act as objective indicators of pain in cows with clinical mastitis
and whether the use of NSAID, meloxicam (Metacam solution for injection, Boehringer
Ingelheim Limited, Bracknell) produced a measurable improvement in these parameters.
It was previously demonstrated in a smaller study of clinical mastitis that when a
threshold measurement device was applied to the ipsi-lateral leg (the same side as
mastitis) the threshold measurement would be lower than that for the contra-lateral leg
(opposite side to the mastitis) (Fitzpatrick and others 1998), and this was investigated
further in this study.
3.2. Materials and Methods
3.2.1. Study population and case recruitment
The cows in this study were commercial dairy cows with naturally occurring clinical
mastitis (cases) or clinically healthy cows (normal). Recruitment and sampling were
described in Chapter 2.
3.2.2. Study design
Cases were allocated randomly to one of three treatment groups (Chapter 2). Group 1:
antibiotics only, Group 2: antibiotics and one dose of meloxicam (O.Smglkg i.v.ls.c.),
Group 3: antibiotics and three doses of meloxicam (O.Smglkg i.v./s.c.) given three days
apart.
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3.2.3. Clinical examination
All cows were observed walking and examined clinically (cases and normal) on every
sampling day, and physiological signs such as heart rate, respiratory rate and rectal
temperature were recorded. Body condition score was graded using a scale 1-5, described
previously by Edmonson and others (1989). The hock-to-hock distance of the cow was
assessed, when the cow was standing squarely, by measuring the distance between the
mid-point of the hocks using a 460mm ruler (Figure 3.1), to act as a proxy for the hindleg
stance of a cow.
Daily milk yield records to estimate cow milk production were collected, where possible,
for the duration of the study. Information on the stage of lactation, milk yield, age and
parity of cows were obtained from farm records. An estimate of cow temperament based
on ease of handling was made as follows grade 1: easy; grade 2: difficult (difficult to put
cow in crush; cow lifting leg when trying to apply strap to leg to enable measurement of
nociceptive threshold); grade 3: very difficult (requires kick bar to allow manipulation of
udder and attachment of strap to measure nociceptive threshold). The temperament of the
cow was recorded as assessed prior to administration of treatment. The presence of teat
lesions was recorded and an estimate of udder cleanliness was made using a scale similar
to that used by Ward and others (2002): grade 1: clean; grade 2: some dirt on udder;
grade 3: very dirty. Udder skin temperature was assessed for all four quarters using an
infra-red thermometer (Raytex Minitemp M1); the area used was approximately 1em
caudal to the teat base. The udder temperature difference was calculated as the mean
temperature for the three unaffected quarters minus the value from the infected quarter,
or in the normal animals the randomly selected quarter. The ambient temperature was
also measured using an infra-red thermometer (Raytex Minitemp MT).
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Figure 3.1: Measurement of hock-to-hock distance (mm) to assess the hindleg stance of
cows with clinical mastitis or normal animals
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3.2.4. Mechanical threshold measurement
Mechanical nociceptive threshold responses were measured using a ramped mechanical
stimulus, using a modification of the method described by Nolan and others (1987). A
mechanical device consisting of a meter connected to compressed gas canister and a strap
with a blunt ended pin was used to assess the threshold to mechanical stimulation (Figure
3.2). The strap was attached to the cow below the point of the hock, such that the blunt
ended pin was over the bony protuberance of the lateral condyle of the metatarsal bone.
The power was turned on, the meter reading was checked and set to zero, if necessary,
and then the gas was allowed to flow through tubing to inflate a balloon within the cuff,
thus gradually pushing on a plate to apply the blunt ended pin against the cow's leg. This
ramped mechanical stimulus was applied to each hind leg in tum, and when the cow
reacted by either shifting her weight or lifting her leg, the machine was turned off and the
reading was recorded in kilopascals (kPa). A maximum cut off point of 70 kPa was
applied, at which point the machine was turned off in those animals that had failed to
respond to stimulation below this pressure. Three readings were recorded for each leg
and a mean value was calculated. Results were expressed as the difference between the
contra-lateral leg (unaffected side) and the ipsi-lateral leg (affected side). The device was
calibrated weekly using an electronic hand held calibration meter (Conmark C9500 series
pressure meters, Conmark Limited, Hertfordshire, England). For each time point when
the threshold measurement was assessed, the start leg was decided at random, prior to the
visit, using blocks of four in the random number generator of Minitab. A schematic
diagram shows the components of the cuff from the mechanical threshold device (Figure
3.3) and Table 3.1. details the properties of the components within the cuff to allow
pressure readings to be converted to force readings, where Pressure = force/unit area,
thus 1 Pascal (pressure) = 1 Newton per square metre (force). Using the radius of the
plate the area of the plate can be calculated (Area of plate/pin= 7t~), and using this the
force at the level of the balloon can be computed. Knowing the force at the balloon, the
force transmitted via the pin and the area of the pin from the radius, the pressure applied
at the interface of the cow can be calculated.
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Cuff containing
balloon and blunt
ended pin
Meter to record
O1echanicalthresholds
Compressed gas
canister attached
to O1eter
Figure 3.2: Gas-driven ramped mechanical threshold device for the measurement of
nociceptive thresholds (kPa) in cows with unilateral clinical mastitis, and in normal
animals to calculate the threshold difference between the contra-lateral and ipsi-lateral
hindlegs
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.._-----l.."loon
4------ blunt-ended pin
Figure 3.3: Schematic diagram of cuff of the mechanical threshold device
Plate Pin
Diameter (m) 0.05000 0.00216
Radius (m) 0.02500 0.00108
Pi1t 3.141592654 3.141592654
Area (mL.) 0.001963 3.66435 x 10-6
Pressure (psi) 10 5359.234
Pressure (kPa) 68.9475 36950.582
Force (kN) 0.135373 0.135373
Force (N) 135.4 135.4
Table 3.1: Dimensions of the plate and pin of the cuff of the mechanical threshold device
and the resultant pressure (kPa) and force (N)
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3.2.5. Data handling and statistical analysis
Data were entered into Microsoft Access 2000 with basic statistical analysis conducted
using Microsoft Excel and Minitab and univariable and multivariable regressions were
performed using S-Plus 2000 and MlwiN version 1.1 as detailed in Chapter 2. Treatment
groups and cases of mild or moderate clinical mastitis, and normal animals were screened
for homogeneity. For the purposes of multivariable analysis grades 2 and 3 for
temperament and udder cleanliness were combined, such that for temperament was
classed as grade 1: easy or grade 2: difficult and for udder cleanliness grade 1: clean or
grade 2: dirty. The goodness of fit was assessed when treatment groups 2 and 3 were
combined, such that the treatment groups were antibiotics only (group 1) versus
antibiotics and meloxicam (groups 2 and 3) and when data for day 3 and day 6 after
diagnosis for treatment group 3 were excluded. Two-by-two tables were constructed to
allow the sensitivity, specificity, predictive values and accuracy to be calculated (Dohoo
and others 2003) for cases with clinical mastitis versus normal animals and mild versus
moderate cases of clinical mastitis. Survival analysis using Kaplan-Meier statistics in
Minitab Statistical Software version 13 (Minitab INC) was used to determine whether the
treatment altered the time for the threshold levels of cases of clinical mastitis to reach
normal levels.
3.3. Results
3.3.1. Cases recruited
One hundred and seventeen cows with clinical mastitis and 45 normal cows were studied.
Fifty six of the clinical cases of mastitis were of mild severity and 61 were of moderate
severity.
The non-completion rate of cases of clinical mastitis in the study was 40% (47/117) of
initially recruited cases. Twenty-one percent (24/117) dropped out on day 6 or before and
33% (39/117) of the cases dropped out of the study before day 20. Reasons for drop-out
included the development of mastitis in more than one quarter, recurrent mastitis in the
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same quarter, development of lameness, development of endometritis, teat trauma, being
culled and adminstration of antibiotics in error within the 45 day study period (Table
3.2). The recurrence case rate was 17% (18 + 2 repeat cases x 100/ 117) and there were
1.3 cases of mastitis per cow (117 + 18 + 10 + 2/ 117). The lameness prevalence in the
non-completion group was six percent (3/47). Sixty-eight percent (32/47) of the drop-out
cases were moderate mastitis cases and 32% (15/47) were mild mastitis cases, with
significantly more moderate cases dropping out compared to mild cases (p=0.005). There
was no significant association between the treatment group and the likelihood of a case
completing the study or not (p=0.13). Of the 20 animals that were recruited as normal
controls for the 45 day period one cow (five percent) dropped out due to a stone being
wedged between cleats on day six.
3.3.2. Demographic details
The majority of the recruited cases and normal animals were of the HolsteinlFriesian
breed (n=134), with small numbers of Pedigree Holstein (n=15), Guernsey (n=S),
Shorthorn cross (n=S), Shorthorn (n=I), Ayrshire (n=l) and Ayrshire cross (n=l) cows.
The age of the cows ranged from 2-14 years with a median age of 6 years and a mean
(±SE) of 5.7 (±0.2) years. The parity of the cows had a similar range of 1 - 10 lactations,
with a median of 4 and a mean (±SE) of 3.5 (±0.1) lactations. The median (Inter-quartile
range (lQR» number of days calved for cases of mastitis was 94 (28-163) days and for
normal cows 117 (73-163) days. There was no significant difference (p>0.05) in days
calved amongst mild or moderate cases of clinical mastitis, or normal cows: the median
time after calving when mastitis occurred was 112 (IQR 39-163) days for mild cases and
77 (IQR 9-154) days for moderate cases of clinical mastitis. The median time after
calving that normal cows were recruited into the study was 117 (IQR 83-146) days.
Descriptive statistics for all the recruited cases categorised into mild and moderate cases
of clinical mastitis are detailed in Appendix 5, Table A5.1.
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Reason for non-completion Number %
Mastitis re-occurred in same quarter 18 38
Mastitis in another quarter 10 21
Mastitis re-occurred In same quarter and 2 4
another quarter
Unresponsive mastitis 5 11
Systemically sick 3 6
Lame 3 6
Cut teat 2 4
Endometritis 1 2
Difficult to handle 1 2
Miscellaneous - given antibiotics, culled 2 4
Table 3.2: Reasons for cases dropping out of study before 45 days (n=47)
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3.3.3. Homogeneity and goodness of fit
Combining treatment groups 2 and 3 did not affect the goodness of fit of the
multivariable model, and therefore for simplicity, was used for this analysis. The
omission of data from day 3 and day 7 after diagnosis did not alter the goodness of fit,
and for simplicity was included in this analysis.
The initial distribution of cases among treatment groups was assessed. There was no
significant difference between treatment groups for age, parity, body condition score,
milk yield, heart rate, respiratory rate, rectal temperature, hock-to-hock distance and pain
threshold difference when cows were enrolled in the study. There was, however, a
significant difference in days calved between treatment groups (p<O.OI). The median
(IQR) days calved were 118 (7S-179), 123 (33-186) and 4S (6-98) days for treatment
groups 1,2 and 3, respectively.
3.3.4. Clinical examination
The mean (SE) rectal temperature for non-complete cases and complete cases on the day
of recruitment were 38.8°C (±O.I) and 38.4°C (±O.1), (p=0.017) while the equivalent
values for milk yield (1)36.S (±1.6) and 29.5 (±1.6) (p=O.OOS).Fifty-two percent (32/61)
of moderate cases of clinical mastitis were in the non-complete group and 48% (29/61) in
complete group whereas 27% (15/56) of the mild cases of clinical mastitis were in the
non-complete group and 73% (41/56) in the complete group. This difference was
significant (p<O.OI).Descriptive statistics for the complete and non-complete cases are
detailed in Appendix 5, Table AS.2.
Table 3.3 shows the mean/median (SEIIQR) heart rate, respiratory rate, rectal
temperature, hock-hock distance, udder temperature, and threshold differences on the day
of recruitment into the study (day 0), for normal animals and mild and moderate cases of
clinical mastitis. There was no significant difference in age, production level and body
condition score among normal, mild and moderate cases of clinical mastitis. Descriptive
statistics for the complete cases categorised into mild and moderate cases of clinical
mastitis and normal animals are detailed in Appendix 5, Table AS.3.
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3.3.4.1. Heart rate, respiratory rate and rectal temperature
Moderate cases of clinical mastitis had higher rectal temperatures, heart and respiratory
rates compared to mild cases and normal animals (p<O.OOI)(Table 3.3). The heart rate,
respiratory rate and rectal temperature of cows over six days were similar for all three
treatment groups and the normal animals (Figure 3.4).
Variables that were included in the final multivariable model are listed in Tables 3.3 for
heart rate, respiratory rate and rectal temperature as outcome variables, respectively.
When variables were explored with multivariable analysis over time, heart rate,
respiratory rate and rectal temperature of the mastitis cases all decreased (Tables 3.4-
3.9). There was no effect of time in the normal animals (Tables 3.10 & 3.11). Heart rate,
respiratory rate and rectal temperature were associated with one another. The heart rate
of cases (both day seven and day 45 models) and normal cows (day 7 model) increased
as the temperament scale increased (Le. heart rate increased in animals classed as
difficult to handle).
The ability of heart rate, respiratory rate and rectal temperature to differentiate between
mild and moderate cases of clinical mastitis and normal animals was determined by
estimating the sensitivity, specificity, negative predictive value, positive predictive value
and overall accuracy. The 'cut-orr point for cases and normal animals were estimated
from the mean of all values of parameters for all cases. Cows with lower heart rate,
respiratory rate and rectal temperature than the mean, Le. <74 beats/minute, <22
breaths/minute and <38.3°C, respectively, were classed as test normal animals and cows
~74 beats/minute, ~2 breaths/minute and ~8.3°C were classed as test cases. Tables
3.12 - 3.14 show that the sensitivity of detecting cases of clinical mastitis using heart
rate, respiratory rate and rectal temperature were 60%, 46% and 50%, respectively while
the specificities were 78%, 64% and 64%, respectively.
The ability of heart rate, respiratory rate and rectal temperature to differentiate between
moderate and mild cases of clinical mastitis was determined by estimating the sensitivity,
specificity, negative predictive value, positive predictive value and overall accuracy. The
'cut-off' points formild and moderate severity was estimated from the mean of the
values of the parameters for all cases. Cases with lower values than the mean, Le. <76
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beats/minute, <23 breaths/minute and <38.4°C, were classed as test mild and cases ~76
beats/minute, ~3 breaths/minute and ~38.4°C were classed as test moderate. Tables 3.15
- 3.17 show that the sensitivities of detecting moderate clinical mastitis were 48%, 66%
and 59%, while specificities were 73%, 68% and 68%.
3.3.4.2. Udder skin temperature
Normal animals had lower absolute udder skin temperatures compared to mild and
moderate cases of clinical mastitis (p<O.OOl) (Table 3.3). There was, however, no
significant difference (p>O.05) in the udder temperature difference between normal
animals and the cases of mastitis (Table 3.3); however, moderate cases did show a larger
udder temperature difference compared to mild cases and normal animals (Figure 3.5).
In the multivariable analysis, respiratory rate was the only variable that was associated
with udder temperature difference in cases of mild and moderate mastitis over the first
seven days (Table 3.18) and respiratory rate and front or back quarter were associated
with udder temperature difference in cases of mild and moderate mastitis over the 45 day
study period (Table 3.19). The respiratory rate increased as the udder temperature
increased and over the 45 day study period, back quarters had larger temperature
differences. In normal animals, there was no association with any variables.
3.3.4.3. Hock-to-hock distance
There was a significant difference in the hindleg stance of cows, as measured by hock-to-
hock distance, between normal animals and test cases (p<O.001) (Table 3.3). There was,
however, no difference in the hock-to-hock distance in cases with mastitis in the front
quarters compared to cases with mastitis in the hind quarters (p>O.05). For all cases of
clinical mastitis the hock-to-hock distance decreased over the first six days and then
levelled off to near normal (Figure 3.6); however, there was no difference among the
three treatment groups over time.
In the multivariable analysis, variables that were positively associated with hock-to-hock
distance over the first seven days after recruitment of cases to the study included body
condition score, parity and heart rate, while time, udder cleanliness, and threshold
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difference were negatively associated with hock-to-hock distance (Table 3.20). Over the
45 day study period, udder temperature difference, body condition score and parity were
positively associated with hock-to-hock distance while threshold difference, udder
cleanliness and time after recruitment to the study were negatively associated with hock-
to-hock distance (Table 3.21). There was no relationship of time or any other variables
with hock-to-hock distances of the normal animals over the first seven days.
The ability of hock-to-hock distance to differentiate between mild and moderate cases of
clinical mastitis and normal animals was determined by estimating the sensitivity,
specificity, negative predictive value, positive predictive value and overall accuracy. The
'cut-orr point for cases and normal animals was estimated from the mean hock-hock
distance for all animals. Cows with lower hock-to-hock distance than the mean, Le. <254
mm, were classed as test normal animals and cows ~54 mm were classed as test cases.
The sensitivity and specificity of detecting cases of clinical mastitis were 64% and 84%,
respectively (Table 3.22).
3.3.4.4. Temperament, udder cleanliness and teat lesions
The temperament of the cows was used as a guide to assess if cows with mastitis were
more difficult or easy to handle as a result of the clinical mastitis. The majority of cows
were classed as having temperament category l. Figure 3.7 shows the percentage of
clinical cases of mastitis, for those cases that were followed for the full 45 days
(complete) and those that were not followed for the full 45 days (non-complete) and
normal animals in the three categories of temperament (easy, difficult and very difficult).
There was no difference between the temperament of normal cows compared to cases of
mild and moderate mastitis. The majority of cows were categorised with a cleanliness
score of 1 (Figure 3.8). Teat lesions were present in 31% (22170)of complete cases, 32%
(15/47) of non-complete cases and 40% (8/20) of normal animals. The most common teat
lesions were hyperkeratosis, papilloma, teat end impaction and teat injury (Figure 3.9).
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Figure 3.4: Mean (SE) (A) Heart rate (beats/min), (B) respiratory rate (breaths/min), (C)
rectal temperatures caC) for cases of clinical mastitis treated with antibiotics only (n=2l),
antibiotics and one dose of meloxicam (n=29) and antibiotics and three doses of
meloxicam (n=20) and normal animals (n=19) over 6 days after recruitment to the study
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Explanatory variable Coefficient (SE) 95%CI LRS Pvalue
Respiratory rate 0.57 (0.07) 0.43-0.72 <0.001
Rectal temperature 0.99 (0.31) 0.38-1.60 <0.01
Temperament <0.001
Easy Reference category
Difficult 3.68 (1.13) 1.47-5.89
Time point <0.001
DayO Reference category
Day 1 -0.30 (0.39) -04.6-1.06
Day2 -0.60 (0.41) -0.20-1.41
Day6 -1.58 (0.42) 0.76-2.40
LRS Likelihood ratio test statistics
Table 3.4: Final multivariable mixed effects model of explanatory variables that were
associated with heart rate of mild and moderate cases of clinical mastitis for the first
seven days after recruitment to the study
Variable Coefficient (SE) 95%CI LRS Pvalue
Respiratory rate 0.78 (0.06) 1.94-2.46 <0.001
Rectal temperature 0.96 (0.29) 1.48-4.62 <0.001
Temperament <0.001
Easy Reference category
Difficult 2.39 (1.04) 1.41-83.7
Parity -0.50 (0.29) 0.93-2.90 <0.05
LRS Likelihood ratio tests statistics
Table 3.5: Final multivariable mixed effects model of explanatory variables that were
associated with heart rate of mild and moderate cases of clinical mastitis for the 45 days
after recruitment to the study
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Explanatory variable Coefficient (SE) 95%CI LRS P value
Heart rate 0.25 (0.02) 0.20-0.29 <0.001
Udder temperature 0.21 (0.10) 0.01-0.41 <0.001
difference
Time point <0.001
DayO Reference category
Day 1 -1.41 (0.27) 0.89-1.93
Day2 -1.94 (0.27) 1.41-2.47
Day6 -2.12 (0.28) 1.57-2.67
LRS Likelihood ratio test statistics
Table 3.6: Final multivariable mixed effects model of explanatory variables that were
associated with respiratory rate of mild and moderate cases of clinical mastitis for the
first seven days after recruitment to the study
Variable Coefficient (SE) 95%CI LRS P value
Rectal temperature 1.02 (0.18)
Udder temperature 0.11 (0.09)
difference
Severity
Mild
Moderate
1.94-3.99
0.94-1.32
<0.001
<0.001
<0.01
1.13 (0.36)
Reference category
1.54-6.20
Time point
DayO
Day 1
Day2
Day6
Day20
Day45
<0.001
-1.53 (0.27)
-2.12 (0.27)
-2.63 (0.27)
-2.57 (0.30)
-2.74 (0.31)
Reference category
2.74-7.81
4.88-14.23
8.13-23.78
7.25-23.50
8.49-28.49
LRS Likelihood ratio tests statistics
Table 3.7: Final multivariable mixed effects model of explanatory variables that were
associated with respiratory rate of mild and moderate cases of clinical mastitis for the 45
days after recruitment to the study
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Explanatory variable Coefficient (SE) 95%CI LRS P value
Heart rate 0.03 (0.01) 0.01-0.04 <0.001
Respiratory rate 0.04 (0.01) 0.02-0.06 <0.001
Hock-hock 0.02 (0.01) 0.00-0.03 <0.05
Ambient temperature 0.02 (0.01) 0.00-0.04 <0.001
Time point <0.05
DayO Reference category
Day 1 -0.16 (0.07) 0.03-0.29
Day2 -0.18 (0.07) 0.04-0.32
Day6 -0.08 (0.08) -0.07-0.22
LRS Likelihood ratio test statistics
Table 3.8: Final multivariable mixed effects model of explanatory variables that were
associated with rectal temperature of mild and moderate cases of clinical mastitis for the
first seven days after recruitment to the study
Variable Coefficient (SE) 95%CI LRS P value
Heart rate 0.02 (0.01) 1.01-1.03 <0.001
Respiratory rate 0.04 (0.01) 1.02-1.06 <0.001
Time point <0.01
DayO Reference category
Day 1 -0.22 (0.06) 1.11-1.39
Day2 -0.25 (0.06) 1.14-1.45
Day6 -0.17 (0.06) 1.04-1.34
Day20 -0.17 (0.07) 1.04-1.36
Day45 -0.16 (0.07) 1.02-1.35
LRS Likelihood ratio tests statistics
Table 3.9: Final multivariable mixed effects model of explanatory variables that were
associated with rectal temperature of mild and moderate cases of clinical mastitis for the
45 days after recruitment to the study
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Outcome variable Explanatory variable 95%CI LRS P value
Heart rate Respiratory rate
Body condition score
Threshold difference
Temperament
Easy
Difficult
Respiratory rate Heart rate
Udder cleanliness
Clean
Dirty
Flectaltemperature Body condition score
Coefficient
(SE)
0.69 (0.14)
5.39 (1.86)
-0.08 (0.04)
0.41-0.97
1.76-9.03
0.00-0.16
<0.001
<0.005
<0.05
<0.001
Reference category
Outcome
variable
Explanatory
variable
Coefficient (SE) 95% Cl
14.6 (3.75)
0.20 (0.04)
-2.10 (0.65)
0.17 (0.08)
1.17-196.9
1.18-1.41
1.00-1.02
7.22-21.9
0.12-0.28 <0.001
<0.01
Reference category
0.83-3.25
0.02-0.32 <0.05
LRS Likelihood ratio test statistics
Table 3.10: Final multivariable mixed effects model of explanatory variables that were
associated with heart rate, respiratory rate and rectal temperature of normal animals for
the first seven days after recruitment to the study
LFlSP value
Heart rate Respiratory rate
Respiratory Heart rate
rate
2.72 (1.31)
0.25 (0.05)
Rectal Heart rate 0.01 (0.01)
temperature
<0.05
<0.001
<0.05
LRS Likelihood ratio tests statistics
Table 3.11: Final multivariable mixed effects model of explanatory variables that were
associated with heart rate, respiratory rate and rectal temperature of normal animals for
the 45 days after recruitment to the study
Maureen H. Milne Chapter 3, 99
True
Cases Normal
Total
Test Cases
Normal I~; ~~ I~~
L.:7=-=0--__:'4~5----' 115Total
Sensitivity
Specificity
Negative predictive value
Positive predictive value
Accuracy
42170=60%
35/45 =78%
35/63 = 56%
42/52 = 81%
77/115 = 67%
95% Cl 48.5 - 71.5%
95% Cl 66.0 - 90.0%
95% Cl 43.8 - 68.2%
95% Cl 70.4 - 91.6%
95% Cl 58.4 - 75.6%
Table 3.12: Two-by-two table to test the ability of heart rate to differentiate between
cases of clinical mastitis and normal animals detailing the sensitivity, specificity,
negative predictive value, positive predictive value and accuracy
True
Cases Normal
Total
Test Cases
Normal I~~~~__ __:.~~~__ --,I:~
70 45 115Total
Sensitivity
Specificity
Negative predictive value
Positive predictive value
Accuracy
32170=46%
29/45 =64%
29/67 =43%
32/48 =67%
611115 = 53%
95% Cl 34.3 - 57.7%
95% Cl 50.0 - 78.0%
95% Cl 31.2 - 43.0%
95% Cl 53.7 - 80.3%
95% Cl 43.9 - 62.1%
Table 3.13: Two-by-two table to test the ability of respiratory rate to differentiate
between cases of clinical mastitis and normal animals detailing the sensitivity,
specificity, negative predictive value, positive predictive value and accuracy
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True
Cases Normal
Total
Test
Total
Cases
Normal I;~ ~: I~
L..,;7;_;_0---4-5----' 115
Sensitivity
Specificity
Negative predictive value
Positive predictive value
Accuracy
35170= 50%
29/45 =64%
29/64=45%
35/51 = 69%
64/115 = 56%
95% Cl 38.3 - 61.7%
95% Cl 50.0 - 78.0%
95% Cl 32.8 - 57.2%
95% Cl 56.3 - 81.7%
95% Cl 46.9 - 65.1%
Table 3.14: Two-by-two table to test the ability of rectal temperature to differentiate
between cases of clinical mastitis and normal animals detailing the sensitivity,
specificity, negative predictive value, positive predictive value and accuracy
True Total
Moderate Mild
Moderate I!~ 11 I!~Mild 30
29 41 70
Test
Total
Sensitivity
Specificity
Negative predictive value
Positive predictive value
Accuracy
14/29 = 48%
30/41 = 73%
30/45 = 67%
14/25 = 56%
44170=63%
95% Cl 29.8 - 66.2%
95% Cl 59.4 - 86.6%
95% Cl 53.3 - 80.7%
95% Cl 36.5 - 75.5%
95% Cl 51.7 -74.3%
Table 3.15: Two-by-two table to test the ability of heart rate to differentiate between
moderate and mild severity clinical mastitis detailing the sensitivity, specificity, negative
predictive value, positive predictive value and accuracy
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Test
Total
True Total
Moderate Mild
Moderate I!~ 13 I~;Mild 28
29 41 70
Sensitivity
Specificity
Negative predictive value
Positive predictive value
Accuracy
19/29 = 66%
28/41 = 68%
28/38 = 74%
19/32 = 59%
47170=67%
95% Cl 48.8 - 83.2%
95% Cl 53.7 - 82.3%
95% Cl 60.1 - 87.9%
95% Cl 42.0 - 76.0%
95% Cl 56.0 - 78.0%
Table 3.16: Two-by-two table to test the ability of respiratory rate to differentiate
between moderate and mild severity clinical mastitis detailing the sensitivity, specificity,
negative predictive value, positive predictive value and accuracy
True Total
Moderate Mild
Moderate I!~ 13 I!~Mild 28
29 41 70
Test
Total
Sensitivity
Specificity
Negative predictive value
Positive predictive value
Accuracy
17/29 = 59%
28/41 = 68%
28/40=70%
17/30= 57%
45170=64%
95% Cl 41.1-76.9%
95% Cl 53.7 - 82.3%
95% Cl 55.8 - 84.2%
95% Cl 39.3 - 74.7%
95% Cl 52.8 - 75.2%
Table 3.17: Two-by-two table to test the ability of rectal temperature to differentiate
between moderate and mild severity clinical mastitis detailing the sensitivity, specificity,
negative predictive value, positive predictive value and accuracy
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Figure 3.5: Udder temperature difference for mild (n=41) and moderate (n=29) cases of
clinical mastitis and normal cows (n=19) on day of recruitment to the study (day 0).
For each group, the median value is represented by the horizontal line within the box and
the mean value denoted by the dot. The bottom and top of the box represent the first and
third quartiles respectively. The vertical lines extending from the box represent the
lowest and highest observations within 1.5x the inter-quartile range below and above the
first and third quartiles respectively. Outliers are denoted by • .
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Explanatory variable Coefficient (SE) 9S%CI LRS Pvalue
Respiratory rate 0.06 (0.02) 0.02-0.09 <0.01
LRS Likelihood ratio test statistics
Table 3.18: Final multivariable mixed effects model of explanatory variables that were
associated with udder temperature difference of mild and moderate cases of clinical
mastitis for the first seven days after recruitment to the study
Explanatory variable Coefficient (SE) 9S%CI LRS Pvalue
Respiratory rate 0.06(0.02) 1.02-l.10 <0.01
Front or back quarter <0.05
Front Reference category
Back 0.28 (0.12) 1.03-1.68
LRS Likelihood ratio tests statistics
Table 3.19: Final multivariable mixed effects model of explanatory variables that were
associated with udder temperature difference of mild and moderate cases of clinical
mastitis for the 45 days after recruitment to the study
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Figure 3.6: Mean hock-to-hock distance ± SE for cases of clinical mastitis treated with
antibiotics only (n=21), antibiotics and one dose of meloxicam (n=29) and antibiotics and
three doses of meloxicam (n=20) and normal animals (n=19) over 45 days after
recruitment to the study
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Explanatory variable Coefficient (SE) 95%CI LRS Pvalue
Heart rate 0.08 (0.50) 0.02-0.15 <0.05
Body condition score 1.65 (0.50) 0.66-2.63 <0.001
Parity 0.56 (0.20) 0.17-0.95 <0.005
Threshold difference -0.02 (0.01) 0.00-0.03 <0.05
Udder cleanliness <0.05
Clean Reference category
Dirty -l.98 (0.75) 0.51-3.45
Time point <0.001
DayO Reference category
Day 1 -l.54 (0.25) 1.06-2.02
Day2 -2.37 (0.26) l.87-2.87
Day6 -3.33 (0.27) 2.80-3.86
LRS Likelihood ratio test statistics
Table 3.20: Final multivariable mixed effects model of explanatory variables that were
associated with hock-to-hock distance of mild and moderate cases of clinical mastitis for
the first seven days after recruitment to the study
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Explanatory Coefficient 95%CI LRS P value
variable (SE)
Udder 0.08 (0.08) 0.92-1.27 <0.05
temperature
difference
Body condition 1.64 (0.46) 2.10-12.5 <0.001
score
Parity 0.48 (0.18) 1.14-2.31 <0.01
Threshold -0.14 (0.06) 1.02-1.31 <0.05
difference
Udder <0.05
cleanliness
Clean Reference category
Dirty -1.94 (0.70) 1.79-26.9
Time point <0.001
DayO Reference category
Day 1 -1.63 (0.24) 3.17-8.18
Day2 -2.63 (0.25) 8.61-22.6
Day6 -3.60 (0.25) 22.3-59.9
Day20 4.44 (0.28) 49.1-146.0
Day45 5.32 (0.29) 115.7-361.9
LRS Likelihood ratio tests statistics
Table 3.21: Final multivariable mixed effects model of explanatory variables that were
associated with hock-to-hock distance of mild and moderate cases of clinical mastitis for
the 45 days after recruitment to the study
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Test
True Total
Cases Normal
Cases I~~ 7 I!~Normal 38
70 45 115Total
Sensitivity
Specificity
Negative predictive value
Positive predictive value
Accuracy
45170= 64% 95% Cl 52.8 - 75.2%
38/45 = 84% 95% Cl 73.3 -94.7%
38/63 = 60% 95% Cl 47.9 -72.1%
45/52 = 87% 95% Cl 77.9 -96.1%
83/115 = 72% 95% Cl 63.8 - 80.2%
Table 3.22: Two-by-two table to test the ability of hock-to-hock distance to differentiate
between cases of clinical mastitis and normal animals detailing the sensitivity,
specificity, negative predictive value, positive predictive value and accuracy
difficult
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easy
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Figure 3.7: Percentage of cases of clinical mastitis that completed (n=70) and cases of
clinical mastitis that did not complete (n=47) and normal animals (n=19) in the three
temperament categories on day of recruitment to the study (day 0)
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Figure 3.8: Percentage of cases of clinical mastitis that completed (n=70) and cases of
clinical mastitis that did not complete (n=47) and normal (n=19) animals in the three
udder cleanliness categories on day of recruitment to the study (day 0)
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Figure 3.9: Percentage of teat lesions for cases of clinical mastitis that completed (n=70)
and cases of clinical mastitis that did not complete (n=47) the 45 day study period and
normal animals (n=19) on day recruitment to the study (day 0)
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3.3.5. Mechanical threshold measurement
The mechanical threshold measurements for the ipsi-lateral leg were lower (p<0.001)
than the mechanical threshold measurements for the contra-lateral leg for all cases of
mastitis (Figure 3.10). The mechanical threshold measurements on both hindlegs of
normal animals were similar to the measurements on the ipsi-lateral leg (p>0.05) of the
cases of mastitis, but were lower than the measurements for the contra-lateral leg of cases
of mastitis (p<0.05) (Figure 3.11). There was no significant difference (p>0.05) between
the measurements for the ipsi-lateral or the contra-lateral leg depending on whether the
mastitis was in frontquarters or hindquarters. There was a large amount of variation in
the individual threshold measurements for normal animals, the ipsi-lateral leg and the
contra-lateral leg of cases of clinical mastitis. The mean (standard deviation) for normal
animal, the ipsi-lateral leg of cases of clinical mastitis and the contra-lateral leg of cases
of clinical mastitis were 28.3 (18.1), 26.2 (17.1) and 39.4 (18.0), respectively. The
mechanical threshold measurements for the normal animals and the ipsi-lateral leg of the
cases of mastitis remained relatively constant throughout the 45 day study period,
however, the mechanical threshold measurements of the contra-lateral leg of the cases of
mastitis decreased over the time period to reach levels similar to the normal animals and
the ipsi-lateralleg of the cases of mastitis by day 45.
There was a significant difference in the mechanical threshold difference between mild
and moderate cases and normal animals on day 0 (p<0.001) (Figure 3.12 & Table 3.3),
but there was no significant difference between mild and moderate cases. The
mechanical threshold difference on the day of recruitment was significantly lower in
cases when mastitis affected the front quarters compared to back quarters (p<0.05)
(Figure 3.13).
The mechanical threshold difference for mild and moderate cases of clinical mastitis over
the 45 day study period was greatest on the day of diagnosis (Figure 3.14). The threshold
difference for the normal animals fluctuated around OkPa (Le. no difference between the
two hind legs) for the 45 day study period. The mechanical threshold difference for the
cases given antibiotics alone decreased gradually over the 45 day period with levels
similar to that of normal animals reached by day 45. The mechanical threshold difference
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of cases given antibiotics and meloxicam decreased rapidly over the first few days and
maintained lower levels than the cases that received antibiotics only for the 45 day study
period. Mechanical threshold differences of mild and moderate cases of clinical mastitis
were similar, but the moderate cases appeared to have a more rapid decrease in threshold
difference relative to the mild cases (Figures 3.15). In moderate cases the cows that
received antibiotics and meloxicam had mechanical threshold differences that were
similar to the normal animals six days after recruitment, whereas the cases given
antibiotics only were similar to normal animals 20 days after recruitment. In mild cases
the cows given meloxicam and antibiotics had normal level mechanical threshold
differences by 45 days after recruitment into the study, whereas the cases given
antibiotics only, had an increased mechanical threshold difference even by 45 days after
recruitment into study.
Multivariable analysis of data from the first seven days after recruitment to the study
showed that mechanical threshold difference increased as the rectal temperature
increased, and the mechanical threshold difference decreased with meloxicam treatment
and over time (Table 3.23). Multivariable analysis for the 45 day study period showed
that the mechanical threshold difference decreased with meloxicam treatment and over
time (Table 3.24) There was no effect of time, or any other variables, on mechanical
threshold responses in normal animals.
The duration of the alteration in response to mechanical stimulation was investigated. In
cases of mild and moderate mastitis the median (IQR) duration of alteration in response
to mechanical stimulation for the animals treated with antibiotics only was 45 (2 - 45)
days and for animals treated with antibiotics and meloxicam was 6 (1 - 45) days. The
cases were subdivided into mild and moderate cases and the median (IQR) duration of
alteration in response to mechanical stimulation for animals treated with antibiotics only
were 45 (1.5 - 45) and 45 (20 - 45) days, for mild and moderate cases respectively, and
for animals treated with antibiotics and meloxicam were 6 (1 - 45) and 2 (l - 32.5) days.
for mild and moderate cases respectively. Survival analysis demonstrated a significant
difference between groups in the time to achieve normal threshold levels such that cases,
treated with meloxicam reached normal threshold levels earlier than cases treated with
antibiotics only (p=0.04) (Figure 3.16).
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Figure 3.10: Mechanical threshold measurements (kPa) for the leg ipsi-lateral (n=70) and
contra-lateral (n=70) to the quarter with clinical mastitis on day of recruitment to the
study (day 0)
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Figure 3.11: Mechanical threshold measurements (kPa) for ipsi-lateral leg (n=70) and
contra-lateral leg (n=70) in cases of mild and moderate mastitis and for normal animals
(n=4S) on day of recruitment to the study (day 0)
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Figure 3.12: Mechanical threshold differences (kPa) for mild (n=41) and moderate
(n=29) cases of clinical mastitis and normal animals (n=45) on day of recruitment to the
study (day 0)
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Figure 3.13: Mechanical threshold differences (kPa) for cases of clinical mastitis in the
front quarter (n=36) and back quarter (n=34) on day of recruitment to the study (day 0)
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Figure 3.14: Mean mechanical threshold differences (kPa) ± SE for cases of mastitis
treated with antibiotics only (n=21), antibiotics and meloxicam (n=49) and normal
animals (n=19) over 45 days after recruitment to the study
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Figure 3.15: Mean threshold difference (kPa) ± SE for cases (mild, moderate) of mastitis
treated with antibiotics only (n=13, 8), antibiotics and meloxicam (n=28, 21) and normal
animals (n=19, 19) over 45 days after recruitment to the study
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Explanatory variable Coefficient (SE) 95%CI LRS P value
Rectal temperature 0.14 (0.12) -0.10-0.37 <0.001
Treatment group <0.001
antibiotics only Reference category
meloxicam -0.84 (0.20) 0.45-1.22
Time point <0.001
DayO Reference category
Day 1 -0.61 (0.18) 0.25-0.97
Day2 -0.77 (0.19) 0.40-1.14
Day6 -0.97 (0.19) 0.60-1.33
LRS Likelihood ratio tests statistics
Table 3.23: Final multivariable mixed effects model of explanatory variables that were
associated with threshold difference of mild and moderate cases for the first seven days
after recruitment to the study
Explanatory variable Coefficient (SE) 95%CI LRS P value
Treatment group <0.001
Antibiotics only Reference category
Meloxicam -0.69 (0.16) 1.44-2.73
Time point <0.001
DayO Reference category
Day 1 -0.68 (0.17) 1.41-2.73
Day2 -0.85 (0.17) 1.50-3.12
Day6 -1.04 (0.17) 2.02-3.96
Day20 -1.07 (0.19) 2.01-4.19
Day45 -1.30 (0.19) 2.50-5.33
LRS Likelihood ratio tests statistics
Table 3.24: Final multivariable mixed effects model of explanatory variables that were
associated with threshold difference of mild and moderate cases of clinical mastitis for
the 45 days after recruitment to the study
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Figure 3.16: Kaplan-Meier survival function for duration of alteration in response to
mechanical stimulation in mild and moderate cases of clinical mastitis treated with
antibiotics only (n=21) or antibiotics and meloxicam (n=49)
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3.3.6. Milk yield
Farmers were requested to record the milk yield for every cases of clinical mastitis for
the 45 day study period, however, compliance was poor. Complete milk yield data was
available from only 10 cases from five different farms. Of these 10 cases, seven were
classified as mild and three as moderate severity. General linear model analysis showed
that the milk yield of cases receiving antibiotics and three doses of meloxicam was
greater than the milk yield of cows given antibiotics only or antibiotics and one dose of
meloxicam (p<0.05) (Figure 3.l7). Milk yield decreased as the number of days calved
increased in both the cases of mastitis and normal cows (p<O.Ol).
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Figure 3.17: Milk yield before the cow had clinical mastitis and for 12 days after clinical
mastitis for cases treated with antibiotics only (n=4), antibiotics and one dose of
meloxicam (n=3) and antibiotics and three doses of meloxicam (n=3)
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3.4. Discussion
Cases of clinical mastitis occurred throughout lactation, but the majority occurred within
the first four months, i.e. early lactation, which has been recognised previously as the
most common time of mastitis occurrence (Bramley and Dodd 1984; Wilesmith and
others 1986; Hogan and others 1989b; Lescourret and others 1995; Miltenberg and others
1996). The age and production demographics were similar for normal animals and cases
of clinical mastitis, indicating that recruited normal animals were representative of the
population at risk of developing mastitis, and thus could be considered as appropriate
controls for the cases of clinical mastitis. On checking the homogeneity of the
assignment to treatment groups, cases receiving antibiotics and three doses of meloxicam
were significantly fewer days calved (p=O.002) than the cases in the other two treatment
groups. This difference is assumed to be due to chance as treatment groups were
randomly allocated and all other parameters were homogeneous between groups.
Mastitis re-occurring in the same quarter, or occurring in another quarter, or proving to
be unresponsive to treatment, were the most common reasons for cases of clinical
mastitis that were recruited into the study failing to complete the 45 day study period.
Bradley and Green (2001) reported that dairy cows suffered a mean of 1.5 cases of
clinical mastitis per year and that 16.4% of quarters had at least one repeat case per year,
in a study of six Somerset herds. Similar findings are represented here from cows in
south-west Scotland and north-west England: cows had a mean of 1.3 cases of clinical
mastitis per year and the re-occurrence rate was 17%.
The development of lameness was the next most common reason for recruited cases
failing to complete the 45 day study period. The lameness rate in 434 British dairy herds
assessed by Whitaker and others (2004) was 20.7%, demonstrating that lameness is
common in dairy cattle and explaining the occurrence of lameness as the second most
common reason for cases in the current study failing to complete the 45 day study period.
The finding that more moderate cases of clinical mastitis failed to complete the 45 day
study period than mild cases of clinical mastitis is biologically plausible as more severely
affected cases may be more difficult to cure, more likely to develop mastitis in another
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quarter, and more likely to develop concurrent infection. This may reflect the fact that
cows that develop clinical mastitis are often immunosupressed, either as a consequence
of the mastitis (Taub and others 1989) or prior to the development of mastitis (Oliver and
Sordilo 1988). The rectal temperature of non-complete cases was significantly higher
than complete cases. This finding is also biologically plausible as it would be expected
that more severely affected (moderate) animals would have higher rectal temperatures
then less severely affected (mild) and that animals with higher rectal temperatures may
be more likely to become systemically ill, as pyrexia is a clinical sign of systemic disease
(Radostits and others 2000).
The normal ranges for the physiological parameters of adult cattle are: heart rate 65-80
beats/minute; respiratory rate 15-35 breaths/minute and rectal/body temperature 38.0-
39.0°C (Rosenberger 1979; Jackson and Cockcroft 2002). The physiological parameters
of clinical cases and normal animals were generally within the normal ranges for cattle
on the day of recruitment to the study, with moderate cases being the top end of normal
for rectal temperature, heart and respiratory rates. These findings suggest that the
subjective grading of mastitis severity by a single observer was good, with the moderate
cases having physiological measurements in the top end of normal range and the mild
cases and normal animals towards the bottom of the normal range. Physiological
parameters may be used to distinguish between mild and moderate cases of clinical
mastitis, as suggested by data from this study. and from this treatment could potentially
be targeted specifically to severity of mastitis. The use of an accurate rectal thermometer
to measure the rectal temperature would be the most convenient and user-friendly
parameter for farmers to use to judge severity and could even be adapted for automated
systems using body temperature sensors. The physiological parameters for the cases of
clinical mastitis in all three treatment groups decreased slightly over the first two days
after recruitment and then remained relatively constant for the remaining period of the
study. The multivariable analysis showed an association between the physiological
parameters; heart rate, respiratory rate and rectal temperature. This inter-relationship
would be expected and has biological inference. The relationship is such that it is not
clear which is the explanatory and which is the response variable, for example some
variance of heart rate can be explained by the association with respiratory rate and some
of the variance of respiratory rate can be explained by the association with heart rate.
There was no effect of treatment on heart rate, respiratory rate and rectal temperature.
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Using the data from this study heart rate, respiratory rate and rectal temperature were
assessed as predictors of clinical mastitis and as predictors of mild or moderate severity.
As predictors of clinical mastitis they had sensitivities and specificities around 50-60%.
Their ability to differentiate between mild and moderate severities had sensitivities and
specificities around 60-70%.
Ward and others (2002) stated that cow cleanliness was vital if mastitis is to be
controlled in a straw yard, and while factors such as the quality and quantity of straw
used, the ventilation rate within the building and stocking density were important, the
major factor was faecal consistency. These authors reported a significant relationship
between faecal consistency and the cleanliness of the udder, flanks and legs of the early
lactation cows (p<0.05), suggesting that diets that result in drier faeces may be beneficial
in the control of environmental mastitis in straw yard systems (Ward and others 2002).
Cook (University of Wisconsin www.vetmed.wisc.eduldms/fapmlforms.htm) and
Hughes (2001) recommended regular hygiene scoring to increase awareness of cow
cleanliness. These authors used a similar subjective, ordinal scale to the one used in this
study. Data from this current study showed no difference in the udder cleanliness
between normal cows and cases of clinical mastitis, however, normal animals were taken
from the same farm as cases and therefore a comparison between different farm
incidences of clinical mastitis according to cow cleanliness was inappropriate in this
instance.
There was no difference in the presence of teat lesions between normal animals and cases
of clinical mastitis, a result that differs from previous studies. Neave and others (1969)
reported that teat lesions were an important source of Streptococci and Staphylococci
spp., and that consequently teat lesions along with the presence of infected milk were
important sources for development of clinical mastitis. It may be that the alteration in the
pathogen profile from udder based pathogens to environmental organisms over the years
(Milne and others 2002) has led to teat lesion colonisation being a less important risk in
the development of clinical mastitis, or indeed the type of teat lesions may influence the
risk and the type of teat lesions may have altered over the years.
Normal animals had smaller hock-to-hock distances compared to cows with clinical
mastitis suggesting that there was an alteration in the hindleg stance of the cow as a result
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of disease. Hock-to-hock distance showed promise as a predictor of clinical mastitis, with
a sensitivity of 64% and specificity of 84%. There was no difference between mild and
moderate cases of mastitis suggesting that increasing severity of mastitis did not result in
the cow further altering her hindleg stance. This is surprising as moderate cases were, by
definition, associated with udder changes and it would be expected that udder swelling
might alter the stance of a cow. The hock-to-hock distance for the normal cows was
relatively constant over the study period suggesting that unaffected cows have a uniform
stance. Treatment did not affect the hock-to-hock distances over time suggesting that the
administration of the NSAID; meloxicam (Metacam, Boehringer-Ingelheim Limited,
Bracknell) did not have any beneficial influence on this variable. This again is surprising,
as if the alteration in the stance of a cow with mastitis is not associated with the presence
of udder swelling (as demonstrated by the lack of difference in hock-to-hock distances
between mild and moderate cases), it might have been expected to be due to localised
pain. It may be that cows with a wider hindleg stance are more predisposed to mastitis
and this could be related to larger udders and greater milk yields. It has been previously
recognised that cows with higher genetic milk yield have an increased risk of developing
clinical mastitis (Bunch and others 1979; Shook 1989). Unfortunately there was
insufficient data on milk yield in this study to assess this further.
Hock-to-hock distance over the first seven days after recruitment of cases to the study
was positively associated with body condition score, parity and heart rate, and negatively
associated with time, udder cleanliness, and threshold difference. An increased hock-to-
hock distance with increased body condition score and parity and a decrease in hock-to-
hock distance with time is biologically plausible. The decrease in hock-to-hock distance
observed in cows with dirty udders might be explained by the fact that cows that stand
with their hindlegs closer together are more inclined to have dirty udders as a result of
the hindlegs contacting the udder more closely.
Previous studies relating to the measurement of mechanical stimulation thresholds were
based on the absolute values from the lame leg of affected animals and compared to the
absolute values of one leg of the normal animal (Nolan and others 1987; Ley and others
1995; Whay and others 1998). Those authors reported that the mechanical thresholds
were significantly lower in the lame animals compared to normal animals. In this current
study threshold measurements were assessed on both hindlegs and it was found that the
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measurements from the ipsi-lateral leg of cases with unilateral mastitis was not
significantly different from those of the normal animals, however, the measurements
from the contra-lateral leg of the cases of mastitis were significantly higher than those of
normal animals and the ips-lateral leg (p<0.05). This finding that normal animals reacted
at similar thresholds to those of the ipsi-lateral leg was surprising and is contrary to the
finding reported by Fitzpatrick and others (unpublished data). Instead the findings from
the current study suggest that the threshold to stimulation is actually higher in the contra-
lateral leg (hypoalgesia) rather than lower in the ipsi-Iateral leg (hyperalgesia) when
compared to normal animals. Hypoalgesia has been reported to occur in dairy cows
subjected to acute stressors (Herskin and others 2004), but in the current study there is no
reason why the case cows were subject to stress and the normal cows were not. Possible
biases in the measurement of normal animals can be ruled out regarding time as normal
animals were recruited and measured concurrently to the cases of mastitis and the
threshold machine was calibrated on a regular basis and was found to be accurate on all
occasions. Also biases in the measurement of the contra-lateral leg can be ruled out as the
study design was such that the milk samples were collected by the farmer not the
researcher therefore the researcher was less likely to recall which quarter was the affected
one, especially as the study period was intense with many cows being measured on the
same day. Instead this phenomenon might be explained by the low power of the study
due to the large variation in the threshold measurements at the individual animal level or
might be a chance finding due to statistical analysis or more probably an alternative
hypothesis needs to be adopted. It might be that the threshold measurements of the ipsi-
lateral leg appear similar to the measurements recorded in normal animals due to the
ability to override the pain reflex for longer as a result of the reluctancy of the cow to
make any movement. The high contra-lateral leg threshold measurements might be due
to the reluctance of the cow to bear weight on the ipsi-Iateral side to the mastitis. The
complex nature of the innervation of the mammary gland is likely to lead to considerable
cross over of nerve impulses at the spinal level making the pain associated with mastits
more difficult to interpret compared to unilateral lameness and may explain why the
contra-lateral threshold measurements alter with time but the ipsi-Iateral measurements
remain relativelty constant
To allow the alterations in threshold response to be monitored further, the difference
between the contra-lateral and ipsi-Iateral leg of animals affected with unilateral clinical
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mastitis and the difference between the two threshold measurements in normal animals
were used, and this negates the individual variations in threshold responses. When
considering the threshold difference, i.e. the reading from the ipsi-lateralleg subtracted
from the contra-lateral leg, normal animals had lower threshold differences compared to
mild and moderate cases of mastitis. The threshold difference was higher for moderate
cases compared to mild cases, but was not significant (p>O.05) on the day of diagnosis of
clinical mastitis. Studies in lameness in cattle reported increased sensitisation to
mechanical stimulus, i.e. reduced thresholds to mechanical stimulation, with increasing
severity of lameness (Whay and others 1997). With a larger dataset it might be that the
alteration in nociceptive pathways are more pronounced with increasing severity of
mastitis. There was no effect of time on the response of normal cattle to the mechanical
threshold device, consistent with findings from Whay and others (1996), who suggested
that cows do not adapt to repeated application of mechanical stimulation to the hindlegs.
The alteration in response to mechanical stimulation in this study lasted between six and
45 days for moderate and mild cases of clinical mastitis, respectively, which was a
similar duration to that reported in a smaller study by Fitzpatrick and others (1998).
These authors reported the alteration in response to mechanical stimulation lasted for up
to four days and 20 days for mild and moderate cases of clinical mastitis, respectively. It
is interesting to note, however, that in the current study the alteration in response to
mechanical stimulation of moderate cases of clinical mastitis lasted for approximately six
days, which was a shorter duration than inmild cases where the alteration in response to
mechanical stimulation lasted for approximately 45 days. This may be due to the
different causal pathogens in the different severities of mastitis and may reflect the
pathogenesis of the specific organisms and their response to therapy.
In sheep with severe 'foot rot', alteration in response to mechanical stimulation was
present for three months after treatment and apparent resolution of the foot lesion (Nolan
and others 1987; Ley and others 1995). Unilaterally lame cattle were examined 28 days
after treatment of the lameness and the pain threshold was reported to still be
Significantly reduced in cows with solar ulcers and white line disease but not in cows
with acute tissue infection compared to normal cows assessed on day of recruitment to
the study (Whay and others 1998). This indicated that alterations in response to
mechanical stimulation were present for at least 28 days in lame cows, but the
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persistence of the alteration in response to mechanical stimulation differed between
lesion type. In this current study, alterations in response to mechanical stimulation were
present for a median of 45 days in cows with mild and moderate clinical mastitis that
were treated with antibiotics only. In cases of mild and moderate clinical mastitis treated
with antibiotics and meloxicam, alterations in the response to mechanical stimulation
were present for a median of 6 days. Treatment with meloxicam in conjunction with
antibiotics, therefore, reduced the duration of alteration in response to mechanical
stimulation in cows with clinical mastitis by 39 days. The finding that there was no
apparent hyperalgesia in the ipsi-Iateral leg of the cases of clinical mastitis in this study,
but there was a treatment effect with NSAID might be due to the quirk of statistical
analysis or due to the central action of NSAID, which would also be consistent with the
lack of treatment effect on the hock-to-hock distance.
In the current study the threshold difference also decreased with time and increased with
increased rectal temperature, which could indirectly represent increased severity as
moderate cases had higher mean rectal temperatures than mild cases. Mean mechanical
thresholds for sheep with mild and severe footrot were increased following
administration of a local anaesthetic block and local infiltration above the affected foot
and below the mechanical testing device using 0.25% bupivacaine Hel (Ley and others
1989). Lascelles and others (1998) used a combination of a VAS scoring system and
mechanical pain threshold testing to assess the NSAID, carprofen, in bitches undergoing
elective ovariohysterectomy. They reported that both pre- and post-operative carprofen
administration significantly reduced the degree of pain exhibited, however, pre-operative
carprofen had greater analgesic properties in the early post-operative period compared to
post-operative carprofen.
The studies by Welsh and Nolan (1994 &1995) used a maximum cut-off threshold of
16N this is considerably lower than the equivalent maximum threshold of 135N used in
this study, however, details of the pin and plate diameters are not specified and thus
calculations of pressure at the pin or plate levels can't be made and a direct comparison
with this study is not possible. In the studies assessing the mechanical thresholds in lame
cows, Whay and others (1997 & 1998) also used a lower maximum force threshold of
20N. These authors used a device with a pin diameter of 2mm, this is marginally smaller
than the pin (diameter 2.l6mm) used in this current study. They report their results in
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units of force and from this and the pin diameter the maximum pressure at the pin level
can be calculated as 6,370kPa. This is considerably smaller than the pressure of
36,950kPa, that was recorded in this study. Whay and others (1997 & 1998) give no
details of the plate area within the cuff, therefore, the pressure at this level can't be
compared. The discrepancy between the pressure and force measurements in this study
and published work by Whay and others (1997 & 1998) may be explained by errors in
the calculations of the force at the cuff level, however, the absence of details of the
dimensions within the cuff makes this difficult to prove. Possible biological reasons for
the difference could include variations in the skin thickness at the hock, more stringent
exclusion criterion, different genetics, different nutritional status especially with respect
to calcium levels, as calcium in involved in nerve function. It does seem unlikely that a
biological reason could explain the 10-fold difference in threshold levels between cows
in the studies by Whay and others (1997 & 1998) and this current study.
Thermal stimulation and mechanical stimulation were used by Nolan and others (1987)
in sheep, who reported that both methods were reliable and reproducible methods for the
assessment of the efficacy of analgesic drugs in sheep. In this current study the threshold
differences, calculated from the threshold responses to mechanical stimulation of both
hindlegs, of normal animals fluctuated around zero for the 45 day study period
suggesting that there was no difference in the threshold response between the two
hindlegs for the duration of the study. These results confirm that there did not appear to
be adaptation due to repeated application of the mechanical device over time in this
study. This suggests that application of a mechanical stimulation and calculation of
threshold responses is also reliable and useful for the assessment of analgesics in cattle.
The greatest economic consequence of clinical mastitis is loss in milk production, which
is a combination of reduction in milk yield, and compulsory discardment of milk
following treatment with antibiotics (Kossaibati and Esslemont 1995). Hortet and
Seegers (1998) reviewed the literature to assess the milk loss associated with mastitis.
These authors estimated that, for an average Holstein cow, the milk losses were 4-6% of
lactation yield, with 40% of cases having negligible loss, 30% losing 150-250
kg/lactation, and 30% losing 950-1050 kgllactation. Lucey and Rowlands (1984)
reported that a clinical case of mastitis resulted in a 6.4% drop in yield. It would be
beneficial from both economic and welfare aspects if the milk loss associated with
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mastitis could be reduced. Although there were limited data on the milk yield and cases
that were given antibiotics alone had a lower milk yield relative to the other treatment
groups before mastitis, there was a suggested yield benefit from the administration of
meloxicam. Multivariable analysis, however, detected an association with days calved
and milk yield with no other variables being significant. It should be noted that cases in
treatment group 3 were significantly fewer days calved than cases in the other groups,
and this alone may explain the suggested yield benefit seen with meloxicam treatment. A
previous study (Shpigel and others 1994) demonstrated a positive benefit on the milk
yield with the use of NSAID in addition to antibiotics in the treatment of naturally
occurring clinical mastitis. The cows recruited into their study were Israeli-Holstein cows
from seven commercial farms, which were accommodated in a zero grazing system and
milked three times a day. They reported a significant improvement in recovery, judged
by return to at least 75% of pre-mastitis daily milk yield, in cows with acute clinical
mastitis in both a non-blinded controlled study and a blinded placebo-controlled study
where a combination of ketoprofen and antimicrobial was compared to antimicrobial
alone. Antimicrobial, 20g sodium sulphadiazine and 4g trimethoprim (Diaziprim Firte,
Vitamed) was administered daily by the intramuscular route until milk production started
to increase, to a maximum of five treatments. Ketoprofen (Ketofen-RM528 10%
solution, Rhone Merieux) was administered intramuscularly once daily for the duration
of the antimicrobial treatment. The cases recruited into the study by Shpigel and others
(1994) included animals that were systemically sick and the antimicrobial therapy was
administered by the intramuscular route and for a longer duration than in the current
study. The inclusion of systemically sick animals may have allowed the difference
between antibiotics only and antibiotics plus NSAID to be more pronounced, due to
NSAIDs anti-endotoxic, anti-inflammatory and anti-pyrexic effects increasing the
treatment response of these systemically sick cows. A larger data set, with stage of
lactation taken into account is required before a true assessment of the effect on milk
yield production by the use of meloxicam can be made.
In summary, threshold difference, udder temperature and hock-to-hock distance are
useful parameters to detect disease at the day of recruitment and physiological
parameters, such as heart rate, respiratory rate and rectal temperature can differentiate
between mild and moderate mastitis on the day of recruitment. These findings may have
implications in improving the detection of mastitis in automated systems with sensors
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detecting udder temperature, body temperature and hock-to-hock distance being possible
innovations. The ability to differentiate between the severities of mastitis can allow the
specific targeting of therapy according to severity. The use of meloxicam in conjunction
with intramammary antibiotics had a significantly beneficial effect on pain threshold
response. Meloxicam, thus, reduced the increased responsiveness to pain measured in
cows with mastitis and its' use could have significant welfare improvements due to
alleviation of pain and returning the cow to normality more quickly.
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Chapter4
Laboratory assessment of pain and
inflammation in cows with clinical mastitis
4.1. Introduction
Many different pathogenic bacteria can infect the mammary gland and there are
considerable differences in epidemiological and predisposing factors with different types
of infection (Dodd and Neave 1970). The most prevalent pathogens isolated from clinical
cases in the UK include S uberis, E coli and Staph aureus (Anon 1999). Mastitis has
adverse effects on the economics of milk production by reducing the quantity and quality
of milk and manufactured milk products (DeGraves and Fetrow 1993). Intramammary
infections are the most important factor influencing the number of somatic cells in milk
(Reneau 1986). There is, however, no widely accepted definition of what constitutes a
low bulk milk somatic cell count (BMSCC), individual cow somatic cell count (ICSCC)
or individual quarter somatic cell count (IQSCC). Published studies have used somatic
cell counts (SeC) of less than 250 xl 03 cells/ml (Barkema and others 1999; de Haas and
others 2002), <200 xl03 cells/ml (Huxley and others 2002), <150 xl03 cells/ml
(Schukken and others 1989) <100 x103 cells/ml (Peeler and others 2000) and <50 x103
cells/ml (Beaudeau and others 2000) to define both low cell count herds and individual
cows. A healthy quarter has been suggested as one with a sce <100 x103 cells/ml and
which is free of mastitis pathogens on routine bacteriological culture of the milk (Dohoo
and Meek 1982; Harmon 1994; Sargeant and others 2001). Increased SCC are associated
with compositional changes, such as decreases in lactose, ec-lactoalbumin and fat, and
changes in the types of proteins (Harmon 1994). Mastitic milk has greatly reduced
concentrations of casein but increased levels of albumin and globulin (Munro and others
1984).
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Milk somatic cells are primarily leukocytes that include macrophages, lymphocytes and
polymorphonuclear neutrophils (PMNs). Following bacterial invasion, inflammatory
mediators produced by cells in the infected gland elicit neutrophil recruitment. This leads
to neutrophil numbers rising from relatively low normal levels observed in the healthy
udder to constitute greater than 90% of the total mammary leukocyte population during
mastitis (Sordillo and others 1997). The role of PMNs is to phagocytose and kill bacteria
(Nickerson 1987; Daley and others 1991) and high concentrations of cells are required to
eliminate the bacteria due to a decreased capacity for phagocytosis in milk compared to
blood (Wisniowski and others 1965; Kent and Newbould 1969; Paape and others 1979).
The dominance of PMNs is short lived as they are not able to reproduce, within 24 hours
mononuclear cell numbers increase, while during resolution or progression to chronicity
macrophages become the most dominant cell type (Higgins and Lees 1984). The acute
phase response to inflammation includes the release of acute phase cytokines which, in
turn, lead to the appearance of, or a rapid increase in, the concentration of a number of
plasma proteins collectively known as the acute phase proteins (APP) (Baumann and
Gauldie 1994; Moshage 1997). In cattle, haptoglobin and serum amyloid A are the most
sensitive APP indicating acute inflammation (Horadagoda and others 1999). The
concentrations of APP can be used to provide an indication of the severity of disease
(Godson and others 1996; Horadagoda and others 1999; Eckersall and others 2001;
Sheldon and others 2001; Nielsen and others 2004). The concentrations of APP in serum
and milk correlated with the severity of clinical signs of mastitis (Eckersall and others
2001) and with an increase in CMT score (Nielsen and others 2004). The concentrations
of APP in serum were increased relative to severity of bacterial contamination of uterus
post-calving (Sheldon and others 2001).
The objective of this study was to assess if laboratory parameters could act as
quantitative markers of severity of clinical mastitis in cows and whether the use of
NSAID, meloxicarn altered these parameters.
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4.2. Materials and methods
4.2.1. Sampling
Milk samples (,.,,90ml)were obtained from the affected mastitic mammary gland of each
cow and from the nominated quarter of the normal cows for somatic cell counting.
differential cell counting. bacteriology and measurement of APP concentrations using
techniques described in Chapter 2. Samples (-65ml) were also taken from the diagonally
opposite quarter to the affected quarter in the mastitic cows for somatic cell counting and
APP determination.
4.2.2. Statistical analysis
Data were entered into Microsoft Access 2000 and basic statistical analysis was
conducted using Microsoft Excel and Minitab Statistical Software version 13 and
univariable and multivariable regressions were performed using S-Plus 2000 and MlwiN
version 1.1 as detailed in Chapter 2. Data were assessed for the first seven days after
recruitment. as this would be the period when the NSAID and antimicrobial activity were
at their peale Data for the 45 day period was also assessed for IQSCC and data for the
first 12 days were assessed for the APP, as these were monitored for 12 days rather than
45 days. The APP were only assessed for the first 12 days to allow the effect of treatment
to be evaluated for all the complete cases, a random selection of diagonally opposite
quarters and normal animals.
A binomial logistic regression was carried out. using the presence of specified
microbiological isolation, or all other microbiological results e.g. S uberis versus all
other culture results, as the outcome, and cow and farm as random effects.
Microbiological groups tested included S uberis, E coli, no growth. Staph aureus, S
dysgalactiae, A pyogenes and miscellaneous. Putative covariates examined were: breed,
the quarter affected. body condition score, parity, severity, days calved, teat lesions,
udder cleanliness, temperament of cow, heart rate, respiratory rate, rectal temperature,
udder temperature difference. hock-hock distance, threshold difference, logIQSCC, fat
content, protein content, lactose content, cube root Hp and cube root mammary-
associated serum amyloid A (M-SAA).
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A maximum value for IQSCC was used for the samples that could not be counted due to
the presence of too many clots. The value used was 24,000 xl 03 cells/ml and the log of
this value was used for the univariable and descriptive analysis.
Two-by-two tables were constructed to allow the sensitivity, specificity, predictive
values and accuracy to be calculated (Dohoo and others 2003) for cases with clinical
mastitis versus normal animals, and mild versus moderate cases of clinical mastitis.
4.3. Results
4.3.1. Cases recruited
As described in Chapter 3, 117 cases with clinical mastitis were recruited into the study,
however, only 70 cases were followed for the fu1l4S day study period. Of these 70 cases,
41 were classified as mild and 29 were classified as moderate clinical mastitis. One
moderate case was difficult to sample due to poor milk let-down and therefore provided
insufficient samples for many of the tests. Twenty normal cows were recruited into the
study; however, only 19 were followed for the fu1l4S day study period.
4.3.2. Bacteriological examination
On bacteriological examination of the recruited cases, 30% of isolates yielded S uberis,
24% yielded no growth, 22% E coli, 11% Staph aureus, six per cent other
microbiological species, four per cent A pyogenes and three per cent S dysgalactiae
(Figure 4.1). The miscellaneous category (six per cent) included other Streptococcus
spp., Corynebacterium spp., coagulase-negative Staphylococcus spp., Pseudomonas spp.,
Candida spp., and C bovis. All normal cows had no significant growth on bacteriological
examination of the randomly selected quarter.
The microbiological results of the cases that did not complete the study were compared
to the cases that completed the study. There was a greater proportion of cases caused by
S uberis, A pyogenes and the miscellaneous category in the cases that did not complete
the study compared to those that did, however, this difference was not significantly
different (p>O.OS) (Figure 4.2).
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The microbiological profiles of the cases, mild and moderate clinical mastitis, were
assessed for differences. There were significantly more isolations of S uberis in the
moderate cases of mastitis (p<0.0 1), and significantly more no growths in cases of mild
mastitis (p<0.01). There tended to be more isolations of E coli in moderate cases and
more isolations of Staph aureus in mild cases, although these were not significantly
different (p>O.OS)(Figure 4.3).
Logistic regression (Table 4.1) was used to identify any associations between the
microbiological result and physiological (Chapter 3) and other laboratory parameters on
day O. The isolation of S uberis from a case of clinical mastitis was positively associated
with severity (p<O.OS).The odds of S uberis mastitis being classed as moderate in
severity was approximately three times (OR 3.09 9S% Cl 1.17-7.40) that of mastitis
being classed as mild. On univariable analysis, the isolation of E coli from a case of
clinical mastitis was positively associated with rectal temperature and heart rate. The
association with rectal temperature was, however, not significant (p>O.OS) at the
multivariable level when included with heart rate. The odds of Staph aureus mastitis
being classed as mild in severity was approximately four times (OR 4.20 9S% Cl 1.09-
16.3) that of mastitis being classed as moderate. The culture result of no growth was
negatively associated with IQSCC (p<0.001).
4.3.3. Somatic cell counting
The IQSCC of normal cows ranged from 6 - 625 xl03 cells/ml with a median of 12 xl03
cells/ml and mean of 53.3 xl03 cells/ml on the day of recruitment to the study (day 0)
(Table 4.2). The milk samples from quarters with mild mastitis had a median IQSCC of
5,966 xl 0
3
cells/ml and a range of 23 - 23,478 x l 03 cells/ml (Table 4.2). Nine of the 41
samples were not suitable for counting due to the presence of too many clots in the milk
sample. Milk samples from quarters diagonally opposite to the quarters affected by mild
mastitis had a median IQSCC of 170 x l 03 cells/ml with a range of 16 _ 10,048 x l 03
cells/ml; three out of the 41 samples were unsuitable for analysis. The IQSCC of milk
samples from quarters with moderate mastitis ranged from 143 _ 22.756 xl03 cells/ml
with d· f 3a me Ian 0 10,707 x l 0 cells/ml (Table 4.2). Ten of the 28 milk samples were
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Figure 4.1: Microbiological isolates from 117 cases of clinical mastitis on day of
recruitment to the study (day 0)
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No growth S uberis E coli Staph aureus A pyogenes S dysgaiactiae miscellaneous
Figure 4.2: Pattern of microbiological isolates from cases that completed the 45 day
study (n=70) and cases that did not complete the 45 day study (n=47) on day of
recruitment to the study (day 0)
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Figure 4.3: Pattern of microbiological isolates from mild (n=41) and moderate (n=29)
cases of clinical mastitis on day of recruitment to the study (day 0)
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unsuitable for analysis. Milk samples from quarters diagonally opposite to the moderate
mastitis had a median IQSCC of 389 xl03 cells/ml with a range of 16 - 4,615 xl03
cells/ml; two of the 28 samples were unsuitable for analysis.
The IQSCC data were log transformed for further analysis. The median log IQSCC for
normal cows (1.08) and the diagonally opposite quarters to the affected quarter in cases
of mild and moderate clinical mastitis (2.42) were significantly lower (p<0.001) than the
IQSCC for affected quarters (4.03) from cases of mild or moderate clinical mastitis
(Figure 4.4).
The median log IQSCC samples from the affected gland of mild (3.90) and moderate
(4.21) cases of mastitis were significantly higher (p<0.001) than samples from normal
(1.08) cows (Figure 4.5). There was no significant difference between the log IQSCC
from the affected gland of mild and moderate cases (p>0.05), however, 36% (10/28) of
samples from moderate cases were not counted, whereas only 22% (9/41) of mild cases
were not counted (p=0.21) due to the presence of too many clots in the samples. There
was no significant difference between the log IQSCC from the diagonally opposite
quarter of mild and moderate cases (p>O.05) (Figure 4.6).
The log IQSCC for the affected quarter and the diagonally opposite quarter for mild and
moderate cases of clinical mastitis over the 45 day study period were highest on day 0,
the day of diagnosis (Figure 4.7). The log IQSCC for the normal animals fluctuated
around log IQSCC 1.2 for the 45 day study period. The log IQSCC for the affected and
diagonally opposite quarters decreased rapidly over the first seven days and then
stabilised around log IQSCC 2. The log IQSCC of the affected quarter from mild and
moderate cases of clinical mastitis for the three different treatment groups followed the
same pattern as the data from the affected quarter in all treatments groups (Figure 4.8).
The log IQSCC for the three treatment groups subdivided according to mild and
moderate severities, were similar to the treatment groups of mild and moderate severity
groups combined (Figure 4.9 & 4.10).
There was no significant difference in the IQSCC of the affected quarter compared to the
diagonally opposite quarter for mild and moderate cases at day 45 after recruitment to the
study (p>0.05). The IQSCC for the affected quarter of mild and moderate cases were
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-mild
Coefficient 95%CI P value OR(95%CI)
(SE)
<0.05
Reference category
1.08 (0.47) 0.25-2.01 3.09 (1.17-
7.40)
0.069 (0.033) 0.00-0.13 <0.05
0.44 (0.31) -0.16-1.04 0.15
1.44 (0.69) <0.05
Reference category
1.44 (0.69) 0.08-2.79 4.20 (1.09-
16.3)
Outcome
variable
Explanatory
variable
S uberis Severity
-mild
- moderate
E coli Heart rate
Rectal
temperature
Staph aureus Severity
- moderate
No growth LogIQSCC -1.03 (0.36) 0.32-1.73 <0.005
IQSCC Individual quarter somatic cell count OR Odds ratio
Table 4.1: Final multivariable binary logistic regression model of explanatory variables
that were associated with microbiological culture results of S uberis, E coli, Staph aureus
or no growth from samples taken on day of recruitment (day 0) of mild and moderate
clinical mastitis
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Group Median Mean (SE) Range
Normal (n=19) 12 53.3 (30.6) 6-625
Mild mastitis (n=41) 5,966 7,050 (1,059) 23 -23,478
Diagonally opposite quarter in 170 779 (295) 16 - 10,048
cows with mild mastitis (n=41)
Moderate mastitis (n=28) 10,707 10,707 (1,595) 143 -22,756
Diagonally opposite quarter in 389 826 (233) 16 - 4,615
cows with moderate mastitis
(n=41)
Samples
not tested"
0/19
9/41
3/41
10/28
2128
*Number of samples that were not suitable for counting due to the presence of too many clots in the milk
sample Itotal number of samples
Table 4.2: Median, mean and ranges of individual quarter somatic cell counts (IQSCC)
xl03 cells/ml of milk in normal animals and cases of mild or moderate mastitis on day of
recruitment to the study (day 0)
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Figure 4.4: Log individual quarter somatic cell count (IQSCC) xl03 cells/ml for affected
(n=69)and diagonally opposite quarters (n=70) from cases of mild and moderate clinical
mastitis and from the selected quarters of normal animals (n=19) on the day of
recruitment to the study (day 0).
For each group, the median value is represented by the horizontal line within the box and
the mean value denoted by the dot. The bottom and top of the box represent the first and
third quartiles respectively. The vertical lines extending from the box represent the
lowest and highest observations within 1.5x the inter-quartile range below and above the
first and third quartiles respectively. Outliers are denoted by •.
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significantly higher than the IQSCC of normal animals at day 45 after recruitment
(p<0.01 for mild and p<0.05 for moderate cases). The IQSCC for diagonally opposite
quarters in mild and moderate cases was significantly higher than the IQSCC of normal
cows 45 days after recruitment to the study (p<0.05).
Multivariable analysis of data from the first seven days after recruitment to the study
showed a positive association with log IQSCC of cases of clinical mastitis and the
concentration of M-SAA and Hp in milk and the microbiological result on the day of
recruitment to the study (p<0.001) (Table 4.3). An increase in log IQSCC was associated
equally with an increase in the concentration of M-SAA and Hp. Increased log IQSCC
was associated more closely with mastitis caused by Corynebacterium spp., S
dysglactiae, A pyogenes and S uberis as indicated by greater coefficients, e.g. coefficient
for Corynebacterium spp. was 0.88.
Multivariable analysis of data for the 45 day study period showed a positive association
between log IQSCC of cases of clinical mastitis and the fat percentage, and the
microbiological result on the day of recruitment to the study (p<O.OOl)and a negative
correlation with time (Table 4.4). An increase in log IQSCC was associated with an
increase in fat percentage. Increased log IQSCC was associated more closely with
mastitis caused by Corynebacterium spp., S dysglactiae, A pyogenes and S uberis. Log
IQSCC was shown to decrease with time from day 6 of the study.
4.3.3. Milk quality
The mean fat percentage for milk samples from normal cows and cows with mild or
moderate mastitis were 2.3,3.0 and 2.7, respectively (Table 4.5). The fat percentage was
not significantly different between normal cows and cases of mild or moderate mastitis
(P>0.05) (Figure 4.11), and there was also no significant difference between affected
quarters and diagonally opposite quarters (p>0.05). The fat percentage of milk samples
from normal cows and from milk samples from affected quarters of mild and moderate
cases of lini I .. flc nuca mastitis uctuated showing no real trend for the duration of the 45 day
stud . d (F'y peno igure 4.12), but for all groups, reached maximal levels at day 45 after
recruitment to study. There were no significant differences in the fat percentage
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Figure 4.5: Log individual quarter somatic cell count (IQSCC) xl03 cells/ml for mild
(n=41) and moderate (n=28) cases of clinical mastitis and normal animals (n=19) on the
day of recruitment to the study (day 0)
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Figure 4.6: Log individual quarter somatic cell count (IQSCC) xl 03 cellslml for normal
animals (n=19), affected quarters of cows with mild (n=41) or moderate (n=28) clinical
mastitis and from quarters diagonally opposite (n=41 for mild and n=29 for moderate)
those with clinical mastitis on the day of recruitment to the study (day 0)
*
normal
(n=19)
mild
(n=41)
*
*
*
diagonally moderate
opposite (n=28)
mild
(n=41)
diagonally
opposite
moderate
(n=29)
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Figure 4.7: Median log individual quarter somatic cell count (lQSCC) xl03 cells/ml ± Cl
for affected (n=69) and diagonally opposite (n=70) quarters from mild and moderate
cases and from selected quarters from normal animals (n=19) over the 45 days after
recruitment to the study
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Figure 4.8: Median log individual quarter somatic cell count (IQSCC) xl03 cells/ml ± Cl
for mild and moderate cases of mastitis in antibiotics only (n=21), antibiotics and one
dose of meloxicam (n=28) and antibiotics and three doses meloxicam (n=20) treatment
groups and diagonally opposite quarters (n=70) and from selected quarters from normal
animals (n=19) over 45 days after recruitment to the study
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Figure 4.9: Median log individual quarter somatic cell count (IQSCC) xl 03 cells/ml ± Cl
for mild cases of mastitis in antibiotics only (n=13), antibiotics and one dose of
meloxicam (n=16) and antibiotics and three doses meloxicarn (n=12) treatment groups
and diagonally opposite quarters (n=41) and from selected quarters from normal animals
(n=19) over 45 days after recruitment to the study
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Figure 4.10: Median log individual quarter somatic cell count (lQSCC) xl 03 cells/ml ±
Cl for moderate cases of mastitis in antibiotics only (n=8), antibiotics and one dose of
meloxicam (n=12) and antibiotics and three doses meloxicam (n=8) treatment groups and
diagonally opposite quarters (n=29) and from selected quarters from normal animals
(n=19) over 45 days after recruitment to the study
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Explanatory variable Coefficient (SE) 95%CI LRS P value
M-SAA 0.16 (0.04) 0.09 - 0.24 <0.001
Haptoglobin 0.16 (0.04) 0.08 - 0.24 <0.001
Bacteria <0.001
- no growth Reference category
- S uberis 0.56 (0.16) 0.24 - 0.87
- E coli 0.07 (0.17) -0.27 - 0.41
- Staph aureus 0.39 (0.20) 0-0.78
-Apyogenes 0.72 (0.35) 0.03 - 1.41
- Sdysgalactiae 0.87 (0.34) 0.21 - 1.53
- CN Staph spp. 0.30 (0.29) -0.26 - 0.86
- Corynebacterium spp. 0.88 (0.47) -0.05 - 1.80
- Contaminated 0.03 (0.47) -0.90 - 0.95
- Candida spp. 0.16 (0.38) -0.59 - 0.90
LRS Likelihood ratio test statistics M-SAA Milk-associated serum amyloid A
Table 4.3: Final multivariable mixed effects model of explanatory variables that were
associated with log individual quarter somatic cell count (IQSCC) x103 cells/ml of mild
and moderate cases for the first seven days after recruitment to the study
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at day 45 between the affected quarter and diagonally opposite quarters of mild and
moderate cases and normal cows (p>0.05).
The protein percentage of milk samples from normal cows ranged from 2.8 - 3.7% with
a mean of 3.2% on the day of recruitment to the study (day 0) (Table 4.5). The milk
samples from quarters with mild or moderate mastitis had mean protein percentages of
3.9% and 4.5%, respectively (Table 4.5). Milk samples from quarters diagonally opposite
to mild or moderate mastitis had mean protein percentages of 3.4% and 3.5%,
respectively. The protein percentage for normal cows was significantly lower (p<O.OOI)
than the protein percentage for affected quarters from cases of mastitis (Figure 4.13). The
protein percentages of the diagonally opposite quarters were also significantly lower than
the affected quarters (p<0.00 1), while there was no significant difference between the
protein percentage of normal cows and diagonally opposite quarters (p>0.05). The
protein percentage for the affected quarter of mild and moderate cases of clinical mastitis
over the 45 day study period was highest on the day of recruitment (Figure 4.14). The
protein percentage for the milk samples from normal animals fluctuated around 3.1-3.2%
for the 45 day study period.
Milk samples from the affected quarter of moderate cases showed a larger increase in the
protein percentage then mild cases, although this was not significantly different (p>O.05).
The protein percentage decreased to reach normal levels 20 days after recruitment to the
study. There were no significant differences in the protein percentage at day 45 between
the affected quarter and diagonally opposite quarters of mild and moderate cases and
normal cows (p>0.05).
The lactose percentage of milk samples from the normal cows ranged from 3.9 - 5.1%
with a mean of 4.7% on the day of recruitment to the study (day 0) (Table 4.5). Lactose
percentages for milk samples from quarters with mild or moderate mastitis had means of
3.6 and 2.8%, respectively (Table 4.5). The lactose percentages of milk samples from
quarters diagonally opposite to mild or moderate mastitis both had means of 4.4%. The
lactose percentage of normal cows was significantly higher (p<O.OOI)than the lactose
percentage of affected quarters from cases of mild or moderate mastitis (Figure 4.15).
The lactose percentage of the diagonally opposite quarters was also significantly higher
than the lactose percent of the affected quarters (p<O.OO1), while
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Explanatory variable Coefficient (SE) 95%CI LRS Pvalue
Fat 0.07 (0.02) 0.04 - 0.11 <0.001
Timepoint <0.001
-0 Reference category
- 1 0.00 (0.00) 0
-2 0.00 (0.00) 0
-6 -0.48 (0.13) 0.22-0.73
- 12 -0.85 (0.12) 0.62-1.09
-20 -0.96 (0.12) 0.72 - 1.19
-45 -1.11 (0.13) 0.86 -1.35
Bacteria <0.001
- no growth Reference category
- Suberis 0.54 (0.15) 0.25 - 0.84
- E coli 0.29 (0.20) -0.09 - 0.68
- Staph aureus 0.36 (0.16) 0.05 - 0.67
-Apyogenes 0.89 (0.32) 0.26 - 1.51
-Sdysgalactiae 0.57 (0.46) -0.32 - 1.47
- CN Staph spp. -0.13 (0.20) -0.27 - 0.53
- Corynebacterium spp. 0.61 (0.38) -0.13 - 1.34
- Contaminated -0.29 (0.64) -0.96 - 2.53
- Candida spp. 0.47 (0.46) -0.44 - 1.37
LRS Likelihood ratio test statistics
Table 4.4: Final multivariable mixed effects model of explanatory variables that were
associated with log individual quarter somatic cell count (IQSCC) xl03 cells/ml of mild
and moderate cases for the 45 day study period
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Figure 4.11: Fat percentages (%) in milk from affected quarters of cases with mild
(n=41) or moderate (n=28) clinical mastitis, quarters diagonally opposite those with
clinical mastitis and from normal animals on the day of recruitment to the study (day 0)
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Figure 4_12: Mean fat percent for mild (n=41) and moderate (n=28) cases of clinical
mastitis and normal animals (n=19) over the 45 day study period
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Figure 4.13: Protein percentages (%) in milk from affected quarters of cases with mild
(n=41) or moderate (n=28) clinical mastitis, quarters diagonally opposite those with
clinical mastitis and from normal cows on the day of recruitment to the study (day 0)
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Figure 4.14: Mean protein percent ± SE for mild (n=41) and moderate (n=28) cases of
clinical mastitis and normal (n=19) animals over the 45 day study period
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there was no significant difference between normal cows and the lactose percentage of
diagonally opposite quarters (p>0.05). The lactose percentage for the milk samples from
normal cows fluctuated around 4.5-4.7% for the 45 day study period (Figure 4.16). The
lactose percentage for the affected quarters of mild and moderate cases of clinical
mastitis was lowest on the day of recruitment and increased to reach normal levels 12
days after recruitment to the study. There were no significant differences in the lactose
percentage at day 45 between the affected quarter and diagonally opposite quarters of
mild and moderate cases and normal cows (p>0.05).
4.3.3. Differential somatic cell counting
It was not possible to perform an accurate differential cell count on samples with low
IQSCC and samples with degenerate cytology. Milk samples were described as having
degenerate cytology when it was not possible to determine the cell type. This tended to
occur in samples that contained many bacteria or were stored over the weekend prior to
examination. All normal animals had low IQSCC at every sampling time, and many of
the samples from cases of mild and moderate clinical mastitis on days 20 and 45 after
recruitment to the study had low IQSCC. On examination of the milk samples from
normal animals there were low numbers of large mononuclear cells. identified
microscopically as macrophages.
On the day of recruitment to the study, PMNs were the predominant cell type in milk
samples from the affected quarter of all cases of mild and moderate clinical mastitis. The
profile of the differential cell count on the day of recruitment for the cases that dropped
out before the 45 day period were similar to the cases that were followed for the full 45
day period.
The mean (SE) PMN proportion for non-complete cases was 88.9% (2.23%) and ranged
from 15 - 97% on the day of recruitment. The mean (SE) lymphocyte and macrophage
proportions for non-complete cases were 6.6% (1.80%) and 4.5% (0.78%). respectively.
Over the 45 day study period the relative proportion of the different cell types in the 70
complete cases changed (Tables 4.6 and 4.7). In mild cases the mean (SE) proportion of
PMNs decreased from 87.9% (1.7%) to 70.1% (5.5%) and there was an increase in the
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Figure 4.15: Lactose percentages (%) in milk from affected quarters of cases with mild
(n=41) or moderate (n=28) clinical mastitis, quarters diagonally opposite those with
clinical mastitis and from normal cows on the day of recruitment to the study (day 0)
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Figure 4.16: Mean lactose percent ± SE for mild (n=41) and moderate (n=28) cases of
clinical mastitis and normal (n=19) animals over the 45 day study period
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mean (SE) proportion oflymphocytes from 3.4% (0.4%) to 9.6% (1.8%) and an increase
in the mean (SE) proportion of macrophages from 8.6% (1.6%) to 19.4% (4.5%) (Table
4.6). In moderate cases the mean (SE) proportion ofPMNs decreased from 93.1% (1.5%)
to 72.6% (11.2%) and there was an increase in the mean (SE) proportion of lymphocytes
from 3.2% (0.4%) to 6.0% (1.6%) and an increase in the mean (SE) proportion of
macrophages from 3.9% (1.4%) to 21.3% (11.2%) (Table 4.7) There was considerable
variation in cell morphology in milk samples from cases of moderate mastitis on the day
of recruitment to the study. Figure 4.17 demonstrates the appearance of neutrophils in
cytospin preparation from a case with moderate clinical mastitis. Figure 4.18 is a
cytospin smear from a cow with moderate clinical mastitis on the day of recruitment to
the study and has a high cellularity, Le. high IQSCC, and demonstrates the cellular
morphology of neutrophils, lymphocytes, macrophages and red blood cells.
4.3.4. Acute phase proteins
Milk samples from normal cows had undetectable concentrations of Hp in milk, Le.
<0.26 ug/ml, the limit of detection (LOD). Milk samples from quarters with mild mastitis
had a median concentration of 27.3 ug/ml (range 0.49 - 274 ug/ml) (Table 4.8), and only
four of the ten samples of milk from the diagonally opposite quarter of these cows had
detectable concentrations of Hp (range 1.69 - 49.0 ug/ml). Milk samples from quarters
with moderate mastitis had a median concentration of 83.8 ug/ml (range 0.4 - 592
ug/ml), and seven out of ten samples of milk from the diagonally opposite quarters of
these cows had detectable concentrations of Hp (range 0.26 - 11.3 ug/ml).
In both mild and moderate mastitis, the milk from the affected quarter had significantly
greater Hp concentrations than in milk from normal cows (p<O.OOI)(Figure 4.19), and in
each group the concentration was significantly higher in the affected quarter than in the
diagonally opposite quarter (p<0.001). The concentration ofHp in milk from the affected
quarters of cows with moderate mastitis was significantly greater (p<0.01) than that in
milk from affected quarter of cows with mild mastitis. The concentration of Hp was
significantly higher in the diagonally opposite quarter of mild (p<O.OI) and moderate
(p<0.001) cases compared to the milk of normal cows.
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PMNs Lymphocytes Macrophages
Days mean (SE) range Mean (SE) range mean (SE) range
0 87.9 (1.7) 51-98 3.4 (0.4) 0-8 8.6 (1.6) 0-45
1 88.9 (2.4) 15-99 5.9 (1.7) 0-60 8.2 (1.2) 0-35
2 79.8 (2.8) 14-96 6.8 (1.1) 0-27 13.4 (2.1) 2-62
6 67.6 (4.5) 27-96 9.7 (1.7) 0-33 22.5 (3.5) 4-61
12 65.5 (5.6) 7-98 11.5 (2.0) 1-36 22.9 (4.5) 1-77
20 75.1 (3.9) 37-93 5.5 (1.0) 2-15 19.3 (3.8) 4-61
45 70.1 (5.5) 20-98 9.6 (1.8) 0-25 19.4 (4.5) 2-67
Table 4.6: Mean (SE) and ranges of polymorphonuclear neutrophils (PMNs),
lymphocytes and macrophages over the 45 day study period for mild cases of clinical
mastitis
PMNs Lymphocytes Macrophages
Days mean (SE) range Mean (SE) range mean (SE) range
0 I 93.1 (1.5) 61-99 3.2 (0.4) 0-7 3.9 (1.4) 0-341 89.6 (2.3) 46-99 6.3 (2.2) 0-54 4.0 (0.6) 0-11
\2 88.4 (2.2) 14-97 4.8 (1.0) 0-24 6.6 (1.9) 0-54
i
6 77.4 (3.7) 40-93 6.5 (0.9) 0-14 15.7 (3.2) 3-50
12 69.6 (5.4) 31-98 10.4 (2.6) 1-33 20.0 (4.5) 1-56
20 68.2 (6.4) 22-96 14.2 (3.6) 2-43 17.4 (4.2) 2-54
45 72.6 (11.2) 0-94 6.0 (1.6) 3 - 16 21.3 (11.2) 2-97
Table 4.7: Mean (SE) and ranges of polymorphonuclear neutrophils (PMNs),
lymphocytes and macrophages over the 45 day study period for moderate cases of
clinical mastitis
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PMNs
Figure 4.17: Polymorphonuclear neutrophils (PMNs) inmilk sample from cow 189 with
moderate clinical mastitis on the day of recruitment to study (day 0) at magnification
x400 and stained withMay Grunwald and Giemsa
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Figure 4.18: Milk sample from cow 171 with moderate clinical mastitis on day of
recruitment to study (day 0) showing high cellularity with mainly polymorphonuclear
neutrophils (PMNs) but also lymphocytes and macrophages with a background of red
blood cells at magnification x400 and stained with May Grunwald and Giemsa
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Mammary-associated serum amyloid A (M-SAA) was present in detectable
concentrations (>0.05 ug/ml) in four of the 15 samples of milk from normal cows and the
median concentration for these four normal cows was 0.09 ug/ml (range of 0.05 - 1.11
ug/ml). Milk samples from quarters with mild mastitis had a median M-SAA
concentration of 20.0 ug/ml (range 1 - 362 ug/ml) (Table 4.8), and nine out of the ten
samples from the diagonally opposite quarter of these cows had detectable concentrations
(range 0.06 - 87.2 ug/ml). Milk samples from quarters with moderate mastitis had a
median M-SAA concentration of 79.9 ug/ml (range ofO.2 - 1,085 ug/ml) and eight out of
ten samples of milk from diagonally opposite quarters in these cows had detectable
concentrations (range 0.11 - 4.29 ug/ml),
In both mild and moderate mastitis, the milk from affected quarters had significantly
higher concentrations of M-SAA than milk from normal cows (p<0.00 1) (Figure 4.20),
and within each group the concentration was significantly greater in the affected quarter
than the diagonally opposite quarter (p<0.05 for mild and p<O.OI for the moderate
mastitis group). There was no significant difference between the concentrations of M-
SAA in the milk from affected quarters of cows with mild or moderate mastitis (p>O.05).
The concentration of M-SAA was significantly higher in the diagonally opposite quarter
of mild (p<0.01) and moderate (p<0.001) cases compared to the milk of normal cows.
There was a significant positive correlation (r=0.66, p<O.OOl)between the concentration
ofHp and M-SAA in milk.
The Hp concentrations in the affected quarter and the diagonally opposite quarter for mild
and moderate cases of clinical mastitis during the 12 day period, were greatest on the day
of recruitment (Figure 4.21), with milk from the affected quarter of moderate cases
having significantly greater Hp concentrations than mild cases, Haptoglobin
concentrations in normal animals were below the limit of detection.
In mastitic cases, the Hp concentrations decreased slightly over the 2 days after
recruitment and then decreased more markedly by day 6 and again by day 12. The Hp
concentrations in the diagonally opposite quarters decreased to reach normal
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normal
(n=15)
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Figure 4.19: Haptoglobin concentrations (Cube root) in milk from normal animals (n=IS),
affected quarters of cows with mild (n=41) or moderate (n=28) clinical mastitis and from
quarters diagonally opposite those with clinical mastitis (n=10 for mild and n=10 for
moderate) on day of recruitment to the study (day 0)
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Figure 4.20: Mammary-associated Serum Amyloid A (M-SAA) concentrations (Cube
root) in milk from normal animals (n=15), affected quarters of cows with mild (n=41) or
moderate (n=28) clinical mastitis and from quarters diagonally opposite those with
clinical mastitis (n=10 for mild and n=10 for moderate) on day of recruitment to the study
(day 0)
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Figure 4.21: Mean haptoglobin (Hp) concentrations (Cube root) ± SE for mild (n=4l) and
moderate (n=28) cases of clinical mastitis and the diagonally opposite quarters (n=20) and
normal animals (n=lS)
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concentrations 6 days after recruitment. The mastitis cases were assessed according to
different treatment groups for mild (Figure 4.22) and moderate (Figure 4.23) cases. There
was no obvious effect of meloxicam treatment, as in general the Hp concentrations for the
affected quarters of all three different treatment groups followed the same pattern as the
data from the affected quarter in all treatments groups (Figure 4.21). There was a
significant difference in the Hp concentration at day 12 between the affected quarter of
mild and moderate cases and normal cows (p<O.OI). The Hp concentration in affected
quarters was significantly higher than the concentration in the diagonally opposite
quarters at day 12 (p<O.05). There was, however, no significant difference in the Hp
concentration at day 12 between the diagonally opposite quarters of mild and moderate
cases and normal cows (p>O.05).
The M-SAA concentrations in the affected quarter of mild cases of clinical mastitis and
the diagonally opposite quarter for mild and moderate cases of clinical mastitis over the
12 day period were greatest on the day of recruitment (Figure 4.24). The M-SAA
concentrations in normal animals fluctuated near the limit of detection. In mild cases, the
M-SAA concentrations decreased slightly over the 2 days after recruitment and then
decreased more markedly by day 6 and then again more gradually to day 12. In moderate
cases, the M-SAA concentrations increased to maximal concentrations two days after
recruitment and then decreased markedly by six days after recruitment followed by a
more gradual decrease until day 12. The M-SAA concentrations in the diagonally
Oppositequarters decreased gradually over the 12 day period. The mastitis cases were
assessed according to different treatment groups for mild (Figure 4.25) and moderate
(Figure 4.26) cases. There was no obvious treatment effect; in general the M-SAA
concentrations for the affected quarters of all three different treatment groups followed
the same pattern as the data from the affected quarter in all treatments groups (Figure
4.24). The exception was mild cases given antibiotics and three doses of meloxicam; that
treatment group showed an increase in M-SAA from day 0 to day 1, after which they
followed the same pattern as the other two treatment groups. There was a significant
difference in the M-SAA concentration between the affected quarter of mild and
moderate cases and normal cows at day 12 (p<O.OOI). The M-SAA concentrations of the
affected quarters were significantly higher than the concentration in the diagonally
opposite quarters at day 12 (p<O.OI). There was, however, no significant difference in the
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Figure 4.22: Mean haptoglobin (Hp) concentrations (Cube root) ± SE for mild cases of
mastitis in antibiotics only (n=13), antibiotics and one dose of meloxicam (n=16) and
antibiotics and three doses meloxicam (n=ll) treatment groups and the diagonally
opposite quarters (n=20) and normal animals (n=lS)
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Figure 4.23: Mean haptoglobin (Hp) concentrations (Cube root) ± SE for moderate cases
4 8 10 12
of mastitis in antibiotics only (n=8), antibiotics and one dose of meloxicam (n=12) and
antibiotics and three doses meloxicam (n=8) treatment groups and the diagonally opposite
quarters (n=20) and normal (n=lS) cows
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Figure 4.24: Mean mammary-associated Serum Amyloid A (M-SAA) concentrations
(Cube root) ± SE for mild (n=41) and moderate (n=28) cases of clinical mastitis and the
diagonally opposite quarters (n=20) and normal animals (n=lS)
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Figure 4.25: Mean mammary-associated Serum Amyloid A (M-SAA) concentrations
2 4 8 10 12
(Cube root) ± SE for mild cases of mastitis in antibiotics only (n=13), antibiotics and one
dose of meloxicam (n=16) and antibiotics and three doses meloxicam (n=11) treatment
groups and the diagonally opposite quarters (n=20) and normal (n=15) cows
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Figure 4.26: Mean mammary-associated Serum Amyloid A (M-SAA) concentrations
(Cube root) ± SE for moderate cases of mastitis in antibiotics only (n=8), antibiotics and
one dose of meloxicam (n=12) and antibiotics and three doses meloxicam (n=8) treatment
groups and the diagonally opposite quarters (n=20) and normal (n=15) cows
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concentration at day 12 between the diagonally opposite quarters of mild and moderate
cases and normal cows (p>0.05).
Multilevel analysis examined the association between APP in milk and physiological
(severity grading, days calved, body condition score, parity, quarter affected, treatment
group, heart rate, respiratory rate, rectal temperature, udder temperature difference,
threshold difference, hock-to-hock distance) and laboratory parameters (bacteriological
isolate, IQSCC, fat percentage, protein percentage, lactose percentage) for the 12 day
period and separately for the first seven days after diagnosis.
The analysis for the 12 day period showed a significant positive association between Hp
concentrations and M-SAA concentrations and the severity of the mastitis, as categorised
on the day of recruitment to the study (Table 4.9). Cases with high Hp concentrations
were likely to be moderate in severity, and also to have high M-SAA concentrations. Data
were assessed for the first seven days after recruitment, and Hp concentrations were
associated with IQSCC, M-SAA concentration, protein percentage and bacteria identified
from milk sample on the day of recruitment. Cases with high Hp concentrations in the
first seven days were likely to have high IQSCC, high M-SAA concentrations, high
protein percentage and have bacteria isolated from the day of recruitment sample rather
than no growth (Table 4.10).
Data analysis for the 12 day period found that M-SAA concentrations were significantly
associated with Hp concentrations and IQSCC (Table 4.11). Cases with high M-SAA
concentrations were likely to have high IQSCC and high Hp concentrations. Using the
data from the first seven days after recruitment into the study, the M-SAA concentrations
were associated with IQSCC, haptoglobin concentrations and protein percentages, such
that cases with higher M-SAA concentrations were likely to have high IQSCC, high Hp
concentrations and high protein percentages (Table 4.12).
The ability of APP concentrations in milk to differentiate between normal animals and
cases of clinical mastitis, and between moderate and mild cases of clinical mastitis, was
determined by estimating the sensitivity, specificity, negative predictive value, positive
predictive value and overall accuracy of the proteins as diagnostic tests.
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Explanatory variable Coefficient (SE) 95%CI LRS P value
M-SAA 0.72 (0.04) 0.64 - 0.79 <0.001
Severity <0.05
Mild Reference category
Moderate 0.53 (0.25) 0.05-1.01
LRS Likelihood ratio test statistics M-SAA Mammary-associated Serum Amyloid A
Table 4.9: Final multivariable mixed effects model of variables that were associated with
haptoglobin concentrations inmilk from mild and moderate cases of clinical mastitis for
the first 12 days after recruitment to the study
Explanatory variable Coefficient (SE) 95%CI LRS P value
IQSCC 0.96 (0.25) 0.46-1.45 <0.001
M-SAA 0.24 (1.08) 0.02-0.45 <0.005
Protein 0.31 (0.16) 0.01-0.61 <0.05
Bacteria <0.001
No growth Reference category
Suberis 0.77 (0.42) -0.05-1.59
Ecoli 0.75 (0.42) -0.07-1.57
Staph aureus 0.79 (0.50) -0.20-1.77
Apyogenes 0.75 (0.91) -1.03-2.53
Sdysgaiactiae 0.15 (0.88) -1.56-1.87
CN Staph 0.18 (0.72) -1.23-1.58
Corynebacterium spp. 0.88 (1.20) -1.47-3.23
Contaminated 0.95 (1.16) -1.32-3.23
Candida spp. 0.18 (1.00) -1.77-2.14
LRS Likelihood ratio test statistics IQSCC Individual Quarter Somatic Cell Count M-SAA Mammary-
associated Serum Amyloid A
Table 4.10: Final multivariable mixed effects model of variables that were associated with
haptoglobin concentrations in milk from mild and moderate cases of clinical mastitis for
the first seven days after recruitment to the study
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Explanatory variable Coefficient (SE) 95%CI LRS P value
IQSCC 0.58 (0.13)
Haptoglobin 0.51 (0.07)
0.33 - 0.83
0.38 - 0.63
<0.001
<0.001
LRS Likelihood ratio test statistics IQSCC Individual Quarter Somatic Cell Count
Table 4.11: Final multivariable mixed effects model of variables that were associated with
mammary-associated serum amyloid A (M-SAA) concentrations of mild and moderate
cases for the first 12 days after recruitment to the study
Explanatory variable Coefficient (SE) 95%CI LRS P value
IQSCC 0.70 (0.17) 0.36-1.03 <0.001
Haptoglobin 0.41 (0.08) 0.25-0.57 <0.005
Protein 0.32 (0.13) 0.07-0.57 <0.005
LRS Likelihood ratio test statistics IQSCC Individual Quarter Somatic Cell Count
Table 4.12: Final multivariable mixed effects model of variables that were associated with
mammary-associated serum amyloid A (M-SAA) concentrations of mild and moderate
cases for the first seven days after recruitment to the study
True
Cases Normal
Total
Test Cases
Normal 1L-~_8 ..:...:°15=--_--I1 ~~
69 15 84Total
Sensitivity
Specificity
Negative predictive value
Positive predictive value
Accuracy
68/69 = 98.6%
15115 = 100%
15/16= 94%
68/68 = 100%
83/84 = 98.8%
Table 4.13: Two-by-two table to test the ability of Hp concentrations to differentiate
between cases of clinical mastitis and normal animals detailing the sensitivity, specificity,
negative predictive value, positive predictive value and accuracy
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The Hp concentrations 'cut-off' point for cases and normal animals was zero, as all
normal animals had Hp concentration < LOD. Table 4.13 showed that the sensitivity of
detecting cases of clinical mastitis from normal animals was 98.6%, while the specificity
was 100%.
The Hp concentrations 'cut-off' point for moderate and mild cases was estimated from the
mean of cube root Hp concentrations for all cases. Cases with lower Hp concentrations
than the mean, <3.584, were classed as test mild and cases ~.584 were classed as test
moderate. Table 4.14 showed that the sensitivity of detecting moderate clinical mastitis
from mild cases of clinical mastitis was 68%, while the specificity was also 68%.
The M-SAA concentrations 'cut-off' point for cases and normal animals was taken as the
highest value for a normal animal, 1.0354. Animals with M-SAA concentrations lower
than 1.0354 were classed as normal and animals with concentrations ~1.0354 were
classed as cases of clinical mastitis. The M-SAA concentrations 'cut-off' point for
moderate and mild cases was estimated from the mean of cube root M-SAA
concentrations for all cases. Cases with lower M-SAA concentrations than the mean,
<2.987, were classed as test mild and cases ~.987 were classed as test moderate. Tables
4.15 & 4.16 show that the sensitivity of detecting cases of clinical mastitis from normal
animals was 88%, while the specificity was 100%. The sensitivity of detecting moderate
clinical mastitis from mild cases of clinical mastitis was 36%, while its specificity was
also 63%.
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True
Moderate Mild
Total
Test Moderate
Mild
Total
Sensitivity
Specificity
Negative predictive value
Positive predictive value
Accuracy
19/28 - 68%
28/41 = 68%
28/37 = 76%
19/32 = 59%
47/69 = 68%
Table 4.14: Two-by-two table to test the ability of Hp concentrations to differentiate
between moderate and mild severity clinical mastitis detailing the sensitivity, specificity,
negative predictive value, positive predictive value and accuracy
True
Cases Normal
Total
Test Cases
Normal IL:=-1 ~:...:.5__ __J1 ~~
69 15 84Total
Sensitivity
Specificity
Negative predictive value
Positive predictive value
Accuracy
61169= 88%
15/15 = 100%
15/23 = 65%
61161= 100%
76/84=90%
Table 4.15: Two-by-two table to test the ability ofM-SAA concentrations to differentiate
between cases of clinical mastitis and normal animals detailing the sensitivity, specificity,
negative predictive value, positive predictive value and accuracy
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True
Moderate Mild
Total
Test Moderate
Mild IL~:":~:'___--=~:":~__ _jl ~
28 41 69Total
Sensitivity
Specificity
Negative predictive value
Positive predictive value
Accuracy
10/28 = 36%
26/41 = 63%
26/44= 59%
10/25 = 40%
36/69 = 55%
Table 4.16: Two-by-two table to test the ability of log M-SAA concentrations to
differentiate between moderate and mild severity clinical mastitis detailing the sensitivity.
specificity, negative predictive value, positive predictive value and accuracy
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4.4. Discussion
The pathogen profile of clinical mastitis for cases recruited in this study showed that the
most prevalent isolates were S uberis (30%), E coli (22%), Staph aureus (11%), other
microbiological isolates (six per cent), A pyogenes (four per cent) and S dysgalactiae
(three per cent). No growth was reported in 24% of the submitted samples. These
microbiological results are consistent with the findings of an investigation of the
prevalence and aetiology of clinical mastitis in Devon by Milne and others (2002), which
highlighted that environmental pathogens, including S uberis and coliforms, were more
commonly isolated from cases of clinical mastitis than contagious pathogens. In the study
by Milne and others (2002), S uberis was isolated in 37% of cases, enterobacteriaceae in
23%, coagulase-negative staphylococci in 10%, other isolates in nine per cent, S
dysgalactiae in four per cent and Staph aureus in three per cent and no growth in 14% of
samples. The Veterinary Investigation Diagnosis Analysis reports (Anon 1982; Anon
1989; Anon 1993; Anon 1999) also demonstrate an increasing prevalence of mastitis
caused by environmental streptococci and coliforms in recent years. This trend seems to
be seen nationally within the UK and is likely to reflect the improvement in the control
and treatment of the contagious pathogens.
The high proportion of no growth from mastitic samples was similar to that found in other
studies of clinical mastitis (Wilson and Kingwi1l1975; Wilesmith and others 1986; Milne
and others 2002) and could have been due to rapid elimination of the pathogen by the host
defences or continued activity of natural inhibitors in the milk between sampling and
culturing, Le. presence of non-viable bacteria, or the presence of exogenous inhibitory
substances. Zorah and others (1993) showed that 51% of 84 samples yielded no growth
on bacteriological culture were identified as containing antigen for E coli. Therefore, the
22% of E coli detected in this study could be an underestimate of the true prevalence. In
the present study farm records were consulted to determine whether any antimicrobial
drugs had been administered to cases of clinical mastitis prior to recruitment to the study,
therefore the presence of inhibitory substances in the milk was unlikely.
A greater proportion of cases of mastitis caused by S uberis failed to complete the 45 day
study period compared to all other isolates, although the difference was not significant.
The high drop out rate of cases of clinical mastitis due to S uberis is consistent with the
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reports suggesting that S uberis is a major problem in the control of clinical mastitis
(Bramley 1982), due to its' ubiquitous nature (Leigh 1999) and its' ability to persist in the
mammary gland (Milne and others 2004).
Moderate cases of clinical mastitis had significantly (p<0.01) more cases caused by S
uberis and there tended to be more cases caused by E coli than in mild cases of clinical
mastitis. A smaller study of mild and moderate clinical mastitis reported that E coli was
isolated in 38% of moderate cases but only in 12.5% of mild cases (Eckersall and others
2001), however, those authors reported a very low incidence of S uberis mastitis.
Published reports confirm that E coli mastitis is often more severe than other causes of
mastitis. Bradley and Green (2001) reported that cases of E coli mastitis were more likely
to have systemic signs than other causes of mastitis, and White and others (1986) noted
that cows with 'general weakness', swollen udder and high body temperature were more
likely to have coliform infection than any other types of mastitis. In a study investigating
the cause of clinical mastitis and associated clinical signs in dairy cattle, Milne and others
(2003) reported that the presence of an abnormal udder texture had approximately twice
the odds of being caused by enterobacteriaceae than by any other group of organisms. At
present, there have been no studies suggesting that S uberis is associated with increasing
severity of disease, however, the results from this current study strongly suggested that S
uberis is more likely to result in abnormalities of the udder in addition to changes in the
milk appearance. The finding that more Staph aureus infections were mild is consistent
with the observation that Staph aureus resides mainly in the udder (McDonald 1977) and
that the majority of Staph aureus infections are chronic subclinical infections, with
occasional clinical cases of mild to moderate severity (Cullor and Tyler 1996).
Clinical signs alone are considered to be insufficient to differentiate between infections
caused by Gram-positive and Gram-negative bacteria with certainty (Morin and others
1998), but recent work indicates that some clinical signs are more likely to be associated
with certain types of pathogens than others (Milne and others 2003). Animals infected
with enterobacteriaceae had the greatest odds of having 'reduced' milk yield, 'swollen' or
'hard' udders, 'watery' milk and/or being systemically 'sick', as judged by the farmer
using carefully defined criteria from all cases of clinical mastitis that occurred in Devon
dairy herds over a 15 month period (Milne and others 2003). In this study, predictors for
Gram-staining characteristics, i.e. Gram-negative or Gram-positive, of the bacteria
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causing clinical mastitis were 'cow demeanour' and 'milk yield'. Thus, a cow with
clinical mastitis that was 'sick' and had a 'reduced' milk yield was likely to have clinical
mastitis caused by a Gram-negative pathogen.
Multilevel analysis of physiological and laboratory data in this study revealed significant
associations with pathogen type. The microbiological finding of no growth from milk
samples taken on the day of recruitment was associated with low IQSCC, and the
isolation of Staph aureus was more likely in mild cases of mastitis. These results suggest
that cases with microbiological result of no growth or Staph aureus in the sample taken
on the day of recruitment are associated with less severe damage to the mammary tissue,
and indeed this links to the finding that there were significantly more culture results of no
growth and tended to be more isolations of Staph aureus in mild cases of mastitis
compared to moderate cases of clinical mastitis. Streptococcus uberis was associated with
increasing severity and is consistent with the occurrence of significantly more S uberis
isolations in moderate cases. Escherichia coli mastitis was associated with higher heart
rates, which agrees with the results of previous studies indicating that E coli
intramammary infections were more likely to induce systemic signs (Bradley and Green
2001). A systemic bacteraemia was identified in 32% of dairy cows with clinical mastitis
caused by coliforms (Wenz and others 2001).
The median log IQSCC were significantly greater in the quarter from the affected gland
of cows with mild or moderate mastitis than the diagonally opposite quarter of these cows
and normal cows (p<0.001). There was no significant difference between the median log
IQSCC of the affected quarter from mild and moderate cases of mastitis (p>O.05). This
result is likely to be unreliable as more samples from moderate (10/28) cases than mild
(9/41) cases could not be tested due to the presence of clots, and thus more moderate
cases were given the maximum value for log IQSCC. It would be expected that milk from
the affected quarter of moderate cases would have a greater IQSCC compared to milk for
the affected quarter of mild cases. The median log IQSCC for affected and diagonally
opposite quarters remained significantly higher than that of normal animals for the
duration of the study, however, there was no significant difference between the affected
quarter and the diagonally opposite quarter in cases of clinical mastitis 45 days after
recruitment to the study. There was no prior information on the cell count of the animals
before recruitment to the study and it may be that the cows that went on to develop
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clinical mastitis had higher cells counts that the normal animals prior to infection. There
was no significant difference in parity and stage of lactation of the clinical cases of
mastitis and the normal cows, and latter were selected from the farms that provided the
clinical cases, suggesting that the normal cows were representative of the population at
risk. Somatic cell counts are used as indicators of disease, but there are a number of other
factors, such as breed, age, stage of lactation and physiological stresses such as
excitement, high temperatures and trauma that can affect levels, making a single result
inconclusive (Cullen 1966; Tolle 1975; Reneau 1986). Multiple sce records for
individual cows or quarters, however, are useful to monitor the dynamics of udder health
and response to treatment (Reneau 1986). Results from the study by Reneau (1986)
showed that following a clinical incident, the IQSCC decreased after treatment but
remained high for prolonged period and with less frequent sampling and monitoring,
cows recovering from clinical mastitis could have been classed as having subclinical
infections. Hillerton (1997) reported that at a cow level (ICSCC) a 'good' cure results in
the cell count being below 400,000 cells/ml in approximately 20 milkings although pre-
infection cell count levels may not be recovered in some animals within 50 milkings. The
SCC data in this study was at the quarter level and explains why the cell count of the
affected quarters was higher for longer period than in the study by Hillerton (1997).
There was no significant effect of mastitis on the fat percentage of milk, as judged by the
comparison of affected quarters to diagonally opposite quarters and to those of normal
cows. The protein content of milk increased with mastitis and the lactose content
decreased compared to that in diagonally opposite quarters and in those of normal cows.
Literature regarding the changes in milk fat and protein per cent were reviewed by Hortet
and Seegers (1998) and were reported to be contradictory. A small decrease in fat
production due to mastitis was reported, but was considered to be trivial for short duration
infections and only important for persistent infections that were carried over into the next
lactation and recurring severe infections (Houben and others 1993). The lack of
significant change in the fat content in this study may have been due to the fact that the
cases studied were all acute infections.
In cows with mastitis the protein concentration was reported to increase slightly (Houben
and others 1993). This was reported more with infections that persisted into the next
lactation, and the milk volume was reduced and therefore the overall total protein
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production was reduced (Houben and others 1993). Other studies (Myllys and Rautala
1995) showed a decrease in protein content, however, the cases with mastitis were of
higher genetic potential and had lower protein and fat contents genetically compared to
the animals used as controls, thereby making comparison difficult. The main importance
of milk compositional changes with mastitis is for manufacturing companies, however,
clinically altered milk has to be removed from human consumption for legislative reasons
and the use of antimicrobials results in the milk being withheld to avoid residues in milk.
In the present study, examination of milk samples from normal cows and from cases of
clinical mastitis 20 and 45 days after the clinical incident demonstrated that the
predominant cells present were macrophages. This is consistent with previous studies
reporting that macrophages were the predominant cell type in milk tissues of healthy
mammary glands (Outteridge and Lee 1981; Riollet and others 2000). The most common
somatic cell type in quarters affected with mild and moderate mastitis on the day of
recruitment to the study were PMNs. Daley and others (1991), Riollet and others (2000)
and Sordillo and Streicher (2002) also reported that PMNs were the principal cell type
present in mammary tissues and secretions during early inflammation. The relative
proportion of PMNs then decreased over the 45 days after recruitment to the study, and
there were consequent increases in lymphocyte and macrophage proportions. The immune
response is activated within 24 hours of initial PMNs influx and results in the increase in
lymphocytes numbers. There was no significant difference in the differential cell count of
mild cases versus moderate cases of clinical mastitis, and there was no effect of
meloxicam treatment.
The median concentrations of Hp and M-SAA measured in the milk of cows with mild
and moderate mastitis in this study were 27.3 ug/ml and 83.8 ug/ml and 20 ug/ml and 8.5
ug/ml, respectively. These results are similar to those reported in other studies of
naturally occurring mastitis in dairy cattle (Eckersall and others 2001; Nielsen and others
2004). Eckersall and others (2001) reported a median Hp concentration of 90 ug/ml and
110 ug/ml in mild and moderate cases of mastitis, respectively, and median M-SAA
concentrations of 2.6 ug/ml and 20.6 ug/ml in mild and moderate cases of mastitis,
respectively. In the current study the median Hp concentrations in the diagonally opposite
quarter to the quarter affected with mastitis were 6.0 ug/ml and 2.7 J.1g/mlfor mild and
moderate cases of mastitis respectively. The median M-SAA concentrations in the
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diagonally opposite quarter were 0.5 ug/ml and 1.2 p,glml for mild and moderate cases of
mastitis respectively. Eckersall and others (2001) reported the Hp range for the diagonally
opposite quarter to the quarter affected with mastitis to be 0.02 - 0.56 ug/ml for the 2/16
cases of mild clinical mastitis and 0.02 - 0.80 ug/ml for the 2/13 cases of moderate
clinical mastitis that had detectable levels. The range of M-SAA concentrations in the
5116 cases of mild clinical mastitis with detectable levels was 0.2 - 9.4 ug/ml and in the
7/13 cases of moderate clinical mastitis with detectable levels was 0.2 - 27 ug/ml. As was
seen in this study, Eckersall and others (2001) also reported that the Hp concentrations in
all normal animals were below the limit of detection. The M-SAA concentrations of 4/15
normal animals with detectable levels had a range of 0.005 - 1.11 ug/ml in this study and
in the study by Eckersall and others (2001) the M-SAA concentrations were detectable in
8/32 normal animals with a range of 0.2 - 0.54 ug/ml in normal animals. Nielsen and
others (2004) reported a mean haptoglobin concentration of 110 ug/ml for the infected
quarter and a mean 1.0 ug/ml for the diagonally opposite quarter and mean M-SAA
concentration of 47.5 ug/ml in the mastitic quarter and a mean of 40.2 ug/ml in the
diagonally opposite quarter. In mastitis, experimentally induced by infusion of
Staphylococcus epidermidis into the mammary glands of sheep, the mean M-SAA
concentration in the milk of the affected gland was 2,49611g1ml(Winter and others 2003).
whichwas much higher than that measured in naturally occurring mastitis in cattle.
The detection of Hp and M-SAA in the milk of affected quarters of cows with mild and
moderate clinical mastitis indicated that an acute phase response had occurred. In the
normal cows no haptoglobin was detected and very low M-SAA concentrations were
detected in only 4/15 normal cows. Haptoglobin and M-8AA concentrations were
detectable in the majority of the diagonally opposite quarters of cows with mastitis.
suggesting release of acute phase proteins from a systemic source or local production in
these quarters due to local activation of an acute phase response. The study conducted by
Nielsen and others (2004) demonstrated that extramammary inflammatory conditions that
induced increases in the serum concentration of 8AA were not accompanied by increases
in M-SAA suggesting that an intramammary inflammatory stimulus is required for
concentrations of M-8AA to increase, however, there were only eleven animals with
extramammary infection in the study. These authors could not assess whether it Was also
the case with Hp due to only one animal with extramammary inflammation having
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detectable serum Hp concentrations. Eckersall and others (2001), however, reported a
significant correlation with Hp concentration in serum and in milk but no association with
SAA and M-SAA. We can conclude that increases in M-SAA in the diagonally opposite
quarters were likely to be due to inflammatory processes in that quarter but the increase in
the milk Hp concentrations could be due to leakage across the blood/mammary gland
barrier from the systemic acute phase response. The hypothesis that there were
inflammatory responses in the diagonally opposite quarters was also indicated by the
increased IQSCC.
In an experimental study (Hirvonen and others 1996) where micro-organisms were
infused into both hindquarters of dairy heifers to induce mastitis, Hp concentrations in
blood increased the day after infusion and maximum levels were reached in 2-3 days. The
levels in heifers with moderate mastitis returned to normal within five days whereas the
levels remained increased for two weeks after inoculation in the heifers with severe
mastitis. In this study concentrations of APP were assessed only in milk and it was found
that Hp concentrations were maximal on the day of recruitment to the study, whereas M-
SAA concentrations reached peak concentrations two days after recruitment to the study.
A difference in the kinetics of Hp and M-SAA was not reported by Hogarth (2004).
Somatic cell counts, Hp and M-SAA concentrations were monitored in milk prior to the
development of clinical mastitis and it was reported that before and after clinical mastitis,
both M-SAA and Hp showed similar kinetics and were similar to SCC. Peak
concentrations of M-SAA and Hp occurred in conjunction with sec and on the same day
as clinical signs in three out of seven cases of clinical mastitis, while in the other four
cases the increase in concentration occurred either prior, to or in conjunction with the rise
in SCC.
Haptoglobin and M-SAA concentrations in milk were sensitive and specific markers of
disease. The aim of this study was to differentiate between cases of clinical mastitis and
normal animals. Haptoglobin was shown to have a sensitivity and specificity of 98.6%
and 100%, respectively, while M-SAA had a sensitivity and specificity of88% and 100%,
respectively. Haptoglobin concentrations from cases of mild clinical mastitis were
Significantly different from cases of moderate clinical mastitis. Haptoglobin
concentrations can therefore be used to differentiate between mild and moderate severities
of clinical mastitis, but with PPV of 59% and NPV of 76% there would be a considerable
Maureen H. Milne Chapter 4, 184
degree of misclassification. In the absence of skilled labour this test could aid in the
targeting of specific therapy. The concentrations of Hp and M-SAA in the affected
quarter of mild and moderate clinical mastitis decreased over the study period but were
still significantly greater than the concentrations in diagonally opposite quarters and in
normal animals. Thus, milk APP concentrations could therefore be valuable and rapid
markers to aid in the clinical diagnosis, prognosis and treatment monitoring of dairy cattle
with intramammary infections and could be used in automated milking systems in the
future.
There was no effect of meloxicam treatment on IQSee and differential cell count,
however, meloxicam would not be expected to alter cellular immune responses.
Meloxicam acts to reduce inflammation, and it was therefore hypothesised that there may
be a treatment effect on the acute phase protein concentrations. This was not seen in this
study and can be explained by the fact that there are many different mediators and
pathways involved in the acute phase response, with meloxicam only acting on the COX
enzymes.
In conclusion, the pathogen profile differed with severity of the clinical mastitis. The
protein percentage decreased and the lactose per cent increased in the presence of
mastitis. There was a dramatic increase in sec, which was largely due to an influx of
PMNs into the mammary gland. Acute phase protein concentrations in the milk increased
rapidly and haptoglobin concentration on the day of clinical signs of the mastitis could be
used to differentiate between mild and moderate cases of mastitis. Differentiation
between different severities of mastitis could be important for therapeutic decisions, such
that analgesics could be administered to the more severe cases of clinical mastitis as a
routine treatment along with intramarnmary antimicrobial preparations.
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Chapter 5
Prostaglandin E2 and meloxicam concentrations
in milk from cows with clinical mastitis
5.1. Introduction
Prostaglandins (pGs) are ubiquitous in most mammalian tissue and organs where they
have numerous diverse biological effects on a variety of physiological and pathological
processes (Uda and others 1990). The production of PGs begins with the liberation of
arachidonic acid from membrane phospsholipids by phospholipase A2 in response to
inflammatory stimuli, following which arachidonic acid is then converted to PGH2 by the
cyclooxygenase enymes COX-l and COX-2 (Harris and others 2002). Cell-specific
prostaglandin synthases convert PGH2 into a series ofPGs including PGh, PGF2a, PGD2
and PGE2. Prostaglandin E2, PGh and PGD2 are powerful vasodilators and contribute to
the redness and increased blood flow in areas of acute inflammation. They also sensitise
pain receptors, thus lowering the pain tolerance threshold (Reyes and others 2002).
Increased concentrations of PGE2 were reported in experimental models of bovine
inflammation (Thomas and others 1995) and in naturally occurring mastitis cases
(Atroshi and others 1987). Anderson and others (1985) reported an increase PGF2a and
TXB2in bovine mastitis and showed that increases in concentrations corresponded to the
clinical severity of mastitis.
Anti-inflammatory drugs are widely used in veterinary practice in order to provide
symptomatic relief in the treatment of both acute and chronic inflammatory conditions
(Cunningham and Lees 1994). The principal value of these drugs is to relieve pain and
reduce swelling. The most commonly used drugs are the corticosteroids (glucocorticoids)
and the NSAID. Non-steroidal anti-inflammatory drugs inhibit the transformation of
arachidonic acid to stable PG (i.e. PGE2 and prostacyclin) (Abramson and Weissmann
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1989). Meloxicam is a NSAID within the group of enolic acids that inhibit COX
enzymes and thus inhibit the production of POs and other inflammatory mediators
(Reyes and others 2002). Meloxicam therefore has anti-inflammatory, anti-exudative,
analgesic and antipyretic properties (Rang and others 1999).
The objective of this study was to assess if POE2 concentrations in milk could act as
quantitative markers of severity of clinical mastitis in cows and whether the use of
meloxicam reduced the concentrations ofPGE2 in milk following treatment.
5.2. Materials and methods
5.2.2. Sample selection
Prostaglandin E2 (PGE2) was measured by radio-immunoassay (Chapter 2) in samples
from the mastitic (affected) quarter of all 69 complete cases of clinical mastitis (there
was an inadequate volume of milk from one cow) on 0, 1 and 2 days after diagnosis of
mastitis. Meloxicam concentrations were measured using High Performance Liquid
Chromatography (HPLC) (Chapter 2) in 16 cases that were selected randomly from all
complete cases using random number generator inMinitab Statistical Software release 13
(Minitab INC). These 16 cases included eight cases from the treatment group that were
given antibiotics and one dose of meloxicam (group 2) and eight cases that were given
antibiotics and three doses of meloxicam (group 3) (Chapter 2). In both treatment groups,
meloxicam was administered by intravenously route, at the rate of 0.5mg/kg. In Group 2
the meloxicam was administered on the day of diagnosis of the mastitis (day of
recruitment) and in group 3 meloxicam was administered on the day of recruitment, three
days and six days after recruitment.
5.2.2. Data analysis
Data were entered into Microsoft Access 2000 and basic statistical analysis was
conducted using Microsoft Excel and Minitab Statistical Software version 13 and
univariable and multivariable regressions were performed using S-Plus 2000 and MlwiN
version 1.1 as detailed in Chapter 2. Data for PGE2 were transformed to improve
normality and stabilise variance. To examine the effect of meloxicam treatment on the
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PGE2 concentrations treatment groups 2 and 3 were combined, such that the treatment
groups were antibiotics only (group 1) versus antibiotics and meloxicam (groups 2 and
3). Groups 2 and 3 were merged as PGE2 concentrations were measured on the day of
recruitment, day 1 and day 2, which was before the second and third doses of meloxicam
were administered for cases in group 3.
Two-by-two tables were constructed to allow the sensitivity, specificity, predictive
values and accuracy to be calculated (Dohoo and others 2003) for cases with clinical
mastitis versus normal animals and mild versus moderate cases of clinical mastitis.
5.3. Results
5.3.1. Prostaglandin E2
Radio-immunoassay (Chapter 2) was performed on milk samples from the day of
recruitment, one day and two days after recruitment for 69 cows with mild and moderate
clinica1 mastitis. The PGE2 concentrations in the milk from the affected quarter for the 69
cases varied widely (Table 5.1), but, in general, the concentrations were higher in the
moderate cases on the day of recruitment compared to mild cases, and higher on the day
of recruitment compared to days one and two after the day of recruitment. The PGE2
concentration in the affected quarter from mild cases ranged from 0 - 3.08 ng/ml with a
median of 0.0 ng/ml and a mean of 0.148 ng/ml on the day of recruitment to the study
(day 0). The PGE2 concentration in the affected quarter from moderate cases ranged from
o - 10.2 ng/ml with a median of 0.095 ng/ml and a mean of 1.01 ng/ml on the day of
recruitment to the study (day 0). The mean log PGE2 concentration for moderate cases
was 0.16 (SE±0.06) and was significantly higher (p<0.05) than for mild cases, where the
mean log PGE2 concentration was 0.04 (SE±O.02) on the day of recruitment to the study
(Figure 5.1).
The mean log PGE2 concentrations were highest on the day of recruitment and decreased
over the next two days for mild and moderate cases of clinical mastitis (Figure 5.2). The
log PGE2 concentrations for the treatment groups that received antibiotics only (group 1)
and antibiotics plus meloxicam (groups 2 and 3) showed similar patterns (Figure 5.3).
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PGE2 concentration (ng/ml)
Treatment Severity DayO Day 1 Day2
Antibiotics Mitd(n=13) 0(0 -0.105) 0(0 -0.015) 0(0- 0.09)
Moderate (n=8) 0.23 (0.08 - 3.09) 0.02 (0 - 0.158) 0(0 - 0.023)
Antibiotics + Mild (n=2S) 0.06 (0 - 0.158) 0(0 - 0.038) 0(0 - O.OS)
Meloxicam Moderate (n=20) 0.05 (0 - 0.275) 0(0 - 0.038) 0(0 - 0.105)
All cases (n=69) 0.07 (0 - 10.2) 0(0 -4.1) 0(0- 6.29)
Table 5.1: Median and inter-quartile ranges of prostaglandin E2 (ng/ml) concentrations in
the milk of cases of mild and moderate clinical mastitis treated with antibiotics only
(group 1) or antibiotics plus meloxicam (group 2 and 3) on the day of recruitment to the
study (day 0) and on the following two days (day 1& 2)
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Figure 5.1: Log PGE2 concentrations for mild (n=41) and moderate (n=28) cases of
clinical mastitis on day of recruitment to the study (day 0).
For each group, the median value is represented by the horizontal line within the box and
the mean value denoted by the dot. The bottom and top of the box represent the first and
third quartiles respectively. The vertical lines extending from the box represent the
lowest and highest observations within 1.Sx the inter-quartile range below and above the
first and third quartiles respectively. Outliers are denoted by *.
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Figure 5.2: Log PGE2 concentrations ±SE for mild (n=41) and moderate (n=28) cases of
clinical mastitis on the day of recruitment to the study (day 0) and the following two days
(day 1 & 2)
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Figure 5.3: Log PGE2 concentrations ±SE for mild and moderate cases of clinical
2
mastitis given antibiotics only (n=21) and antibiotics plus meloxicam (n=48) on the day
of recruitment to the study (day 0) and the following two days (day 1 & 2)
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When cases were separated into different severities, the treatment groups again showed
the same general trend of highest concentrations of PGE2 on the day of recruitment with
a decrease over the next two days. Mild cases of clinical mastitis (Figure 5.4) had lower
concentrations PGE2 than moderate cases of clinical mastitis (Figure 5.5), but there was
no significant (p>0.05) treatment effect on the concentrations of PGE2, either one or two
days after the day of recruitment into the study.
The PGE2concentrations varied with the different causal pathogen of mild and moderate
clinical mastitis cases (Table 5.2). The highest concentrations were detected in milk
samples from the day of recruitment in cases caused by Suberis and E coli, with the peak
concentrations ofPGE2 in these cases being 10.2 ng/ml and 9.86 ng/ml, respectively. The
log PGE2 concentrations for mastitis caused by Staph aureus showed a narrow range of
concentrations (0 - 0.09), whereas mastitis caused by S dysgalactiae (0 - 0.42) and
miscellaneous organisms (0.04 - 0.66) had wide concentration ranges. There were,
however, only three cases caused by S dysgalactiae and three cases caused by
miscellaneous organisms (Figure 5.6). There was no significant difference in the log
PGE2 concentrations between any of the bacteriological groups, but the environmental
organisms, such as S uberis, E coli and A pyogenes, and no growths had a greater range
in concentrations and greater median and mean values than mastitis caused by Staph
aureus,
Univariable screening of log PGE2 concentrations and physiological parameters, such as
parity, days calved, body condition score, treatment group, heart rate, respiratory rate,
rectal temperature, milk yield, udder lesions, udder cleanliness, hock-to-hock distance
and threshold difference (Chapter 3) and laboratory parameters, such as bacteriological
culture result, log IQSCC, fat percentage, protein percentage, lactose percentage, cube
root Hp concentration and cube root M-SAA concentration (Chapter 4) showed no
significant association with any variable and the log PGE2 concentrations in this data set.
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Figure 5.4: Log PGE2 concentrations ±SE for mild cases of clinical mastitis given
antibiotics only (n=13) and antibiotics plus meloxicam (n=28) on the day of recruitment
to the study (day 0) and the following two days (day 1 & 2)
2
Maureen H. Milne
Chapter 6, 194
PGE2 concentration (ng/ml)
Isolated pathogen DayO Day 1 Day2
S uberis (n=19) 0.05 (0 - 0.15) 0(0-0.13) 0(0 - 0.11)
E coli (n=15) 0.10 (0 - 0.28) 0.02 (0 - 0.06) 0(0 - 0.07)
No growth (n=18) 0.07 (0 - 0.23) 0(0 -0.06) 0(0 - 0.09)
Staph aureus (n=9) 0.0 (0-0) 0(0- 0) 0(0 -0.08)
S dysgalactiae (n=3) 0.07 (0 - 1.6) 0(0-0) 0(0-0.04)
A pyogenes (n=2) 0.16 (NA) 0.08 (NA) 0.08 (NA)
Miscellaneous (n=3) 0.16 0.03 (0 - 4.07) 0(0 -1.65)
NA not applicable as there were only two samples
Table 5.2: Median and inter-quartile ranges of PGE2 (ng/ml) concentrations in the milk
of cases of mild and moderate clinical mastitis caused by S uberis (n=19), E coli (n=15),
no growth (n=18), Staph aureus (n=9), S dysgalactiae (n=3), A pyogenes (n=2) and
miscellaneous organisms (n=3) on the day of recruitment to the study (day 0) and the
following two days (day 1& 2)
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Figure 5.6: Log PGE2 concentrations for clinical mastitis caused by S uberis (n=19), E
coli (n=lS), no growth (NG) (n=18), Staph aureus (n=9), S dysgalactiae (S dys) (n=3), A
pyogenes (n=2) and miscellaneous organisms (Misc) (n=3) on day of recruitment to the
study (day 0)
True Total
Moderate Mild
Test Moderate I!~ 6 I~~Mild 35
Total 28 41 69
Sensitivity 10/28 = 36% 95% Cl 18.2 - 53.8%
Specificity 35/41 = 85% 95% Cl 74.1 - 95.9%
Negative predictive value 35153 = 66% 95% Cl 53.2 - 78.8%
Positive predictive value 10/16 = 63% 95% Cl 39.3 - 86.7%
Accuracy 45/69=65% 95% Cl 53.7 -76.3%
Table 5.3: Two-by-two table to test the ability of log PGE2 concentrations to differentiate
between moderate and mild severity clinical mastitis detailing the sensitivity, specificity,
negative predictive value, positive predictive value and accuracy
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The ability of PGE2 concentrations to differentiate between moderate and mild cases of
clinical mastitis was determined by estimating the sensitivity, specificity, negative
predictive value, positive predictive value and overall accuracy. The log PGE2
concentrations 'cut-off point for mild and moderate severity was estimated from the
mean oflog PGE2 concentrations for all cases. Cases with lower log PGE2 concentrations
than the mean, <0.0886, were classed as test mild and cases ~0.0886 were classed as test
moderate. Table 5.3 showed that the sensitivity of detecting moderate clinical mastitis
was 36%, while its specificity was 85%.
5.3.2. Meloxicam
Meloxicam concentrations were measured for eight cows given antibiotics and one dose
of meloxicam (group 2) and eight cows given antibiotics and three doses of meloxicam
(group 3). The retention times for meloxicam and piroxicam were approximately 7.1 and
5.7 minutes, respectively (Chapter 2) and this knowledge, along with spiking of the
samples with prioxicam, allowed the concentration of meloxicam from samples of the
cases of clinical mastitis to be estimated. A typical chromatogram for a cow (cow 14)
treated with antibiotics and three doses of meloxicam is shown in Figure 5.7.
There were no detectable levels of meloxicam in milk samples collected on the day of
recruitment or day 12. There were high levels ofmeloxciam in the samples taken on day
one and day seven and there were low levels of meloxicam detectable in milk samples
from day three and day six after recruitment to the study.
5.3.2.1. One dose of meloxicam
In the eight cases of clinical mastitis that were treated with antibiotics and one dose of
meloxicam, the meloxicam concentration peaked one day after treatment and
subsequently decreased to low levels two days later and six days after treatment
concentrations were undetectable (Figure 5.8 and Table 5.4). The mean concentration of
meloxicam measured in the milk one day after treatment was 0.11 ug/ml. The inter-
animal range was more variable at 0.03 - 0.38 J.1g/ml.The mean concentration of
meloxicam two days after drug administration was 0.04 ug/ml, with the inter-animal
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Figure 5.7: Typical chromatograms of meloxicam concentrations in the milk from the
affected quarter of a cow (cow 14) treated with antibiotics and three doses of meloxic811l
(group 3) and spiked with piroxicam (0.5J.lglml) from day of recruitment to the study
(day 0), day 1, day 2, day 3, day 6, day 7 and day 12 after recruitment
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ranges being 0.00 - 0.10 ug/ml. In all eight animals the concentration of drug had
declined to less than the detectable level by six days after the last drug administration.
5.3.2.2. Three doses of meloxicam
In the eight cases of clinical mastitis that were treated with antibiotics and three doses of
meloxicam, the meloxicam concentration peaked one day after treatment (day one, day
four and day seven: no data were available for day four after treatment) and subsequently
decreased to low levels two days later (day two, day five and day eight: no data available
for days five and eight) and six days after treatment concentrations were undetectable
(Figure 5.9 and Table 5.5). The mean concentration of meloxicam measured in the milk
one day after treatment was 0.11 ug/ml, The inter-animal range was quite variable, being
0.00 - 028 ug/ml, The mean concentration of meloxicam two days after treatment was
0.04 ug/ml with the inter-animal ranges being 0.01 - 0.12 ug/ml, Three days after
treatment the meloxicam concentration was 0.02 ug/ml with the inter-animal range being
0.00 - 0.09 ug/ml, On day six, three days after the latest treatment with meloxicam
(administered on day three) the mean concentration was 0.00 ug/ml and the inter-animal
range was 0.00 - 0.01ug/ml. The mean concentration on day seven, one day after the
latest treatment with meloxicam (administered on day six), was the same as for day one,
0.11 ug/ml, The inter-animal range was 0.05 - 0.25 ug/ml. In all eight animals the
concentration of drug had declined to less than the detectable level by six days after the
last drug administration, this being day 12 for cases in group 3.
It was not possible to examine the relationship between the concentrations of meloxicam
and PGE2 one day after meloxicam treatment because 87.5% (14/16) of the cases in
which the meloxicam concentrations were measured had PGE2 concentrations below the
LOD one day after recruitment to the study. The PGE2 concentrations one day after
recruitment for all cases (n=69) was used to compare to the concentrations in the 16
cases that also had meloxicam concentrations measured. In the cases that were treated
with antibiotics, 66.7% (14/21) had PGE2 concentrations below the LOD one day after
recruitment to the study, with the mean (SE) for the log PGE2 concentrations one day
after recruitment to the study being 0.05 (0.03). In cases that were treated with antibiotics
and meloxicam, 72.9% (35/48) had PGE2 concentrations below the LOD one day after
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Figure 5.8: Mean meloxicam concentrations ± SE for eight cases of clinical mastitis that
were treated with antibiotics and one dose of meloxicam (group 2) followed for six days
after recruitment to the study
Day/Case ID 1 2 3 4 5 6 7 8 Mean± SD
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 ± 0.00
1 0.10 0.08 0.38 0.10 0.07 0.05 0.03 0.03 0.11 ± 0.12
2 0.00 0.00 0.l0 0.01 0.08 0.01 0.02 0.07 0.04 ± 0.04
6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 ± 0.00
Table 5.4: Meloxicam concentrations (ug/ml) in milk from eight cows treated with
antibiotics and one dose of meloxicam (group 2) administered on day O. Milk samples
were taken prior to the administration of mel oxic am
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Figure 5.9: Mean meloxicam concentrations ± SE for eight cases of clinical mastitis that
were treated with antibiotics and three doses of meloxicam (group 3) followed for 12
days after recruitment to the study
Day/Case ID 9 10 11 12 13 14 15 16 Mean±SD
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 ± 0.00
1 0.14 0.08 0.19 0.08 0.01 0.28 0.l3 0.00 0.11 ± 0.09
2 0.01 0.02 0.05 0.06 0.01 0.05 0.12 0.03 0.04 ± 0.04
3 0.00 0.01 0.00 0.00 0.00 0.01 0.09 0.02 0.02 ± 0.03
6 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 ± 0.00
7 0.05 0.07 0.l2 0.08 0.06 0.16 0.25 0.10 0.11 ± 0.07
12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 ± 0.00
Table 5.5: Meloxicam concentrations (ug/ml) in milk from eight cows treated with
antibiotics and three doses of meloxicam (group 3) administered on day 0, 3 and 6. Milk
samples were taken prior to administration of meloxicam
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recruitment to the study, with the mean (SE) for the log PGE2 concentrations one day
after recruitment to the study being 0.04 (0.01). There was no significant difference
between the log PGE2 concentrations for cases treated with antibiotics only and those
treated with antibiotics and meloxicam.
5.4. Discussion
Prostaglandin E2 can be measured in milk of mastitic cows using a radio-immunoassay
technique. The median concentration of PGE2 for affected quarters of mild and moderate
cases of clinical mastitis was 0.07 ng/ml, equivalent to 70 pg/ml. Atroshi and others
(1987) reported similar concentrations of 61.3 pg/ml (mean) in the milk of mastitic cows.
They reported that PGE2 concentration in milk samples from the affected quarter of cows
with mastitis were approximately 40% greater than the concentrations of PGE2 in normal
control cows. In this study PGE2 was not assessed in normal cows, however, the
concentration of PGE2 on the day of recruitment to the study was significantly increased
in moderate cases of mastitis compared to mild cases. Atroshi and others (1987) reported
a significant correlation between somatic cell count and PGE2, however, the samples that
were selected for measurement of PG concentration were selected based on having
somatic cell count <120 x 103/ml for 'normal' and somatic cell count >500 x 103/ml for
'mastitic'. Other arachidonic acid metabolites, such as prostaglandin F2a and
thromboxane B2, have been measured in milk of cows with clinical mastitis (Anderson
and others 1985; Atroshi and others 1987). These mediators were also increased in cases
of mastitis compared to normal cows, Anderson and others (1985) reported that the
increase in the concentrations of prostaglandin F2a and thromboxane B2 were positively
correlated with the clinical severity of mastitis.
The sensitivity of using PGE2 concentrations to assess whether clinical mastitis was
moderate in severity was very poor (36%) but the specificity was good (86%). From this
study approximately four in ten cases of clinical were moderate rather than mild in
severity. If the PGE2 concentration detected the case as being moderate in severity. then
it has a 63% chance of being truly moderate, and conversely if the PGE2 concentration
detected the case as not being moderate in severity it had a 66% chance of being truly
moderate, thus the use ofPGE2 concentration has the potential to misclassify one third'of
cases.
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The concentrations of PGE2 decreased for mild and moderate cases over the two days
following diagnosis and treatment of clinical mastitis. A treatment effect on the
concentrations of PGE2was not detected in this study, but this may have been due to the
frequency of sampling. A small experimental study by Banting and others (2000)
reported a significant treatment effect of meloxicam on the concentrations of
thromboxane B2in milk, where the concentrations of thromboxane B2 in the meloxicam
treated group were significantly lower than in the control group. Lees and others (1991)
reported that the subcutaneous exudate concentration of PGE2, PGF2a and thromboxane
B2were significantly (p<O.05) reduced by meloxicam, in an experimental model in the
horse. Both these studies monitored the concentrations of the eicosanoids every two
hours after treatment administration. The PGs have very short half lives and some of the
more potent PGs are very unstable (Higgins and Lees 1984). In experimental studies in
dogs after injection of endotoxin the PGE2 response was rapid, levels increased within
two minutes in one study (Kessler and others 1973) and 30 minutes in another study
(Fletcher and Ramwell 1977). In humans, injection of PGE} and PGE2 induced local
oedema and redness with the maximum reaction within 15-30 minutes and subsidence of
the reaction after 1-2 hours (Crunkhorn and Willis 1969). The value of measuring PGE2
concentration in milk of mastitic cows might be increased with more frequent sampling.
The different pathogenesis of microbiological causes of bovine clinical mastitis leads to
differing degrees of invasion and destruction of the mammary gland depending on the
causal agent and the strain of the pathogen. Approximately 80% of Staph aureus
intramarnmary infections cause subclinical mastitis, and when they result in clinical
infection the signs are mainly mild (Vestweber and Leipold 1993). In contrast, 80-90%
of intramarnmary infections with Escherichia coli result in clinical mastitis (Smith and
others 1985) with 10-15% causing severe toxic cases (Tadich and others 1998). This
study did not include severe cases of clinical mastitis, however, it might be expected that
those would have even greater concentrations of PGE2 compared to cases of moderate
clinical mastitis. The mean, median and range of concentrations of prostaglandin E2 in
clinical cases due to the environmental organisms, such as S uberis, E coli and A
pyogenes, were greater than clinical cases due to Staph aureus. The log prostaglandin E2
concentrations in mastitis due to Staph aureus were more similar, i.e. they had a
narrower range and had lower mean and median values than the cases of mastitis with
environmental organisms and cases from which no growth were detected. There was no
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significant difference among the microbiological groupings for the mastitis organisms
and the concentration of PGE2 in this study but a trend was seen and perhaps with a
larger dataset a significant result may be seen.
In this study, correlation with the concentrations of meloxicam and PGE2 one day after
treatment was administered was not possible due to the majority of cases having PGE2
concentrations below the LOD. More frequent sampling might allow examination for a
correlation between meloxicam concentrations and PGE2 concentrations.
Meloxicam is reported to have a half-life of 17.5 hours after subcutaneous injection in
lactating cattle (Anon 2003). Non-steroidal anti-inflammatory drugs are highly protein
bound, >99% in some cases. This extent of protein binding explains the extended
therapeutic activity in inflamed tissues which these drugs display relative to their plasma
elimination half-life (Nolan 2000). An experimental study reported that the
administration of meloxicam 50 hours before challenge with E coli endotoxin inhibited
the rise in thromboxane A2 and prevented severe adverse clinical signs of endotoxaemia,
thus indicating a long duration of action. In this study the results of the meloxicam assays
in treatment group 3 (antibiotics and three doses of meloxicam) demonstrated that the
concentrations of meloxicam in milk were below the LOO in 50% (4/8 day three) to 88%
(7/8 day six) of cases three days after treatment was administered.
Prostaglandin E2 acts as a typical mediator of inflammation, and could, as this study and
previous studies by Atroshi and others (1987) suggested, be used as a marker for mastitis
and mastitis severity. Non-steriodal anti-inflammatory drugs could be targeted at the
cases with higher concentrations of PGE2. Further studies should be undertaken to assess
the effect of meloxicam on the concentrations of PGE2 in mastitic cows with more
frequent sampling following the administration of the meloxicam.
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Chapter6
General discussion and conclusions
6.1. Overview
Mastitis is a common disease of dairy cows, with the UK national incidence estimated to
be 35-40 cases per 100 cows per year (Booth 1997; Whitaker and others 2004). Mastitis
causes a considerable economic impact (Wilson and Kingwill 1975; Esslemont and
Peeler 1993; Hortet and Seegers 1998; Yalcin and others 1999) and has also significant
welfare implications. It was reported by Esslemont and Kossaibati (1997) that mastitis
accounted for over 10% of premature disposals from dairy farms in England and that
mastitis was the most common cause of death in adult dairy cows (Menzies and others
1995; Esslemont and Kossaibati 1997). Over the last decade, partly as a consequence of
the BSE crisis and foot and mouth outbreak, the Government has increasing concerns
about the health and welfare of livestock. This has lead to the development of an 'Animal
Health and Welfare Strategy', which aims to manage the impact of animal disease and
improve the welfare of animals kept by man, whilst protecting the economic and social
well-being of people and the environment. The framework of this initiative is to promote
disease prevention and provide appropriate care to allow animals to produce higher
yields and remain productive for a longer period of time. Traditional methods for disease
detection rely on visual observation, however, increasing herd sizes and reduced
manpower (Anon 2004) has resulted in a shortage of available skilled labour and
increasing reliance on mechanised systems. Clinical mastitis is characterised by grossly
abnormal milk and was traditionally detected by visual observation of the milk. Due to
less time per individual cow being available, many farmers do not examine the foremilk
despite this being a legal requirement (A.M. Biggs personal communication). The need
for automated systems to monitor animal health and fertility has been recognised both for
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economic and welfare reasons and there has been increasing interest in the use of
biosensors (Mottram and others 2002).
6.2. Study objectives
This study was an intervention study following naturally occurring clinical mastitis cases
over a six week period and aimed to assess the value of physiological and laboratory
parameters as indicators of severity of clinical mastitis and pain possibly associated with
the disease, and to examine the impact of the use of analgesic drugs in combination with
intramammary antimicrobial infusion. The ability to assess clinical severity of mastitis
may allow the use of more appropriate treatment for mastitis, while the use of some
physiological and laboratory parameters as indicators of the presence of disease could
have value in automated milking systems.
6.3. Study design
One hundred and seventeen cases of clinical mastitis were recruited into the study,
however, only 70 cases were followed for the complete six week period. Forty seven
cases were dropped from the study due to the re-occurrence of mastitis in the same
quarter, development of mastitis in another quarter, or the development of lameness,
which again highlights the prevalence of mastitis in dairy cows.
Ideally the trial would have been double-blinded to minimise observer and reporter bias,
however, owing to the considerable difference between the regimens an open design was
unavoidable. Random allocation of treatment groups and random selection of the initial
leg for the measurement of mechanical threshold helped to minimise bias.
The antimicrobial product used in the trial, cefquinome (Cephaguard Le intramammary,
Intervet UK limited, Milton Keynes), is a third generation cephalosporin preparation.
This product was selected for its broad spectrum of activity and due to the absence of any
corticosteroid. Corticosteroids have anti-inflammatory properties and are often used in
intramammary preparations to reduce the inflammation in the udder tissue (McKellar and
others 1991). A preparation containing corticosteriod would confound the effect of
NSAID. A parenteral preparation of NSAID was selected as a previous study by
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Fitzpatrick and others (1998) reported that a single intravenous dose of NSAID reduced
the alterations in nociceptive pathways to mechanical stimulation but a specially
prepared intramammary infusion containing NSAID was not effective in reducing these
alterations in cows with clinical mastitis. Repeat dosing of NSAID to give a longer
duration of analgesia was also carried out in this study as Fitzpatrick and others (1998)
reported that the single intravenous dose of NSAID reduced the alterations in pain
processing but only over a one day period after drug administration.
Although all cases were observed walking by the researcher on every sampling day,
bilateral subclinical lameness could have been overlooked and could have interfered with
clinical and laboratory results. In future projects lifting each hindleg in tum and paring
the top surface of the solar hom off to allow examination for lesions could reduce the risk
of recruiting cases of clinical mastitis that also had bilateral subclinical lameness.
In this current study it was not possible to assess if there was a breed effect on any of the
physiological or laboratory parameters, as most farms consisted principally of one breed
and breeds differed among farms. It was likely that management differences rather than
the breed could explain any variation in physiological and laboratory parameters among
farm.
The basis of the pain assessment was the use of mechanical pain threshold testing. Pain
threshold testing is the application of a noxious stimulus such that physiological pain is
induced and the response to the stimulation can be measured and quantified. This
technique has been used reliably in lameness studies in sheep (Nolan and others 1987;
Ley and others 1989) and cattle (Whay and others 1996) and in a previous study of
mastitis in dairy cattle (Fitzpatrick and others 1998).
6.4. PhYSiological parameters
The heart rate, respiratory rate and rectal temperature of cases with moderate clinical
mastitis were significantly higher than those in mild cases of clinical mastitis. These
parameters were assessed for usefulness as predictors of severity of clinical mastitis and
the sensitivities and specificities of categorising clinical mastitis as moderate in severity
using the heart rate, respiratory rate and rectal temperature were 48%, 66% and 59%, and
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73%,68% and 68%, respectively. As predictors of disease these parameters had similar
sensitivities of 60%, 46% and 50%, respectively. These values would mean that
approximately 40-50% of cases would be misc1assified. The hindleg stance of cows with
clinical mastitis was different from normal cows (p<0.001). Cases of clinical mastitis
were shown to stand with their hindlegs further apart than normal cows and as a predictor
of clinical mastitis, hock-to-hock distance had a sensitivity of 64% and specificity of
84%. These physiological parameters may act as additional tools with the aim of aiding
in the decision to administer anti-inflammatory and/or analgesics to the cases with more
severe mastitis.
The results from the mechanical threshold testing demonstrated that alterations in the
response to mechanical stimulation were a feature of acute clinical mastitis in dairy cows.
There was no evidence of adaptation to repeated use of the mechanical threshold device,
as demonstrated by the normal animals, which reacted at similar thresholds (26.5± 1.60
kPa) for the six week study duration. Whay and others (1996) also reported no effect of
time on the response of normal cattle to a mechanical nociceptive stimulus.
Whay and others (1997) reported that lame cows demonstrated increased sensitisation to
mechanical stimulation with increasing severity of lameness, as judged by a numerical
rating scale. In the current study the threshold difference on the day of recruitment to the
study was higher in moderate cases of mastitis compared to mild cases, but was not
significant. In a larger dataset this trend might become significant, such that an alteration
in the nociceptive pathways in response to noxious stimulation might be seen with
increasing severities of mastitis. Whay and others (1998) demonstrated that the duration
of hypersensitivity was different for different types of lesions in dairy cattle lameness.
They reported that cows with solar ulcers and white line disease displayed
hypersensitivity for a minimum of 28 days. In this study alteration in response to
mechanical stimulation lasted for between six and 45 days; we could not demonstrate
that alteration in response to mechanical stimulation lasts for different durations
depending on the causal pathogen or duration of infection, but this may be due to the
limited power of the study.
Normal cows reacted at similar threshold levels to the ipsi-lateral leg in cases of mastitis
and the threshold measurements of the contra-lateral leg in the cases of mastitis were
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significantly higher than in normal cows. This may be because the threshold to
stimulation is truly higher in the contra-lateral leg, or because cows are reluctant to shift
weight onto the ipsi-Iateral leg. If the threshold to stimulation is higher in the contra-
lateral leg than in normal animals, it would be more accurate to describe the phenomenon
seen as hypoalgesia or hyposensitivity of the contra-lateral leg rather than hyperalgesia or
hypersensitivity of the ipsi-lateral leg. This phenomenon is likely to be due to the
complexity of the innervation of the mammary gland and indicates that the alterations in
pain processing in mastitis is harder to explain than those seen in lame animals.
Non-steroidal anti-inflammatory drugs are the most widely available analgesics for cattle
in the UK and are used for their anti-inflammatory, antipyretic, anti-endotoxic and
analgesic properties. The use of meloxicam, a NSAID, had a significant beneficial effect
on the pain threshold levels in cows with mild and moderate clinical mastitis. We did not
demonstrate a significant positive effect of NSAID treatment on the milk yield of cases
of clinical mastitis, however the limited results from this study did suggest a potential
yield benefit. This is in contrast to a study by Shpigel and others (1994) who showed a
significant effect of the use ofNSAID on the milk yield.
6.5. Laboratory parameters
The microbiological results from the present study showed that the most prevalent
isolates from clinical mastitis cases were S uberis (30%), E coli (22%), Staph aureus
(11%), other microbiological isolates (6%), A pyogenes (4%) and S dysgaiactiae (3%).
No growth was seen in 24% of submitted samples. These results are similar to those of
other studies (Anon 1982; Wilesmith and others 1986; Erskine and others 1988; Anon
1989; Anon 1993; Booth 1993; Anon 2000; Bradley and Green 2001; Milne and others
2002), that environmental pathogens, including S uberis and E coli, are the most
commonly isolated pathogens from clinical cases of mastitis in dairy cows. Morin and
others (1998) consider that clinical signs alone are inadequate to differentiate between
clinical mastitis caused by Gram-positive and Gram-negative bacteria, however, Milne
and others (2003) reported that certain clinical signs were associated with specific
pathogen types. This study reports significant associations between microbiological
results and physiological and laboratory parameters. The isolation of Staph aureus was
more likely in mild cases, no growth more likely in cases with relatively low IQSCC, S
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uberis isolation more likely in moderate cases with relatively high IQSCC and E coli
more likely in cases with higher heart rates.
Somatic cell counts may be used to estimate the degree of inflammation within the udder
of a cow and hence the presence of mastitis (Dohoo and Meek 1982; Cullor and Tyler
1996; Sears and others 1993). Data from quarter samples provides the most accurate
assessment of the prevalence of infection in the herd, as IQSCC will not be affected by
the dilution oflow SCC milk from non-infected quarters of the same cow in an ICSCC or
of all cows in a BMSCC (Reneau 1986). In this study IQSCC were significantly
increased in the affected quarters and the contra-lateral quarters of cases of mild and
moderate clinical mastitis on the day of recruitment into the study compared to normal
cows. Hillerton (1997) reported that the IQSCC for clinical infections with Staph aureus
could be 4 million cells/ml and for clinical infections with S uberis or coliforms the
IQSCC could be 20 million cells/ml. In this study the median IQSCC for the affected
quarter in mild and moderate cases of clinical mastitis was 10 million cells/ml. The
IQSCC for the affected and diagonally opposite quarters of cases with mild or moderate
clinical mastitis decreased over the 45 day study period, however, they were still
significantly higher than the normal cows at the end of the 45 day study period. There
was no significant difference between the affected quarters and the diagonally opposite
quarters of mild or moderate cases of clinical mastitis. This suggests that IQSCC for the
affected quarters reached 'normal' levels for that cow, although the IQSCC for the
affected quarter of cases of clinical mastitis were still significantly different to normal
animals by day 45 after recruitment to the study. There was no information on the
IQSCC or ICSCC prior to recruitment into the study and it is possible that normal cows
could have had lower ICSCC than the cows that subsequently developed mastitis.
The milk composition was altered due to clinical mastitis, protein content was increased
and lactose content was decreased. Other studies have shown decreases in fat (Houben
and others 1993) and protein content (Myllys and Rautala 1995), therefore suggesting
that the milk composition is not a reliable indicator of mastitis.
The differential cell count of the milk samples did vary considerably over the 45 day
study period, however there was no difference in the cell proportions between mild and
moderate cases and between the cases that completed and those that did not complete. the
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study. In cases of clinical mastitis the predominant cell type was PMNs and over the 45
day period the proportion decreased with the proportion of macrophages and
lymphocytes doubling. The differential cell counts were not useful predictors of severity
of disease or likely outcome.
In contrast APP concentrations have been shown to be useful indicators of mastitis. The
concentration of Hp in milk increased with increased severity of clinical mastitis - a
phenomenon that was also reported in respiratory disease of calves (Godson and others
1996). Mammary-associated serum amyloid A was significantly increased in clinical
mastitis and its local production (Vreugdenhill and others 1999; McDonald and others
2001) makes it a very specific indicator of mastitis. The concentration of M-SAA,
however, did not increase with increasing severity of mastitis on the day of diagnosis and
many cases of mastitis had low concentrations of M-SAA on the day of recruitment to
the study. This result contradicts the findings of Nielsen and others (2004), who reported
that M-SAA concentrations increased with increasing CMT score. In this study the
ability of Hp and M-SAA to differentiate between mild and moderate severities was
investigated. The sensitivity and specificity of differentiating mild clinical mastitis from
moderate clinical mastitis using Hp were 68% and 68%, respectively and using M-SAA
concentrations the sensitivity and specificity were 63% and 36%, respectively. These
results confirm that in this dataset Hp concentrations were more useful than M-SAA
concentrations in distinguishing between mild and moderate clinical mastitis.
Prostaglandins are recognised mediators of inflammation that are released via the
arachidonic acid pathway as a consequence of tissue damage and/or inflammation (Xie
and others 1992). Previous studies have demonstrated an increase in eicosanoid
concentration in bovine mastitis (Anderson and others 1985; Atroshi and others 1987). In
this study PGE2 concentrations were measured in milk with concentrations ranging from
o - 10.2 ng/ml for mild and moderate cases of clinical mastitis on the day of recruitment
to the study. The concentrations significantly increased with increasing severity of the
mastitis. The sensitivity and specificity of differentiating between mild and moderate
cases of clinical mastitis using PGE2 concentration were 85% and 36%, respectively.
Meloxicam concentrations were measured over a six day period in eight cows that were
treated with meloxicam on the day of recruitment and over a 12 day period in another
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eight cows that were treated with meloxicam on the day of recruitment, three and six
days after recruitment. The kinetics of meloxicam followed a similar pattern for all 16
cows; the peak concentration occurred one day after administration and there was a rapid
decline to less than half the peak concentration by two days after administration. The
current milk withdrawal period following parenteral administration is five days, however,
the results from this study suggest that concentrations of meloxicam were below the limit
of detection in 50-88% of the cows three days after administration.
6.S. Future direction
A non-invasive method to detect the daily variations in body temperature of a cow and
the assessment of the hock-to-hock distance by use of laser or infra-red technology
would be useful tools for automated systems. These technologies could be used to
recognise early signs of disease and improve the welfare of dairy cows. They could also
be used to tailor and monitor therapy.
The theory that cows with unilateral mastitis are reluctant to shift weight onto the ipsi-
lateral leg could be tested using pressure plates placed underneath the feet of the cow.
The use of pressure plates could well be easier to perform routinely and be more user
friendly than the current mechanical threshold device. Pressure plate devices could be
adapted for use in milking parlour and would especially be suited to robotic milking
systems.
The mechanism behind the alterations in the threshold measurements in cows with
clinical mastitis needs to be examined further to explain the findings of hypoalgesia in
the contra-lateral leg and the fact that the ipsi-lateral leg responds at a similar threshold
level to normal animals.
Further studies examining the effect on milk yield could be undertaken. In addition, the
monitoring of feed intake might also serve as a good indicator of a positive effect of
NSAID.
Investigations into the cell type that is responsible for the local production of M-SAA
could be performed.
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6.7. Conclusions
Reduced manpower on UK farms often means that dairymen have less time to spend on
individual cows in the parlour and there is increasing reliance on automated systems to
detect mastitis. It is necessary to have a rapid and accurate means of detection clinical
mastitis, as the milking of mastitic milk into the bulk milk tank will result in wide
fluctuations in the total bacterial count (TBC) or bactoscan (Davidson and Jackson 1984)
and could lead to the BMSCC exceeding >400,000 cells/ml and this has financial
implications. The European Community Health and Hygiene Directive 92/46, detailing
standards for the hygienic quality of milk intended for human consumption, requires bulk
milk to have a TBC < 100,000 bacterialml and SCC < 400,000 cells/ml.
The ability to differentiate between mild and moderate cases of clinical mastitis is
improved when the physiological parameters, heart rate, respiratory rate and rectal
temperature, were combined with the laboratory parameters, Hp and PGE2• There is
approximately a thirteen times increased likelihood that the clinical mastitis is mild in
severity if lower values and concentrations for these parameters are present. There is
approximately a five times increased likelihood that the clinical mastitis is mild in
severity when using low values of rectal temperature, and low concentrations of PGE2
and Hp as predictors of severity. The development of non-invasive techniques to assess
body temperature and concentrations of PGE2 and Hp that could be adopted into
automated systems would be useful to allow more severe cases of clinical mastitis to
receive more specific treatment.
In summary, the combined use of physiological, mechanical threshold stimulation testing
and laboratory parameters has been shown to useful in differentiating between clinical
cases of mastitis and normal animals, and mild and moderate clinical mastitis. These
parameters could have potential value as indicators to allow therapy to be targeted as
appropriate to the severity of the mastitis. Some of these parameters will also increase the
available armoury to identify disease and monitor the health and welfare of dairy cows in
automated milking systems. Importantly, the use of meloxicam produced a demonstrable
reduction in the duration of the alterations in response to mechanical stimulation in cases
of mild and moderate clinical mastitis. The routine use of NSAID in cases of clinical
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mastitis would serve to increase animal comfort and welfare and increased usage should
be encouraged.
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Exclusion criteria
A case of clinical mastitis will be excluded from the project if;
• The cow is systemically illon any of the sampling days, or
• The cow is lame during the sampling period
• Has a concurrent inflammatory condition, e.g. metritis, endometritis, retained
foetal membranes, septic arthritis, pneumonia, endocarditis, gastro-enteritis, other
any other focal sepsis or inflammation including ear tagging, tattooing or freeze
branding, on any of the sampling days
• Has had previous incidents of mastitis in the same quarter in the same lactation
period that have not responded to treatment
• The cow has mastitis in two or more quarters
• The cow is to be 'dried orr in less than eight weeks time
• Mastitis recurs in the affected quarter or any other quarter of the cow during the
sampling period
• The cow displays an adverse reaction to the treatments
• The cow is difficult to handle
• The cow is sold or dies during the sampling period
• Dry cow therapy is administered to the cow during the sampling period
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Random numbers - treatment allocation
Tx 1 Tx 2 Tx 3
2 3 1
9 4 5
10 7 6
16 12 8
17 14 11
21 19 13
22 25 15
23 27 18
26 31 20
28 34 24
30 40 29
32 41 35
33 42 39
36 47 43
37 48 44
38 49 45
52 51 46
53 56 50
54 59 55
60 61 57
63 65 58
64 73 62
66 75 68
67 80 69
79 81 70
82 85 71
86 88 72
90 89 74
91 95 76
93 96 77
94 99 78
97 103 83
98 104 84
101 106 87
102 107 92
105 109 100
111 110 108
112
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Aseptic milk collection- instructions for farmers
It is essential that clean milk samples are obtained to ensure that the correct cause of
mastitis is identified in the laboratory.
Milk samples for diagnosis of mastitis must be taken before any treatment is given.
Please ensure that the person who takes the milk sample follows the procedure below.
1. Prepare all teats as for routine milking (e.g. wash. dry).
2. Use cotton wool soaked in disinfectant to clean all teats. Use a clean piece of
wool for each teat. Concentrate especially on the teat end - make sure it is as
clean as possible.
3. Draw out a few steaks of milk and discard these.
4. Use another clean piece of cotton wool soaked in disinfectant to rub only the teat
end.
5. Put on gloves.
6. Draw milk into the container. Hold the container at an angle so that dust/dirt does
not fall into it. Only fill the container to the half-way mark. Do not touch the end
of the contained with your fingers. Keep the cap of the container clean. Replace
the cap.
7. Label the tube with the date, cow number and quarter affected.
221
Appendix 4
222
Bovine Haptoglobin Assay (Tridelta Development Ltd,
Ireland)
Assay principle
The haptoglobin assay is designed to detect the acute phase protein in milk and serum.
The haptoglobin assay kit is a solid phase Enzyme Linked Immuno Sorbent Assay
(ELISA). In this assay haemoglobin is coated onto microtitre plates which binds the free
haptoglobin in the well. Samples, including standards of known haptoglobin content, are
added into the wells and allowed to incubate. Any haptoglobin present in the well is
captured onto the plate by the haemoglobin. The microwells are then washed to remove
any unbound haptoglobin. A HRP-Iabelled anti- haptoglobin monoclonal antibody is then
added to the well, which will bind to any haptoglobin present, and allowed to incubate.
After washing for a second time TMB substrate solution is added. The intensity of the
colour produced is proportional to the concentration of haptoglobin present in the
original specimen.
Sample and reagent preparation
Samples - Milk
Milk samples should be collected into suitable vials. Samples should be diluted 1120 in
Ix calibrator/sample diluent prior to testing. Vortex samples prior to dilution.
All samples can be stored for up to 24 hours at 2-8°C. For longer periods, storage at _
20°C is recommended where samples are not for immediate assay. If specimens have
levels of haptoglobin greater then the top standard, they should be diluted out further in
the calibrator/sample diluent and retested.
Wash concentrate (20x)
Dilute 1 volume of wash buffer concentrate (20x) in 19 volumes of distilled water. Store
both the wash buffer and working buffer (lx) in the refrigerator. Diluted wash buffer is
stable for up to 2 weeks when stored at 4°C.
Diluent buffer (lOx)
Dilute 1 volume of diluent buffer concentrate (lOx) in 9 volumes of distilled water. Store
both the diluent buffer concentrate and working buffer (Ix) in the refrigerator. Diluted
diluent buffer is stable for up to 24 hours when stored at 4°C.
Calibrator
Dilute calibrator 111000 in calibrator sample diluent (Ix) IO)!1in 10ml. This is solution
A.
Furth~r dilute this to a final concentration of 114000by adding Irnl of solution A to 3ml
of cahbrator/sample diluent. This is solution B.
It is recommended that either solution A or solution B is aliquoted and stored frozen for
future use.
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S h d d fillet up t e stan ar curve as 0 ows:
Tube No. Volume Calibrator Volume Diluent Tube Concentration
Cl 2S0J,11Solution B - SOOng/ml
C2 2S0J,11Solution B 2S0J!1 2S0ng/ml
C3 2S0J,11C2 2S0}-l_1 12Sng/ml
C4 2S0J,11C3 2S0}-l_1 62.Sng/ml
CS 2S0J,11C4 2SQ!!1 31.3ng/ml
C6 2S0).11CS 2S0!!1 lS.6ng/ml
C7 - 2S0~1 Omg/ml
Prepared calibrators are stable for 8 hours when stored at room temperature (20-2S0C).
Procedure
1. Determine the number of 8-well strips needed for the assay. Re-bag extra strips,
seal bag and store in refrigerator.
2. Vortex the serum or milk samples to be examined in the test. Dilute the serum or
milk as directed in the samples preparation. Add 100).11,in duplicate, of diluted
sample or standard to each well.
3. Cover the plate with dust cover and incubate plate for 1 hour at 37°C.
4. After incubation aspirate or decant and wash the plate four times with diluted
wash buffer. After the last wash, tap the plate dry on absorbant paper.
S. Add 100!!1of conjugate to each well.
6. Cover the plate with dust cover and incubate for 1 hour at 37°C.
7. After incubation aspirate or decant and wash the plate four times with diluted
wash buffer. After the last wash, tap the plate dry on absorbant paper.
8. Add 100!!1ofTMB substrate.
9. Cover the plate and incubate in the dark at room temperature for 15 minutes.
10. Add 100!!1of the stop solution.
11. Read the absorbance of each well at 450nm using 630nm as reference, if
available. Alternatively blank the plate reader against a TMB blank composed of
100Jll of TMB substrate and 100!!1of stop solution.
Interpretation of test results
1. Calculate the mean absorbance for each sample, control or standard.
2. Plot the absorbance of the standard concentrations on standard graph paper. (If
necessary, the background absorbance for the Ong/ml may be subtracted from
each of the data points, including the standards, unknowns and controls prior to
plotting). Draw the best smooth curve through these points to construct the
standard curve.
3. Determine the concentrations of the test samples and controls from the standard
curve by multiplying the interpolated value by the appropriate dilution factor (eg.
milk samples diluted 1120should be multiplied by 20). Samples that have a signal
greater than the highest standard should be further diluted in diluent buffer and
re-analysed.
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Phase™ range Serum Amyloid A Assay (Tridelta Development
Ltd, Ireland)
Assay principle
The Serum Amyloid A assay is designed to detect the acute phase protein in serum and
plasma. The test can also be used to detect SAA in milk, cell culture medium, and in
other biological fluids. The SAA assay kit is a solid phase sandwich Enzyme Linked
Immuno Sorbent Assay (ELISA). A monoclonal antibody specific for SAA has been
coated onto the wells of the microtitre strips provided. Samples, including standards of
known SAA content, are added into microwells along with biotinylated ant- SAA
monoclonal natibody. Any SAA present in the well is both captured on the plate by the
immobilized antibody and labelled with the conjugate antibody in a one step procedure.
After washing to remove all of the unbound material, Streptavidin-Horse Radish
Peroxidase conjugate is added to the well and incubated. Following the second
incubation, TMB substrate solution is added. The intensity of the colour produced is
proportional to the concentration of SAA present in the original specimen.
Sample and reagent preparation
Samples - Milk
Milk samples should be collected into suitable vials. Samples should be vigorously
vortexed to assure accurate determination of SAA concentration. Samples should be
diluted 1/50 in diluent buffer prior to testing.
All samples can be stored for up to 2 days at 4°C or stored frozen at -20°C for longer
periods. If specimens have levels of haptoglobin greater then the top standard, they
should be diluted out further in the calibrator/sample diluent and retested.
Diluent buffer (l Ox)
Dilute I volume of diluent buffer concentrate (lOx) in 9 volumes of distilled water.
Prepared reagent is stable only for one day at room temperature and should not be stored
for extended periods.
Wash buffer (20x)
Dilute I volume of wash buffer concentrate (20x) in 19 volumes of distilled water. Store
both the wash buffer and working buffer (Ix) in the refrigerator. Diluted wash buffer is
stable for up to 2 weeks when stored at 4°C.
NOTE: Ensure that any crystals that may have developed in the wash buffer or diluent
have been completely dissolved prior to dilution for use.
Biotinylated anti-SAA (All biological fluids)
Dilute ~/IOO in l x diluent buffer. Prepare appropriate volume of the diluted conjugate
dependmg on the number of strips used:
501l~of conjugate is used for each well (400llllstrip). Discared any excess diluted
conjugate.
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Streptavidin-HRP
Dilute the streptavidin peroxidase to a 114000final dilution by adding 5~1of the stock
solution to 20ml of Ix diluent buffer. At 100~1per well this is sufficient for twelve 8-
well strips. Dilute only as much conjugate a will be used in the assay and return the
excess streptavidin-HRP stock to the refrigerator. Discard any excess diluted conjugate.
Dilution of SAA standards
1. Reconstitute the standards by adding 200~1 of distilled water to the vial. Vortex
vigorously to dissolve completely.
2. Label6 tubes Cl to C6. Add diluent to each tube as directed in Table 1. To tube
Cl add 60~1of reconstituted standard from step 1 to 240~1 diluent (see table 1).
This is further diluted two-fold serially 4 times (tubes C2 to CS) to provide the
working standards as indicated in table 1 below. Tube C6 contains diluent only.
Note: The top standard and subsequent values will vary depending on the species
under investigation. The working ranges for each species are provided in Table 2.
Excess reconstituted standard can be stored at -20°C.
Tube No. Volume of Volume of diluent Serial dilution
calibrator
Cl 6Qg_1 240J..11 -
C2 - 15011.1 150J..11Cl
C3 - 150J..11 IS0J..11C2
C4 - 150_!!l 150J..11C3
CS - 150~1 150J..11C4
C6 - 150J..11 -.Table 1: Preparation of working standard curves
Standards Bovine (ng/m!)_ Porcine (ng/ml) Canine (ng/ml) Human (ng/ml)
Cl 300 2000 160 200
C2 150 1000 80 100
C3 75 500 40 50
C4 37.5 250 20 25
CS 18.8 125 10 12.5
C6 0 0 0 0.Table 2. Concentration of calibrators or serum, plasma or milk
Procedure
Allow test reagents and samples to reach room temperature before use.
1. Determine the number of 8-well strips needed for the assay. Re-bag extra strips,
seal bag and store in refrigerator.
2. Add 50~I of diluted Biotinylated anti-SAA to each well.
3. Vortex the serum, plasma or milk samples to be examined in the test. Dilute the
se~ and pla~ma 11500and milk samples 1/50 in 1x diluent buffer. Add 50~1, in
duplicate, of diluted sample or standard to each well. Tap sides of the plate gently
to mix.
4. Cover the plate with dust cover and incubate plate for 1 hour at 370C.
5. After incubation aspirate or decant and wash the plate four times with diluted
wash buffer. After the last wash, tap the plate dry on absorbant paper.
6. Add 100~1of streptavidin-peroxidase to each of the wells.
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7. Cover the plate with dust cover and incubate in the dark at room temperature
for 30 minutes.
8. After incubation aspirate or decant and wash the plate four times with diluted
wash buffer. After the last wash, tap the plate dry on absorbant paper.
9. Add 100~1ofTMB substrate.
10. Cover the plate and incubate in the dark at room temperature for 30 minutes.
11. Add 50~1of the stop solution.
12. Read the absorbance of each well at 450nm using 630nm as reference, if
available. Alternatively blank the plate reader against a chromogen blank
composed of 100~1of T~B substrate and 50).!1of stop solution.
Interpretation of test results
4. Calculate the mean absorbance for each sample, control or standard.
5. Plot the absorbance of the standard concentrations on semi-logarithmic or
standard graph paper. (If necessary, the background absorbance for the Ong/ml
may be subtracted from each of the data points, including the standards,
unknowns and controls prior to plotting). Draw the best smooth curve through
these points to construct the standard curve.
6. Determine the concentrations of the test samples and controls from the standard
curve by multiplying the interpolated value by the appropriate dilution factor (eg.
serum and plasma diluted by 11500should be multiplied by 500). Samples that
have a signal greater than the highest standard should be further diluted in diluent
buffer and re-analysed.
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